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I- Arginine requirement 
The sources of free arginine within the body are dietary protein and endogenous 
synthesis. Dietary sources of arginine account for about 5-6 grams per day (1, 2) which 
corresponds to -25% of the daily whole-body arginine flux (3-5), In adult rodents and 
humans, -40% of dietary arginine is catabolized by the intestine before entering the 
circulation. Most of the remaining arginine required is provided by endogenous synthesis 
of arginine from citrulline, with the kidneys being the major net producer (6). Arginine is 
classified as a conditionally essential amino acid, meaning that under normal conditions, 
the endogenous biosynthesis of arginine suffices to meet daily requirements in healthy 
adults. In rapidly growing infants and children, and in adults under catabolic stress or 
with intestinal or renal dysfunction, arginine becomes an essential amino acid (7-9). 
Arginine catabolism is the major regulator of arginine homeostasis (10) as is 
indicated by the finding that the endogenous biosynthesis rate of arginine from citrulline 
is essentially unaffected by circulating arginine concentrations (5). This was 
demonstrated in homozygous arginase II- knockout mice which show elevated plasma 
arginine levels thereby indicating that arginase II participates in regulating arginine 
concentration. Furthermore, healthy human volunteers fed an arginine-free diet show a 
decrease in serum arginine but unaltered rates of whole body synthesis (5). 
II- Arginine synthesis 
All mammals are capable of covering their arginine requirements under normal 
physiological conditions through endogenous arginine biosynthesis (6, 11-13), except the 
Felidae, which have very low levels of pyrroline-5-carboxylate synthase and ornithine 
aminotransferase in the intestinal mucosa and can, therefore, not produce sufficient 
ornithine for arginine biosynthesis (14-17). Figure 1 depicts the enzymes that are 
involved in de novo arginine synthesis from proline and glutamine. Proline and 
glutamine metabolism to citrulline occurs in the mitochondria, whereas the conversion of 
citrulline to arginine takes place in the cytoplasm (18). Citrulline derives from three 
sources in vivo. The major source of citrulline is its synthesis in the small intestine 
enterocytes from proline in the perinatal period and from glutamate/glutamine in 
adulthood (19-21) (Figure 1). Furthermore, small quantities of citrulline are produced by 
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nitric oxide synthase (NOS) and from the degradation of asymmetric dimethylarginine 
(ADM A), a metabolic by-product of protein modification in the cytoplasm. 
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Figure 1. Enzymes involved in the synthesis of arginine. Abbreviations: I, phosphate-
dependent glutaminase; 2 and 3, P5C synthase; 5, ornithine aminotransferase; 6, 
ornithine carbamoyltransferase ; 7, argininosuccinate synthetase; 8, argininosuccinate 
lyase; 9, N-acetylglutamate synthase; 10, carbamoylphosphate synthetase I; 11, proline 
oxidase; 12, aspartate aminotransferase. OAA, oxaloacetate; CP> carbamoylphosphate. 
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a) Hepatic arginine metabolism 
The liver is the only organ, which expresses all the enzymes of the ornithine cycle. Here 
the highest rate of arginine synthesis is found (22), but this does not result in net arginine 
* 
production due to the abundant expression of arginase 1. The ornithine cycle functions 
efficiently due to the organization of the five major ornithine cycle enzymes in a so-
called metabolon (23) carbamoylphosphate synthetase I (CPS) and ornithine 
transcarbamoylase in the mitochondrial matrix, and argininosuccinate synthetase, 
argininosuccinate lyase and arginase 1 in the cytosol. The three soluble cytoplasmic 
enzymes of the ornithine cycle are grouped in such a way around the mitochondria that 
direct product transfer between consecutive enzymes occurs without substrate diffusion 
(24) Expression of the ornithine cycle enzymes in the liver lobule is restricted to the 
periportal compartment (25) and is regulated by glucagon, insulin and glucocorticoids. 
There are controversial data on the hepatic absorption of arginine. Some recent 
tracer studies using stable isotopes showed that only 5% of the urea produced is derived 
from plasma arginine (4) implying a very low uptake of arginine by the liver and the 
strict segregation of hepatic and plasma arginine pools. Other authors showed rapid 
absorption of arginine in the liver specially after burn injury in rats (26) probably via a 
Na+-independent transport system y+ (27). 
b) Intestinal arginine synthesis 
In rapidly growing mammals like piglets and rats, the arginine extracted from milk is not 
enough for optimized growth and metabolic function (28-31). This is reflected by the 
fact that the percentage of arginine in milk is - 3.3% of the total protein whereas the 
percentage of arginine in total carcass protein is 7% in rats (29). This apparent deficiency 
accounts for the presence of an important amount of arginine being synthesized by the 
neonatal intestine to compensate for the low levels of arginine present in the milk. 
Significant intestinal arginine production has been demonstrated in neonatal rodents and 
pigs (32-34). The two cell types of the intestine in which arginine biosynthesis can take 
place are the enterocytes and the neurons of the enteric nervous system (35). The 
difference between these two sites of arginine production is that the enterocytes produce 
arginine only in the perinatal period (6), whereas neurons retain the capacity to produce 
arginine throughout life. Enterocytes differ from hepatocytes in that they have the 
capacity to produce ornithine (19). This capacity is due to the co-expression of 2-
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pyrroline-5-carboxylate synthase (2-P5C-S) and ornithine aminotransferase (OAT) in the 
small intestine (36). OAT catalyzes the reversible reaction between ornithine and 
glutamate as shown in figure 1. The direction of the reaction evolves through 
development in the sense that during the neonatal period, OAT favors production of 
ornithine whereas in the post-weaning period OAT favors the synthesis of the P5C (37-
39). Complementary to this, there seems to be no significant uptake of arterial proline 
by the enterocytes in young pigs, indicating that the enteral diet is the major perinatal 
source of proline for citrulline synthesis in the gut (40) Interestingly, parentally fed 
neonates develop hyperammonemia (37, 41) which implies that the absence of intestinal 
proline catabolism to citrulline prevents proper functioning of the ornithine cycle. The 
expression of the enzymes that are necessary for local arginine biosynthesis in the 
perinatal gut is accompanied by little, if any, arginase (42). After weaning, the 
enterocytes of rodents cease to express ASS and ASL (43), while the expression of ASS 
in human and porcine enterocytes becomes markedly reduced (42). It has also been 
shown that in postweaned pig and rat (35) enterocytes, intestinal type II arginase is 
expressed in a glucocorticoid-dependent fashion (42). After weaning, the intestinal 
contribution to arginine biosynthesis becomes limited to the production of citrulline, 
which is secreted to the blood and used for arginine synthesis in the kidneys and 
elsewhere (44, 45). 
The essential role of the small intestine in arginine or arginine precursor 
synthesis in postnatal mammals is demonstrated by the arginine deficiencies that result 
when intestinal citrulline synthesis is blocked. Inhibitors of OTC or OAT or an arginine-
free diet after near-complete resection of the small bowel (39, 46) resulted in weight 
loss, a negative nitrogen balance, a decrease in circulating arginine concentrations, 
sparse fur, elevated blood pressure and low organ arginine concentration (46-48) in these 
animals. The OAT knockout mice exhibited neonatal hypoornithinaemia and lethality, 
and could be rescued by arginine administration (39). One of the questions that we have 
addressed in this thesis is the role of perinatal intestinal arginine synthesis. It has been 
speculated that neonatal intestinal arginine synthesis compensates for the low arginine 
concentration in milk and insufficient renal arginine synthesis. It was assumed that 
around weaning, the kidneys have reached their full biosynthetic capacity, making 
arginine synthesis in the small intestine superfluous (31,49, 50) We and others (43) 
have, however, recently shown that the kidneys express substantial amounts of ASS 
15 
already in 14-day-old mice, roughly a week before natural weaning (see chapter IV) a 
finding that reduces the plausibility of this argument. 
c) Renal arginine synthesis 
Although the arginine synthesizing enzymes are already present in the kidneys of rodents 
in the perinatal period (51) their expression in suckling rodents is considered to be low 
(43) With the decline of arginine production in the gut in the post-weaning period, renal 
arginine production is increased to ensure sufficient arginine availability for whole-body 
requirements (43) Intestinal citrulline is transported via the blood to the kidneys for 
arginine production (52) the two organs, therefore, form the arginine "intestinal-renal" 
axis (6). In the kidneys, ASS and ASL are localized in the proximal convoluted tubules 
(50, 53-55) Renal arginine synthesis in humans amounts to ~2g of arginine per day (56) 
which accounts for approximately 60% of net endogenous whole-body arginine 
biosynthesis, and for 10% of the total daily arginine requirements of a healthy adult (1, 
2, 4) The rate of arginine synthesis depends on citrulline delivery and does not appear to 
be regulated by dietary arginine availability (57, 58) This mechanism fails in individuals 
suffering from chronic renal insufficiency, who have elevated plasma levels of citrulline 
(59, 60) However, there is little or no decrease in plasma arginine. The basis for the 
maintenance of plasma arginine probably involves a combination of increased arginine 
synthesis at extrarenal sites and hypertrophy of unaffected proximal tubules (61, 62) 
Another important regulator of circulating arginine levels is arginine catabolism to 
ornithine (57, 63) 
d) Endothelial arginine biosynthesis 
Arginine is the sole precursor for nitric oxide, the endothelium-derived relaxing factor 
which is crucial in regulating vascular tone and hemodynamics (64-67) In order to 
sustain nitric oxide production in the endothelium lining the arterial walls, a constant 
arginine supply for endothelial NOS (NOS3) needs to be maintained. The availability of 
arginine to NOS3 is governed by the import of arginine from circulating plasma, the 
recycling of citrulline, the other product of NOS, to arginine by ASS and ASL or its 
degradation via arginase (68) The enzymes ASS and ASL are ubiquitously expressed 
(69) including the endothelium (18) Endothelial recycling of citrulline to arginine and 
NO production take place in the caveolae, a sub compartment of the plasma membrane 
16 
(see Figure 2). During activation of NO production, recycling is co-activated to the 
extent that more than 80% of the citrulline produced is recycled to arginine (70) 
Figure2. Endothelial arginine metabolism. Arginine is transported into the cell by CAT-
1. NO S3 converts intracellular arginine into NO and citrulline. Citrulline is recycled to 
arginine via ASS. Intracellular arginine can be catabolized by arginase. At low 
intracellular arginine concentrations, NO S3 uncouples and produces superoxide (red) 
rather than NO, Note that NOS3, ASS and CAT-1 all co-localize at the caveolar 
membrane and that a cell contains numerous caveolae (invaginations of the plasma 
membrane) (diameter: ~5Q nm). 
The importance of arginine resynthesis in substrate delivery to NOS3, has been 
demonstrated by knocking down ASS expression in aortic endothelial cells. ASS-
specific small interfering RNA diminished their capacity to produce NO, despite the 
presence of saturating levels of arginine in the medium (71) Resynthesis of arginine from 
citrulline is also the major route for NO production in rat blood-brain barrier endothelial 
cells (72) and porcine endothelial cells of the cerebral arteries (73). 
e) Neuronal arginine synthesis 
ASS expression has been detected in the neurons of the myenteric plexus of mice (35) 
and dogs (74) We have recently also demonstrated the presence of ASS in ganglia of the 
human small intestine in samples of all ages (ranging from fetal to elderly). These 
ganglia that are important in intestinal relaxation for food propulsion, co-express NOS1, 
suggestive of similar arginine recycling from citrulline as demonstrated in endothelial 
cells (see Figure 2). Brain neurons, on the other hand, seem to have a spatially different 
expression pattern for arginine- and NO-synthesizing neurons. ASS and ASL are 
expressed constitutively in neurons, but contrary to the intestinal ganglia, ASS and ASL 
Arg 
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hardly co-localize with each other or with NOS1 in the same neurons (75) Therefore, 
trafficking of citrulline and arginine between neurons necessitates transport capacities in 
these cells, which are fulfilled by the cationic and neutral amino acids transporters (75). 
f) Lymphocytic arginine synthesis 
Macrophages and microglia (76) are able to use citrulline as a substrate for arginine 
synthesis, which is then metabolized either by arginase or nitric oxide synthase (to be 
discussed in section II of this introduction). Although ASS and ASL have been detected 
in these cells, extracellular arginine seems to be the major source for cytokine-induced 
NO production by NOS2 (73). 
Ill- Arginine metabolism 
Quantitatively, the availability of arginine is primarily regulated by arginase, which 
metabolizes arginine into ornithine and urea, and, to a lesser extent, by nitric oxide 
synthase, which metabolizes arginine into citrulline and nitric oxide. In addition, 
arginine is a building block for protein synthesis, and a precursor for creatine, and 
agmatine. The knowledge of arginine catabolism in vivo is, nevertheless, limited. This is 
largely due to the complex compartmentalization of arginine metabolism at tissue and 
cellular levels. 
nitric oxide 
protein 
synthesis 
L-citrulline 
arginine creatine 
agmatine T 
L-ornithine 
urea 
^ putrescine 
Figure 3. Arginine metabolism 
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a) Ornithine 
1) Ornithine cycle localization 
In the liver, the ornithine cycle (Figure 2) ensures that excess ammonia released by 
protein breakdown is detoxified by conversion of arginine into urea. The ornithine cycle 
is active in the periportal hepatocytes of the liver. The capacity of the liver for urea 
production is much higher than the normal basal rates of ammonia production. 
Furthermore, the KM of the ornithine cycle for ammonia is high, namely, about 0.6 mM 
in human fetal liver and 0.45 mM in adult liver (77) Both features ensure that the cycle 
can immediately respond to acute increases in circulating ammonia concentration. All 
ornithine-cycle enzymes have also been detected in the post-weaning small intestine (78, 
79) and several investigators have hypothesized that a metabolically significant ornithine 
cycle may function in this organ (49, 79) Indeed, it has been shown in young pigs, that 
the enterocytes were able to generate urea from glutamine, ammonium, ornithine and 
aspartate (80) but the responsible arginase isoform, i.e. arginase 1 or 2 has not been 
identified. In rodents, neither Argl nor Arg2 are found in the small intestine before 
weaning. Our group has been able to show (manuscript submitted (81)) that in healthy 
human small intestine, only arginase 2, a mitochondrial enzyme but not arginase 1, the 
cytosolic enzyme is expressed. This could explain why intestinal urea production 
functions at a considerably lower rate than in hepatocytes (49, 79, 82) since it requires 
transport of arginine across the mitochondrial membrane. 
2) Ornithine Cycle Disorders (OCDs) 
Whenever one or more of the enzymes involved in the ornithine cycle is inactivated, the 
transfer of nitrogen from ammonia to urea is stopped. Five autosomal recessive disorders 
involving different defects of the enzymes of the ornithine cycle have been described: 
Ornithine transcarbamylase (OTC) (83) deficiency, carbamoylphosphate synthetase 
deficiency, argininosuccinate synthetase (ASS) deficiency, or citrullinemia, 
argininosuccinate lyase (84, 85) deficiency, and arginase deficiency (86). For instance, 
citrullinemia is characterized by increased levels of blood citrulline and ammonia (87) 
Two major types of citrullinemia can be distinguished. In classical citrullinemia 
mutations in the ASS gene lead to either abnormal kinetics (20-40,000-fold higher KM 
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than normal for citrulline (0.05 raM) (88)) or to undetectable or very low enzyme levels 
(88, 89) This form of citrullinemia is classified as a neonatal disease with an 
approximately 100-fold elevated plasma concentration of citrulline in young children 
(90) The other type of citrullinemia is an adult-onset disease caused by a dysfunction of 
the citrin protein. This mitochondrial carrier protein is encoded by the SLC25A13 gene 
localized at chromosome 7q21.3 (91, 92) and is predominantly expressed in liver and 
kidneys (93). It is an aspartate/glutamate carrier (AGC) which is differentially expressed 
in different organs during development (94) to be afterwards predominantly expressed in 
the liver. It functions to supply aspartate to the cytosol for urea, protein and nucleotide 
synthesis by exchanging mitochondrial aspartate for cytosolic glutamate and proton, and 
transporting cytosolic NADH reducing equivalent to mitochondria as a member of 
malate aspartate shuttle essential for aerobic glycolysis (95) Although the function of the 
citrin transporter have been elucidated, it is still not known how its deficiency leads to 
the type II citrullinemia. These ornithine cycle disorders (classically known as urea cycle 
disorders or UCDs) are accompanied by the accumulation of metabolites upstream of the 
reaction catalyzed by the inactive enzyme. OCDs are characterized by the triad of 
hyperammonemia, encephalopathy and respiratory alkalosis due to accumulation of 
bicarbonate not neutralized in urea. 
b) Other arginine metabolites 
1) Proline & Glutamate 
Much of the ornithine generated by arginase outside the liver is metabolized by OAT to 
generate P5C. P5C can subsequently be utilized for the synthesis of proline and 
glutamate. In enterocytes of post-weaning pigs, proline is the major product of arginine 
catabolism, accounting for about 55% of the metabolized arginine carbon atoms (96) 
OAT deficiency accordingly leads to the occurrence of hyperornithinaemia in adult 
humans and mice (39). 
2) Creatine 
The kidney is the main organ, in which the first step of creatine synthesis, namely the 
conversion of arginine to guanidoacetate by L-Arginine:Glycine Amidinotransferase 
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(GATM) takes place. Guanidoacetate is then methylated, a reaction that primarily takes 
• 
place in the liver (S-adenosyl-L-methionineiN-guanidinoacetate methyl transferase 
(GAMT)). The resulting creatine is then phosphorylated by creatine kinase using ATP as 
phosphate donor. Creatine phosphate serves as a storage form of high-energy phosphate. 
The latter reaction is reversible such that when energy demand is high (e.g. during 
muscle contraction), creatine phosphate donates its phosphate to ADP to yield ATP. 
Both creatine and creatine phosphate are found in muscle, brain and blood (97, 98). 
3) Agmatine 
Agmatine is formed by the decarboxylation of L-arginine through arginine 
decarboxylase (ADC) in bacteria and plants. Although a putative cDNA encoding 
arginine decarboxylase has been reported (99-101), other groups have not been able to 
confirm that it actually encodes arginine decarboxylase (99, 100). One group actually 
suggested that the predicted arginine decarboxylase is an ornithine decarboxylase 
antizyme (100), It is therefore not yet clear whether the known agmatine functions such 
as activation of imidazoline receptors and the o l adrenoceptor (102-105) are also 
important as a signaling pathway of endogenous agmatine or are relevant only in a 
pharmacologic context Recently, it was reported that agmatine also acts as a blocker of 
the NMD A glutamate receptor (106) and an inhibitor of nitric oxide synthase in neonatal 
rats (107). Agmatine seems also to play a role in macrophage metabolism since both the 
putative ADC and agmatinase are modulated by both LPS and cytokines (108). 
4) Nitric Oxide 
NO, also known as endothelium-derived relaxing factor, is a naturally occurring gas that 
in the body serves as a short-lived signaling molecule with diverse functions. NO is 
important in the maintenance of vascular tone, has neurotransmitter functions in both the 
central and peripheral nervous system, and mediates cellular defense. In addition, NO 
interacts with mitochondrial systems to regulate cell respiration and to augment the 
generation of reactive oxygen species, thus triggering mechanisms of cell survival or 
death. To date, no nucleated mammalian cell has been described that does not express at 
least one of the three major NOS isoforms (109), 
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1} NO synthesis 
L-argmme n the only endogenous substrate for the nitric oxide synthases {NOS), 
Relative rate* of NO .synthesis from plasma argmme are law. In healthy adults, NO 
synthesis from plasma argmme represents only i .2% of the flux of plasma arginine (4) 
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tetrah vdn tbu fpterin iBH4i, argmme is wed for SO production 
This accounts for about half of the total NO production. The arginine necessary for the 
remaining NO production is presumably derived from intracellular sources, such as local 
arginine synthesis at sites of NO synthesis as discussed above. 
ii) NOS isoforms 
Three isoforms of nitric oxide synthase exist, namely, neuronal NOS (nNOS or NOS I), 
inducible NOS (iNOS or NOS2) and endothelial NOS (eNOS or NOS3). They all three 
have the same substrate, arginine, mid reaction mechanism but differ in their dependence 
on CV ions, as well as in their expression pattern and activities. NOS3 and NOS1 are 
constitutively expressed and activated by an elevation in intracellular Ca2 f. In contrast, 
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NOS2 is not activated by CV influx but is only expressed upon external stimulation. All 
NOS enzymes function as homo-dimers. The dimerization process of the two monomers 
for all three iso forms is dependent on the presence of the co-factors and its substrate, 
since both BH4 (l KM 12) and arginine can promote and stabilize the active dimeric 
form of all three isoforms (110s 113, 114). In addition, arginine availability has a 
regulatory function for the three NO synthases. Both arginase and NOS activity deplete 
the local arginine pool This decrease in arginine concentration causes the GCN2-
mediated phosphorylation of the eukaryotic initiation factor (eIF2a), which in turn, 
downregulates translation of NOS mRNA. Substrate availability, sensed by GCN2, a 
kinase sensitive to amino-acid deprivation in cells, therefore, represents an important 
step in the regulation of NOS activity (115 )Table 1 below shows the distribution of the 
three different isoforms of NOS in different organs. 
N0S1 
Neuronal NOS (NOS1) is a cytosolic enzyme present in central and peripheral neural 
tissues but also in skeletal muscle, epithelial cells and cells of the immune system (117) 
In neurons, constitutively expressed NOS1 is activated by agonists that increase 
intracellular Ca ion levels and enhance calmodulin binding. The NO synthesized by 
NOS1 acts as a neurotransmitter. Bound to caveolin, NOS1 is also found in skeletal 
muscle (118, 119). It is now considered as the most complex human gene yet described 
in terms of promoter diversity and alternative splicing variants (120-123). Indeed, nine 
unique exon 1 variants expressed from a unique 5'-flanking region have been observed, 
combined with elaborate splicing patterns of different exons (122). 
NOS2 
NOS2 expression can be induced in most tissues (Table 1), but due to its well-described 
role in innate immune defense in macrophages, it is also known as macNOS. Its 
expression is induced by cytokines, such as IFN-y, TNF-a and IL-1 and microbial 
products such as LPS (124, 125). The major difference compared to the two other 
isoforms is its Ca2+-in dependent activation (126). It shares 51% amino acid homology 
with NOS1 with the greatest degree of divergence in the calmodulin binding domain. 
NO produced by NOS2 has been described to have microbiocidal, antiviral, antiparasital 
and antitumoral effects (109, 126). However, aberrant NOS2 induction may be involved 
in the pathology of many chronic inflammatory diseases (asthma, arthritis, multiple 
sclerosis, colitis, psoriasis), neurodegenerative diseases, tumor development, transplant 
rejection, and septic shock (109, 127). The level of expression of NOS2 is tightly 
controlled both on the transcriptional and the translational level. Moreover, protein 
stability is influenced by TGF-p at least in some cells, where enzyme degradation 
through the proteasome is stimulated. Posttranslational modification and substrate 
availability are additional mechanisms to control enzyme activity. 
NOS3 
NOS3 is localized in the small Invaginations of the plasma membrane called caveolae. It 
is responsible for most of the vascular NO production and generates NO primarily in 
response to shear stress (66). The NO generated by NOS3 plays an important role in 
vascular smooth-muscle proliferation, platelet aggregation and extravasation of 
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leukocytes 167, 128-131) Two sources of arginine are available for SOS3 to sustain NT) 
production- the recycling of atrullme via ASS and A SI., within the cell and the uptake 
from the blood!depicted in F igure2) The relative contribution of these respective 
s ärgmine sources has so far remained unknown 
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Table 1. NOS isoform expression profile in animal tissues (adapted from (116)), 
NO and its functions 
NO functions are numerous as it can influence the activity of transcription factors and 
signaling cascades, mRNA stability and translation (109) These functions are mediated 
through cGMP, nitrosylation of proteins and peroxynitrite formation and will be precised 
in the following subchapters. 
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1 Cyclic guanosine monophosphate (cGMP) 
Many of the physiological actions of NO, including the regulation of vascular tone and 
blood pressure, prevention of platelet aggregation and inhibition of vascular smooth 
muscle proliferation, are mediated via the activation of soluble guanylyl cyclase and the 
subsequent production of cGMP (66) There are three known targets for cGMP: cGMP-
dependent protein kinase (132), cGMP-regulated phosphodiesterase and cGMP-gated ion 
channels (133). In smooth muscle cells, cGMP-dependent protein kinase phosphorylates 
the inositol 1,4,5-triphosphate receptor, leading to a decrease in Ca ion concentration 
and, ultimately, smooth muscle relaxation. The third target of cGMP, cyclic nucleotide-
gated ion channels are non-specific cation channels found in many tissues, 
2 S-nitrosylation 
S-nitrosylation is a process by which the nitric oxide group is reversibly transferred to 
cysteine sulfhydryls on proteins thereby transforming them into S-nitrothiols (134-136) 
S-nitrosylation represents a form of redox modulation with mostly an inhibitory effect on 
the function of the S-nitrosylated protein. It was discovered in red-blood cells where the 
S-nitrothiol form of hemoglobin inhibits platelet aggregation (137, 138). Interestingly, 
the enzymatic activity of ASS is also suppressed by S-nitrosylation (139) and this may 
represent a feedback mechanism to control the amount of NO produced in cells through 
substrate availability. In humans, of the five cysteine residues present in ASS, only 
cysteinel32 is S-nitrosylated, resulting in enzyme inhibition. The same kind of feedback 
regulation via S-nitrosylation was also shown both in vitro and in vivo for NOS3 (140). 
The transcription factor N F - k B that regulates the expression of numerous genes active in 
the inflammatory response, including NOS2 is also inhibited by S-nitrosylation (141). 
Moreover, nitric oxide inhibits apoptosis and inflammation by S-nitrosylation of the 
active site cysteine of caspases (142). This represents a feedback mechanism to prevent 
excessive inflammatory processes. In addition, NO has been described to regulate the 
phosphorylation of creatine to creatine phosphate by S-nitrosylation of the creatine 
kinase. 
3 Peroxynitrite 
Under sub-saturating arginine or BH4 concentrations or in the presence of NOS 
inhibitors, all three NOS isoforms are able to produce detectable quantities of superoxide 
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next to NO (143, 144). The very rapid reaction of superoxide with NO which is under 
the control of diffusion rates, results in peroxynitrite formation (145). Peroxynitrite is an 
oxidant that can react with DNA, proteins, and lipids under physiological conditions, 
leading to cellular damage and cytotoxity. In proteins, peroxynitrite attacks tyrosine 
residues, forming nitrotyrosines. In inflammatory cells, peroxynitrite activates 
cyclooxygenase and increases prostaglandin synthesis, which is associated with a variety 
of vascular diseases, diabetes, chronic inflammatory diseases, cancer, and 
neurodegenerative disorders (146). With a short half-life and a low steady-state 
concentration direct measurement of peroxynitrite in vivo is very difficult (147). 
c) Arginine in the immune system 
In order to generate an efficient immune response, T cells require the assistance of 
myeloid-derived accessory cells that make antigen available to the clonotypic T-cell 
receptor (TCR) expressed by T cells. This immune response is controlled by myeloid 
suppressor cells (MSCs), a subset of immunosuppressive myeloid cells that enter the 
lymphoid organs and peripheral tissues during immune stress. They use two enzymes 
involved in arginine metabolism to control T-cell responses: NOS2 and arginase 1 
(ARG1). The MSCs exploit the metabolism of arginine to render lymphocytes 
unresponsive to antigen stimulation. NOS2 blocks T-cell function by interfering with the 
IL-2 pathway whereas arginase 1 depletes L-Arg from the local environment, leading to 
the GCN2-mediated stress response in T-cells, resulting in a repression of the pro-
inflammatory response (148). MSCs also use another enzyme, namely indoleamine 
dioxygenase, to deplete the amino acid tryptophan with similar consequences (148). 
Classically and alternatively activated macrophages use the same arginine metabolizing 
enzymes to fulfill their different functions, defense and healing, respectively (149). The 
Th1 cytokine IFN-y, which drives the classical pathway of macrophage activation 
increases NO release through NOS2 activity and inhibits IL-4 or IL-10-driven ARG1 
activity. Alternative activation is regulated by TH2 cytokines, such as IL-4 and 11-13, and 
IL-10 and TGF0, all of which inhibit NOS2 activity and induce ARG1 (see Figure 6). 
Classically activated macrophages release pro-inflammatory cytokines leading to 
microbiocidal activity and cellular immunity. In contrast, alternatively activated 
macrophages are essential for humoral immunity and are also involved in tissue repair 
and fibrosis via the production of polyamines and proline by ARG1 (150). They play a 
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role in tolerance in pregnancy and in the gut-associated lymphoid tissue. These TH2-
driven macrophages are also involved in allergic and antiparasitic responses (151), 
d) Arginine, a building block for proteins 
Like most other amino acids, arginine is a building block for proteins. Initiation of 
protein synthesis in eukaryotic cells begins with the formation of the 43S "preinitiation 
complex" that is composed of a ternary complex of eukaryotic initiation factor 2 (eIF2) 
bound to GTP and Met-tRNAiMet associated with a small (40S) ribosomal subunit. This 
43S complex binds mRNA near its capped 5'-end, migrates downstream along the 
mRNA and, upon reaching the first AUG codon, joins with the 60S subunit to form 
the80S "initiation complex" (for a review of this "scanning mechanism", see (153)). 
Following AUG recognition, the GTP bound to eIF2 is hydrolyzed and eIF2 is released 
as an inactive eIF2-GDP binary complex. Exchange of the bound GDP with GTP is 
catalyzed by eIF2B, Once correctly positioned, the 80S ribosomal complex stepwise 
adds amino acids by in-frame translation of the mRNA in a process termed elongation. 
IL-4.IL-13 
Figure 5. Arginine metabolism in macrophages. Activated macrophages can use 
arginine in response to either inflammatory signals leading to TH1 activation or 
inflammatory signals leading to TH2 activation. NO generated in activated macrophages 
is an important cytotoxic molecule in the defense against pathogens and tumor cells 
(152) in a TH1 response. The immune effects of arginine-depletion in a TH2 response 
remain to be defined. 
IFN-
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The key steps in the elongation process are the entry of each succeeding aminoacyl-
tRNA, the formation of a peptide bond and the translocation of the ribosome with respect 
to the mRNA. Arginyl-tRNA synthetase is the enzyme catalyzing the ligation of arginine 
to it cognate tRNA, arginyl-tRNA. Arginine is incorporated whenever one of the 
following 6 codons is encountered: AGG, AGA, CGA, CGC, CGG or CGU. 
Intriguingly, there are only three amino acids that are encoded by 6 different codons, 
namely leucine, serine and arginine, whereas all other amino acids have to do with less. 
Once a stop codon is detected, specific proteins are recruited which cause the release and 
dismantling of the ribosomal complex. 
e) Arginine as metabolic regulator 
To date, three major pathways, in which arginine functions as signaling molecule, have 
been identified, namely, through its absence resulting in uncharged arginyl-tRNA, 
stimulation of protein turnover via their N-terminal arginylation, and induction of 
secretion of hormones. In addition, arginine can inhibit the activity of its own 
synthesizing enzymes ASS and ASL in some non-hepatic cell-lines (154) but this effect 
is probably caused by S-nitrosylation (section II-b-4-2). 
1) Arginyl-tRNA 
Arginine binds to its cognate tRNA (arginyl-tRNA) to allow protein synthesis. When the 
intracellular pool of arginine decreases, the concentration of uncharged arginyl-tRNA 
increases. Uncharged tRNAs bind to general control non-derepressible 2 kinase (GCN2), 
which causes a conformational change activating the kinase domain (155, 156). This 
kinase phosphorylates the a-subunit of eukaryotic initiation factor 2 (eIF2) on serine52 
(115) (Figure 6), which, in turn, prevents the recycling of eIF2 by eIF2B and blocks the 
formation of the preinitiation complex (157) (see chapter protein synthesis) and, thereby, 
general protein synthesis. Parallel to this blockade of general protein translation, 
translation of specific mRNAs is upregulated, including those for the transcription factor 
ATF4 and the cationic amino acid transporter CAT-1 (153). In this respect, arginine 
itself acts as a signaling molecule, since its decline causes a dose-dependent and 
reversible inhibition of general protein synthesis (153). Any enzyme or transporter that 
decreases local arginine concentrations can therefore induce this rather general control 
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mechanism. For example, the myeloid suppressor cells (MSCs), described above, use 
this of arginine depletion to control cell function (148). 
2) N-ierminal arginylation 
Protein arginylation, although discovered more that 40 years ago, remains poorly 
understood at the molecular level (159) It is mediated by Arg-transfer RNA protein 
transferase which transfers arginyl from tRNA to the N-terminus of proteins (160, 161) 
This post-translational arginylation is believed to be critical in mouse embryogenesis, 
cardiovascular development and angiogenesis (162). More recently, it was shown that (3-
actin is a target for N-arginylation that then inhibits actin filament clustering thereby 
regulating the actin cytoskeleton and cell motility (162), Regeneration of the central 
nervous system (CNS) following injury requires degradation of certain proteins, which is 
triggered by transfer RNA-mediated posttranslational addition of amino acids to the N-
terminus of acceptor proteins (163). Arginine is one of the most frequently added amino 
acids. This so-called N-terminal arginylation is part of the ubiquitin-dependent N-end 
rule pathway of protein degradation. In mammals, aspartate, glutamate and cysteine are 
substrates for arginylation by Arg-tRNA-protein transferases (164). . 
3) Arginine, a potent secretogogue 
Arginine is a secretatogue for growth hormone, insulin, adrenal hormones and prolactin 
(165-167). In humans, arginine administration results in a two-fold increase in plasma 
growth hormone levels (168). Growth hormone secretion from the anterior pituitary 
gland is primarily governed by growth-hormone-releasing-hormone (GHRH). GHRH 
secretion is mediated by ghrelin (169) and somatostatin (170-172). These two hormones 
have antagonist actions in the hypothalamus, ghrelin promoting the release of growth 
hormone and somatostatin blocking its secretion. Arginine may either block the release 
of somatostatin (168, 173) or induce the release of GH directly by the same mechanism 
that promotes insulin release from the islands of Langerhans (174, 175), that is, 
depolarization of the plasma membrane. There, absorption of the positively charged 
extracellular arginine into the pancreatic cells causes depolarization of the plasma 
membrane which subsequently causes an insulin burst via a Ca -mediated pathway 
(176) . 
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Amino-acid 
deprivation 
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tRNA 
ncharged 
tRNA 
General protein synthesis 
Transcription 
& translation 
ATF4 & CAT-l 
• 
Transcription of amino-
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transporting proteins and CHOP 
Figure 6. GCN2-mediated stress response. In absence of arginine binding to its cognate 
arginyl-tRNA, growwg population of uncharged tRNA causes the activation of GCN2 
kinase. The subsequent phosphorylation of the a-subunit of the eIF2 causes an arrest in 
protein translation by inhibiting the formation of the ternary preinitiation complex. 
mRNAs with special 3 '-UTRs such as the transcription factor ATF4 and the cationic 
amino acid transporter CA T-l -will be preferentially translated under these conditions. 
ATF4 then induces the transcription of other transcription factors and genes involved in 
amino acid synthesis and transport. > GCN2-activation leading to a decrease in NOS 
translation (115, 158). Interestingly, this GCN2-mediated inhibition of translation is not 
specific for arginine deprivation but rather general as indicated by its name and can be 
activated by a lack in any amino acid. 
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IV- Arginine transporters and their regulation 
1) Nomenclature of arginine transporters 
The supply of arginine to cells may become rate-limiting for enzymatic reactions that use 
arginine as a substrate. In the past decades, arginine carrier proteins were defined as 
belonging to systems y+, b0,+, B0,+ or y+L (177-179) based on functional properties such 
as ion-dependence, kinetics, substrate specificity, and regulation of activity (177) Table 
2 links these transporter groups to the genes of the solute carrier (SLC) family. 
2) Arginine transporters 
Among the different transporters that are part of the y+ group, there are the high affinity, 
Na+-independent transporters of arginine, lysine and ornithine, which are responsible for 
a major part in the arginine transport. These transporters, also known as the cationic 
amino acid transporters (CAT) are CAT-1, -2B and -3 (Table 2). These CAT transporters 
(SLC7A) have 14 putative transmembrane segments and are glycosylated. Among them, 
CAT-1 and CAT-3 are most closely related (~ 60 % identity) (182). 
The first member of the SLC7 family (mC AT-1, for mouse cationic amino acid 
transporter) was originally identified as the receptor for the ecotropic murine 
retroviruses. CAT-1 seems to be the major system y+ transporter and is expressed almost 
ubiquitously with the exception of adult liver where it is virtually absent. Expression 
levels in other tissues vary considerably. CAT-1 expression is modulated by cell 
proliferation, growth factors, cytokines and hormones (188). 
In contrast to normal cap-dependent protein synthesis that is down-regulated during 
nutrient limitation, translation of CAT-1 mRNA is increased under these conditions 
(189) and its mRNA (190) is stabilized. 
A remarkable property of CAT-1 is its ability to bind and form complexes with 
other proteins, such as NOS3 in aortic endothelial cells, which enhances the production 
of NO (191). Moreover, it was shown that CAT-1 is complexed with caveolin in 
endothelial cells (192), that is, in the same compartment where NOS3, ASS and ASL are 
present, suggesting that arginine transport and recycling are essential for NOS3 function 
(see Figure 2 above). In renal epithelial cells, CAT-1 is restricted to the basolateral 
membrane where it regulates the transport of arginine from and to these cells (193). The 
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importance of CAT-1 is reflected in the finding that homozygous CAT-1 knockout mice 
are 25% smaller than their littermates at birth, die on postnatal day 1, and suffer from 
severe anemia, whereas heterozygous littermates exhibit no apparent phenotype 
(194).CAT-2A and -2B are splice variants of the SLC7A2 gene and differ in a stretch of 
42 amino acids, CAT-2A is expressed in liver, muscle and skin and is a low affinity 
arginine transporter (177, 195), whereas CAT-2B is a high-affinity transporter, which is 
expressed in brain, lung, testis and activated T-cells (177,196). CAT-2B expression is 
co-induced with NOS2 in a wide variety of cell types (197-201) indicating that arginine 
transport capacity needs to be increased to support the elevated rates of NO synthesis . It 
was also demonstrated in vivo by generating a CAT-2 knockout mouse, that, indeed, 
CAT-2B is required to allow sustained NO production by macrophages after 
inflammatory stimuli (202). 
Plasma membrane transporters accepting arginine as substrate 
Apparent KM 
Transport Na+- for arginine 
Protein Gene system dependent (mmol/L) Ref. 
CAT-1 SLC7A1 + y no 0.10-0.16 (180) 
CAT-2A SLC7A2 ND no 3.40-3.90 (180) 
CAT-2B SLC7A2 + y no 0.25-0.70 (180) 
CAT-3 SLC7A3 y no 0.20-0.50 (181) 
CAT-4 SLC7A4 » - - (182) 
y+ L AT2+ SLC7A6 y L yes 0.12±0.035 (182, 183) 
y ' LAT11 SLC7A7 y+L no/yes 0.091/0.34 (182,184) 
B0,+AT* SLC7A9 b0,+ no - (182) 
rBAT SLC3A1 no 0.08-0.20 (185, 186) 
4F2hc SLC3A2 +T y L no 0.12-0.34 (183, 184) 
ATB°'+ SLC6A14 B 0,+ yes "h CI" 0.10-0.15 (187) 
32 
V- Arginine-related proteins and their transgenic 
models 
In order to elucidate the metabolic fates of arginine, several transgenic animal models 
were developed in the last 3 decades. A list of some of the transgenic models related to 
arginine metabolism is given in Table 3. 
gene phenotype ref 
Ass 
1 -2 days postnatally lethal; hyperammonemia, 
hypercitrullinemia 
(203) 
Asl 
~ 48 hours postnatally lethal;hyperammonemia, 
hyperargininosuccinemia, hypoargininemia 
(204) 
Arginase-I 
-10 days postnatally lethal; hyperargininemia, 
hyperammonemia 
(10) 
Arginase-II Viable, only hyperargininemia (10) 
Cat-1 
1 day postnatally lethal; severe anemia & 25% smaller than 
littermates 
(194) 
Cat-2 
Healthy, fertile; >90% decreased NO production & 95% 
decreased arginine uptake by macrophages 
(202) 
Nosl Sphincter dysfunction and hypertrophy (205) 
Nos3 Hypertension (206) 
Nos2 Less resistant to infections (207) 
Citrin No phenotype (208) 
Table 5. List of some constitutive KO mice for arginine-associated enzymes or 
transporters and their observedphenotypes. 
These animal models were often used to study human arginine-related pathologies. 
Although humans and mice share homologous genes, knocking out a gene in the mouse 
does not always result in the same phenotype as observed in humans. The mitochondrial 
carrier, citrin is an example. Citrin deficiency in humans causes type II citrullinemia (93) 
but the citrin knockout mouse has no phenotype. On the other hand, inactivation of ASS 
or arginase 1 yield the same phenotype in humans and in mice. 
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VI- Synopsis and scope of thesis 
Arginine is a precursor for proteins, creatine and the signaling molecules agmatine 
and nitric oxide. Arginine is also a secretagogue for growth hormone, insulin, glucagon, 
and prolactin. Arginine deficiency acts as a signal, controlling general protein synthesis 
via activation of the stress kinase GCN2. Furthermore, arginine is an intermediate of the 
ornithine cycle. This thesis intends to identify how the availability of arginine controls 
organ development and function by using genetically modified mice. 
The suckling small intestine of the mouse was identified as a producer of arginine from 
proline. This capacity is lost after weaning, when ASS and ASL are no longer expressed. 
To investigate the relevance of this transient biosynthetic capacity, a murine model of 
chronic arginine deficiency was developed by overexpression of arginase I in the 
enterocytes of the small intestine (the "F/A" mice). The deficiency of arginine caused 
severe retardation in general growth in these mice. In Chapter II we characterized this 
mouse model in vivo in combination with several in vitro models. We show that arginine 
deficiency inhibits the release of the growth hormone from the pituitary gland and 
ubiquitously activates the stress kinase GCN2 leading to a general shut-down of protein 
synthesis. Our findings demonstrate the signaling properties of arginine on the growth 
hormone axis and on the protein synthesizing machinery, 
Overexpression of arginase may, however, suffer from a lack of specificity. Since 
arginase is a very active enzyme, overexpression of arginase in the gut may transform 
this organ into an arginine sink, meaning that not only newly synthesized arginine is 
degraded but also dietary arginine and plasma arginine are broken down excessively. To 
specifically investigate intestinal arginine synthesis but also synthesis in any other tissue 
where arginine metabolism is important, we created a conditional knock out mouse for 
argininosuccinate synthetase (ASS). The lethal effect of total inactivation of ASS but 
above all the ability to specifically inactivate the gene in a given tissue led us to opt for 
conditional inactivation of the gene. To date, 50 different mutations in the human ASS 
gene have been identified, some of which result in total inactivation of the enzyme (209). 
The absence of exon 7 or 13 in ASS mRNA is a consequence of abnormal splicing. In 
the case of exon 13 this is caused by a single base change in the intron region IVS-13+5 
(a transition of G to A at the 5th nucleotide position within the 5' splice cleavage site). 
Exon 13 deletion leads to a reduction of ASS activity to <0.5 % of controls (210). As the 
ASS enzymatic activity is completely eliminated by the absence of exon 13, deletion of 
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exon 13 represents the perfect choice to generate a conditional knock-out mouse with 
specific excision of this particular exon. 
To specifically inactivate a gene in vivo one needs to target the gene in mouse 
embryonic stem (ES) cells (211). Tissue-specific gene inactivation is achieved by 
excision of the critical region of the gene in the tissue of interest. In order to obtain the 
specific excision, the critical region is flanked on either side with a small recognition 
sequence for a certain recombinase enzyme. This recombinase enzyme identifies the 2 
recognition sequences and eliminates the flanked region. Tissue-specificity of the 
recombinase is achieved by using a tissue-specific promoter to drive expression of the 
recombinase. Nowadays, the two mostly widely used recombinases are FLP recombinase 
from the yeast 2-micron episome and Cre recombinase from the coliphage PI (212). A 
comparative biochemical analysis showed that Cre and FLP have temperature optima 
concordant with their original hosts -the temperature optimum of Cre is at 37°C and the 
temperature optimum of FLP is at 30°C (212), making Cre the recombinase of choice in 
most applications in mice. Chapter III describes how we succeeded in generating 
conditional knock-out mice for proteins regulating intracellular arginine concentration, 
viz. ASS, arginase 1 and the major arginine transporter CAT-1, This chapter is a trouble-
shooting guide for the generation of a conditional KO mouse. 
It is believed that perinatal intestinal arginine synthesis compensates for insufficient 
arginine concentrations in maternal milk to ensure appropriate development. To test this 
hypothesis, we inactivated arginine synthesis in the gut by specifically inactivating ASS 
expression in the enterocytes of the small intestine. The characterization of these mice is 
reported in Chapter IV. ASS protein was totally absent in the mouse enterocytes but was 
normally present in all other tissues and cell types. In contrast to mice overexpressing 
arginase 1 in the enterocytes, mice deficient of ASS in their enterocytes showed no 
major phenotype. Absence of intestinal arginine biosynthesis leads to an increased 
production of citrulline by the gut and an increased hepatic absorption of arginine. 
Furthermore, arginine synthesis in the kidneys was increased. In the absence of arginine 
synthesis in the perinatal small intestine, other organs can apparently compensate for the 
resulting arginine shortage. By comparing the two arginine-deficient mice described in 
Chapter II and IV, we were able to demonstrate that intestinal arginase overexpression 
indeed renders the gut an active arginine sink. This change in function of the gut causes a 
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global reduction in circulating arginine, which in turn causes the phenotypes described in 
Chapter II. 
Arginine is not only important for development and growth but it also plays a role in 
vascular function as the precursor for nitric oxide. Endothelial cells are the sites of nitric 
oxide production. ASS together with argininosuccinate lyase (ASL) co-localizes with 
NOS3 in these cells. In mice in which ASS, arginase 1 or CAT-1 were specifically 
inactivated in the endothelium, we were able to preliminarily characterize the importance 
of local arginine recycling, arginine import, and arginine catabolism for endothelial 
function (Chapter V). 
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Summary 
Transgenic ""F'AZ" mice ovcrexprcss argina.se-I in their entemcvtev Suckling I A 2 mice 
develop a syndrome (hvpoargminernia, reduced hair and muscle growth, impaired H-cell 
maturation) that resembles IGF-1 deficiency We hypothesized that the syndrome results 
from an interaction of the growth-hormone'IGI -I axis and the amino acid-sensing 
GCN2 stress-kina.se pathway. Cells were cultured in different argininc concentrations, 
F-'A2 and Gcn2 mice were studied. Strcss-kinase activation was assayed as cIF2a 
phosphorylation, and induction of ATF4 and CHOP expression. Arginine deficiency 
inhibited GH secretion in pituitary' cells. In F/A2 mice, pituitary GH content was 2,5-fold 
elevated, whereas liver and muscle Igf-t inRNA content was K-10-fold decreased. CiH 
supplementation increased tissue Igf-1 mRNA 3-fold m wild-type and F/A2 mice, but 
did not enhance growth. In vitro, the Ckn2 pathway was activated at < 50p.M arginine, 
whereas IGF-1 enhanced myoblast differentiation at >25jaM arginine only. In 1-day-old 
F/A2 mice, circulating and muscle arginine levels were 4,5-fold decreased and the Gcn2 
pathway was activated in all organs investigated. Gcn2-deficient F/A2 mice did not 
increase ATF4 and CHOP expression, and died shortly after birth, demonstrating that 
GCN2 mediated the stress-kinase response. Conclusion: The arginine-deficiency 
syndrome develops due to GCN2 activation, suppression of GH sec ret ion, and 
interference with the growth-stimulatory effects of IGF-1. 
52 
Abbreviations: 
F/A2 mice overexpressing arginase-I under control of Fabpi promoter 
GCN2 general control non-derepressible 2 (Eif2ak4) kinase 
GH growth hormone 
IGF-1 insulin-like growth factor-1 
ND neonatal day 
CI confidence interval 
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Introduction 
Arginine is a substrate for the synthesis of proteins, ornithine, creatine, agmatine and 
nitric oxide (1). In addition, it functions as a secretagogue for hormones, such as growth 
hormone (GH) and insulin (2-4). Under normal conditions, endogenous arginine 
synthesis in adult mammals suffices to sustain daily requirements (5). A dietary source 
of arginine may, however, become necessary when demand increases under anabolic or 
catabolic conditions (5). For this reason, arginine is considered a conditionally essential 
amino acid. 
The enterocytes of the small intestine of suckling rodents express all enzymes 
necessary to synthesize arginine (6-9), but not the major arginine-catabolizing enzyme 
arginase (10). To examine the function of intestinal arginine synthesis, a transgenic 
mouse model that overexpresses arginase-I in the enterocytes of the small intestine was 
produced (11-13). During the suckling period, these "F/A2" mice suffer from a selective 
deficiency of circulating arginine levels (which decline to -30% of controls), reduced 
growth of hair and skeletal muscle, and inhibition of B-cell maturation (11). Thus far, we 
have been able to rule out deficiency of creatine or polyamine production, and ADP-
ribosylation of proteins as causes of the described symptoms (11-14). Furthermore, mice 
that are deficient in all three nitric-oxide synthases do not show the same phenotype as 
F/A2 mice in the suckling period (15) (and Tsutsui, personal communication). This 
leaves two functions of arginine as likely candidates to account for the highly 
characteristic phenotype of arginine deficiency in suckling mice, viz. its role as a 
building block in protein synthesis and as a secretagogue of hormones. 
Aminoacyl-tRNA synthetases catalyze the charging of tRNAs with their 
corresponding amino acids. Whenever the intracellular concentration of arginine 
decreases below 10-20|iM, the charging process of its corresponding tRNA slows down 
and the concentration of uncharged tRNA increases (16). Uncharged tRNAs bind to the 
"general control non-derepressible2" kinase (Gcn2/Eif2ak4), which then phosphorylates 
the a-subunit of the eukaryotic initiation factor 2 (eIF2a) (17) and thus initiates the 
"integrated stress response" (18,19). This response causes the arrest of 5' cap-dependent 
protein synthesis and an increased expression or activation of transcription factors such 
as ATF2, ATF4 and CHOP (20), which induce the transcription of genes necessary for 
amino-acid synthesis and transport. GCN2 is expressed in almost all mouse tissues and is 
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required for the adaptation to amino-acid deprivation (21). In the present study, we 
addressed the question whether the integrated stress response is activated in arginine-
deficient F/A2 mice. 
The most remarkable phenotypic features of F/A2 mice, namely impaired 
muscle and hair growth and impaired B-cell maturation, are all affected by insulin-like 
growth factor-1 (IGF-1) (22-26). Because the growth hormone (GH)/IGF-1 axis plays a 
predominant role in growth and development (27) and because arginine is a potent GH 
secretogogue (28), we also investigated the function of the GH-IGF-1 axis in F/A2 mice. 
Our findings show that arginine deficiency in the neonatal and suckling period activates 
the integrated stress response and interferes with GH/IGF-1 signaling. 
Methods 
Cell cultures 
Myoblasts of the murine skeletal muscle cell line C2C12 (ATCC # CRL 1772, 
Manassas, VA) were cultured on gelatinized Petri dishes (0.1% gelatin in PBS) in 
Iscove's Modified Dulbecco's Medium (IMDM; Gibco,The Netherlands), 50U/mL 
penicillin, 50^g/mL streptomycin (Gibco), lx Glutamax (Gibco), 10% fetal bovine 
serum (Gibco). Cultures were grown to 80% confluence. To induce myogenesis, fetal 
bovine serum was replaced by 2% heat-inactivated horse serum ("differentiating 
medium"; Gibco). In some experiments, the arginine concentration in differentiating 
medium was varied and/or lOng/mL insulin-like growth factor-1 (IGF-1) was added. The 
rat pituitary cell line GH3 (ATCC # CCL-82.1) was also grown in IMDM. For the 
primary B-cell culture, the IL-7 secreting mouse myeloma cell-line J558-IL7 was 
cultured on ST2 medium (DMEM; Gibco, 10% FBS, lOOU/mL penicillin, 100^ig/rnL 
streptomycin, 2mM Glutamax). Throughout the culture period, the cells were 
continuously shaken and IL-7-conditioned medium was harvested after 4 days. The ST2 
cells, used as feeder cells for the B cells, were irradiated with a Tandentron irradiator 
r 
(IONEX) with 20 gray. The cells were then seeded at a density of 3*10 cells/cm . Mice 
were sacrificed at 2 weeks after birth. The bone marrow from the femur and tibia of the 
hind legs was removed by flushing the marrow with 2mL 2%» FBS in PBS via a 25-
gauge needle. After centrifugation at 1,000 rpm (250g) for 5 min at 4°C, the pellet was 
washed with PBS and centrifiiged. The pellet was re-suspended in ice-cold erythrocyte-
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lysis buffer (ImM NH4HC03, 114mM NH4C1) and incubated on ice for 3 min. The cell 
solution was diluted 10 times with ice-cold PBS and centrifuged at 1,000 rpm for 5 min 
at 4°C. The pellet containing B-cells was re-suspended in B-cell medium (IMDM 
containing 2 mM Glutamax, 0.4mM arginine, 36mM NaHC03) 50pM 
mercaptoethanol, lOOU/mL penicillin, 100|ig/mL streptomycin, lOOjig/mL gentamycin, 
5% foetal bovine serum and 2% IL-7 (ST2) conditioned medium) and seeded on an 
r A 
irradiated feeder layer of ST2 cells at a density of 3* 10 cells/cm . Cells were counted 
using a Neubauer cell counter. 
Growth-hormone ELISA 
GH3 culture media were harvested and stored at -80°C until used, GH3 cells were 
washed, trypsinized, washed again, sonicated on ice and kept at -80°C until used. The 
GH content was measured in 50^L of 1 Ox-diluted medium or in sonicated cell lysates, 
using a one-step sandwich-type immunoassay with the ACTIVE Mouse/Rat Growth-
Hormone ELISA kit (Diagnostic Systems Laboratories, Inc., Texas, USA). The 
absorbance was measured at 450nm. The quantity of GH in each sample was based on a 
standard curve. 
Myogenic differentiation in C2C12 cells 
The myogenic index (M.I.) was determined on May-Grunwald-Giemsa-stained cells 
(Sigma, Saint Louis, MO). To determine muscle creatine kinase (CK) activity, cells were 
washed twice, lysed in 0.5% Triton X-100, and scraped off the dish with a rubber 
policeman. Lysates were centrifuged for 2 min at 16,000g and the supernatant was stored 
at -80°C. CK activity was determined using the CK (UV-RATE) Stanbio (Texas, USA) 
kit (# 0910-206). Protein was measured with the Bradford method (43). 
Transgenic mouse lines and animal husbandry 
Transgenic mice that overexpress arginase-I in their small-intestinal 
enterocytes (F/A2 line(l 1)) were bred hemizygously. Gcn2_/" mice (38) (129SvEv 
background) originated from the colony of D. Ron (New York, NY). All mice were 
housed in humidity- and temperature-controlled rooms on a 12-hour light/12-hour dark 
cycle with food and water ad libitum. Control animals were littermates of the 
experimental animals. Animal studies were reviewed and approved by the committee for 
animal care and ethics of Maastricht University (DEC). 
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GH administration 
Litters were limited to 5 animals on neonatal day 1 (ND1) and weighed daily. Starting on 
ND3, 3mg/kg body weight of human recombinant growth hormone (hrGH; Humatrope, 
Lilly, kindly provided by Dr. Gerver, Dept. of Endocrinology, Academic Hospital 
Maastricht) (44) was administered subcutaneously in 250jliL of vehicle twice daily from 
day 3 to day 21 postnatal. Control animals were injected with vehicle alone. 
Blood and tissue collection 
Animals were sacrificed by decapitation. Blood was collected into heparin-containing 
tubes and centrifuged at 2,000g for 5 min at 4*C. 80JIL of plasma was added to 6.4mg of 
lyophilized sulphosalicylic acid, vortexed and stored at -20°C. For amino acid 
measurements, the tissues were homogenized with silica mini-beads in 0.33M 
sulphosalicylic acid. Tissues were collected at NDO, ND10, ND17 and ND21. Amino-
acid concentrations were determined by HPLC, as described (45). Tissues for protein 
and mRNA analysis were isolated, snap frozen in liquid nitrogen and stored at -80°C. For 
histological analysis, tissues were fixed in 4% buffered formalin immediately after 
isolation and embedded in paraffin. 
RNA extraction and cDNA synthesis 
The TRI Reagent (Sigma) was used for RNA isolation from cells and tissues. RNA 
integrity was assessed by denaturing gel electrophoresis and purity by the ratio of the 
optical density at 260 and 280nm. RNA concentration was determined with a NanoDrop-
ND1000 spectrophotometer (Isogen Life Science BV, The Netherlands), ljig of total 
RNA was used for cDNA synthesis with the iScript cDNA synthesis kit (Bio-Rad, CA, 
USA). 
Real-time quantitative PCR 
The primers and their characteristics are given in Table 1. PCR was performed using 
qPCR Mastermix Plus for SYBR Green I (Eurogentec, Belgium). cDNA samples for 
mRNA determination were diluted 60-fold before use and those for 18S rRNA 200-fold. 
The reaction volume was 25 pL. CHOP, ATF-4 and 18S RNA levels were measured 
using the RNA TaqMan® Gene Expression Assays (ABI Applied Biosystems, USA), 
Primary fluorescent data were exported and analyzed with the Lin-Reg Analysis program 
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(46). Between-session variations in replicate experiments were corrected using factor 
correction (47). 
Western blots, immunostaining and immunofluorescence 
For Western-blotting assays, 1 OOjxg of protein were loaded per lane. Antibodies used are 
described in Table 2, Antibody binding was visualized using the Super Signal West 
Femto Maximum Sensitivity Substrate (Pierce, USA). For detection of the 
phosphorylated and unphosphorylated forms of eIF2a, the Odyssey Infrared Imaging 
system (Li-cor Bioscience, UK) with a two-color detection program was used. 
For immunostaining, 5jim sections of paraffin-embedded tissues were prepared. After 
deparaffination, the sections were pre-incubated with Teng-T (lOmM Tris (pH=7.6), 
5mM EDTA, 150mM NaCl, 0.25% gelatin, 0.05% Tween-20)/10% normal goat serum 
(NGS) for 30 min, followed by an overnight incubation with the primary antibody 
diluted 1:100 in Teng-T/10% NGS. Slides were then washed with PBS and incubated 
with Teng-T/10% NGS for 15 min followed by 90 min incubation with the secondary 
antibody (Table 2) in Teng-T/10% NGS). The slides were washed and incubated with 
alkaline phosphatase substrate (NBT/BCIP tablets; Roche) at 37°C. Staining was stopped 
by washing with Millipore water, followed by dehydration in graded ethanols and 
UltraClear (Mallinckrodt Baker BV, The Netherlands). Coverslips were mounted using 
UltraKitt Histograde (Mallinckrodt Baker). Digital images of the sections were captured 
with a Sony 3CCD camera mounted onto a Leica DM RXA microscope. The images 
were analyzed with the Leica Quantimet 500 Image Analysis System, v3.2, as described 
(48). For immunofluorescence studies, ATF4, eIF2a, and [pS51] phospho-specific 
eIF2a antibodies, in combination with fluorescently labeled secondary antibodies, were 
used (Table 2). For nuclear staining, Hoechst 33258 (Molecular Probes, The 
Netherlands), diluted 1: 10,000 in 90% glycerol, was used. Pictures were captured using 
a Leica CCD camera and the fluorescent staining intensities were quantified using the 
QWin program (Leica). All results shown are representative of at least 3 separate 
experiments and 3 individual animals. 
Statistical analysis 
The significant difference for one variable between two distinct groups was analyzed 
using an unpaired student t-test with a P-value given. For more complex analyses of 
58 
significance for variables with different controls, each gene was analyzed using Gaussian 
linear regression including 18S as housekeeping gene. When appropriate, additional 
explanatory variables such as tissue type, strain, and time were included in the model. 
The treatment group was then added to the model. Finally, interactions among the 
included variables were considered. The inference criterion used for comparing the 
models is their ability to predict the observed data, i.e. models are compared directly 
through their minimized minus log-likelihood. When the numbers of parameters in 
models differ, they are penalized by adding the number of estimated parameters, a form 
of the Akaike information criterion (AIC) (49). If the most likely model contains the 
treatment effect, the fold change (FC) representing the ratio between the variable of the 
treated group and the same variable for the control can be computed as well as its 95% 
confidence interval (CI). 
Results 
Arginine deprivation blocks growth-hormone release 
The phenotype of F/A2 mice is compatible with a deficiency of GH and IGF-1, We, 
therefore, investigated the GH content in the somatotropes of the pituitary gland 
by quantitative immunohistochemistry (Figure 1A). The somatotropes of 3-week-old 
homozygous F/A2 mice contained 2.5-fold more GH than those of their wild-type 
counterparts (Figure IB). The somatotropes from hemizygous mice had an intermediate 
GH content, indicating a correlation with the degree of arginine deficiency (11,13). 
The rat pituitary cell line GH3, which produces GH (29,30), was then used to assess the 
direct effects of arginine on GH production and secretion. GH content in the GH3 cells 
was assessed by quantitative immunohisto chemistry (Figure 1C and D) and ELISA 
(Figure IE). Both assays showed that, after 24 hours of culture in the presence of 0 -
200jiM arginine, the cellular GH content decreased from ~50pg to ~25pg GH per cell at 
OjnM and 200|iM arginine in the medium, respectively (Figure IE). This 2-fold decrease 
in tissue GH content was accompanied by a 1.5-fold increase in concentration of GH in 
the medium, revealing a pronounced effect of arginine on GH secretion. After 72 hours, 
the arginine-dependent GH secretion profile was similar to that observed after 24 hours 
(not shown). These data show that below 50pM ambient arginine GH secretion is 
reduced. 
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Figure 1. Detection of growth hormone in somatotropes of 21-day-old-mice and in GH3 
cells. Panel A, leftside: Sections ofpituitary glands of 21-day-old homozygous F/A2 
mice (F/A2tg/tg), hemizygous F/A2 mice (He; F/A2tg/-)t and wild-type (WT; F/A2-/-) 
littermates were stained for the presence of growth hormone (GH). Bar: 5pm. Panel A, 
right side: Optical density (OD) in GH-positive cells as measured with the QWin 
program (mean ± SEM; n-3 mice per genotype; sigriificance: wild-type vs. hemizygotes: 
P = 0.009 (unpairedstudent's t-test); hemizygotes vs. homozygotes: P ~ 0.02). Panel C: 
The pituitary cell line GH3 was cultured in the indicated arginine concentrations for 24 
hours. Left row: DAPI-stained nuclei; right; purple-stained row: the same GH3 cells 
after staining for the presence of GH. Bar: JOpim. Panel D: Quantification of GH-
staining intensity with correction for the number of cells using the DAPIfluorescence. 
The intensity of immunostaining decreased with increasing arginine concentrations in 
the medium with a half maximal staining intensity at ~3 5pM arginine. Panel E: Gil 
content in GH3 cells and in the medium as quantified with ELISA (mean of three 
experimentst ± SEM). Intracellular GH content decreased with increasing arginine 
concentration in the medium, whereas GH concentration in the medium increased, 
indicating that arginine induces GH secretion. 
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Figure 2. The effect of GH treatment on growth, and on GH-receptor and Igf-1 
expression in suckling F/A2 mice. Panel A: Change in body weight of F/A2 mice and 
their wild-type littermates during treatment with GH (twice daily 3mg hrGHfkg body 
weight subcutaneously) between postnatal day 3 and day 21 (n~6 animals per genotype). 
F/A2 mice show a lower growth rate compared to wild type mice. Injection of GH had no 
effect on the growth rate in either wild-type or F/A2 mice. Panel B: Expression of the 
GH receptor in liver. Total RNA from the liver of 0-, 10- and 21-day old wild-type and 
F/A2 mice was quantified by RT-PCR. NC: negative control Both wild-type and F/A2 
mice expressed comparable levels of GH-receptor mRNA. Panel C: Quantification of 
Igf-1 mRNA in liver and muscle of 17-day-old mice. Igf-1 mRNA levels in both tissues 
were ^11-fold higher in wild-type than in homozygous F/A2 mice (CI: 8.2-14.3). 
Growth-hormone injections induced a 2.5-fold increase in Igf-1 mRNA in wild-type 
tissues (CI: 1.9-3.3) and an 8-fold increase F/A2 tissues (CI: 6.2-10.2). Data represent 
the mean ± SEM of 3 experiments. 
The GH/IGF-1 axis is functional but repressed in F/A2 mice 
As early as ND3, F/A2 mice can be distinguished from their wild-type littermates by a 
lower body weight(l 1). To assess whether the typically hypomorphic tissues of F/A2 
mice (myocytes, hairs, and B-cells (12)) respond to GH treatment, the mice were 
injected subcutaneously twice daily with 3mg/kg human recombinant (hr)GH between 
day 3 and day 21 after birth. Figure 2A shows that the growth rate of vehicle-treated 
F/A2 mice (control) was -50% of that of wild-type mice. Treatment with rhGH did not 
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change the growth rate of either wild-type or F/A2 mice. GH action is mediated by GH 
receptors (GHR) and results in the synthesis and secretion of IGF-1 in target tissues. 
Figure 2B shows that GHR mRNA is equally expressed in ND1, ND10 andND21 wild-
type and F/A2 livers. To assess the functionality of the GHRs, Igf-1 mRNA levels were 
quantified in liver and muscle of GH-treated and control mice (Figure 2C). 
In both tissues, Igf-1 mRNA levels were decreased 8-10-fold in F/A2 relative 
to control mice. rhGH injections increased Igf-1 mRNA 8-fold in F/A2 liver and muscle 
as compared to 2.5-fold in wild-type liver and muscle. These observations show that 
F/A2 mice suffer from low tissue IGF-1 levels, which respond strongly to GH 
stimulation, indicating the presence of fully functional GHRs. 
Nevertheless, absolute IGF -1 levels remain much lower in GH-supplemented F/A2 than 
in wild-type animals. The data shows that muscle is quantitatively more affected than 
liver. 
Arginine is essential for muscle development 
To investigate the role of arginine during muscle growth and development, C2C12 
myoblasts were cultured in both growth and differentiation medium in the presence of 
different concentrations of arginine (Figure 3). Figure 3 A and B shows representative 
pictures after 4 days of myogenic differentiation in the absence or presence of arginine 
(200jiM), respectively. Both the myogenic index (the fraction of nuclei residing in cells 
containing three or more nuclei; Figure 3C) and the cellular concentration of the late 
differentiation marker creatine kinase-M (CK; Figure 3D) increased with increasing 
arginine concentration to plateau at -50[xM arginine. Myogenic differentiation is, 
therefore, clearly dependent on arginine availability, with a half-maximal effect at 
~20|iM arginine in the medium. 
Arginine deficiency induces the integrated stress response in vitro 
Amino-acid deficiency can activate the GCN2 stress-kinase pathway (31). The first step 
is the phosphorylation of translation factor eIF2a (32). We, therefore, investigated 
whether eIF2a becomes phosphorylated in arginine-deprived myocyte cultures. C2C12 
cells were grown to 80% confluence in standard growth medium and were then deprived 
of arginine. Western blots with phospho-specific eIF2a antibodies revealed that eIF2a 
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was phosphorylated immediately after arginine deprivation and remained phosphorylated 
for at least 2 hours (Figure 4A). 
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Figure 5. The effects of arginine on myogenic differentiation. C2C12 myoblasts were 
cultured for 4 days in differentiation medium containing 0-200[iM arginine. Panel A: 
Culture grown in the absence of arginine (left column) and in the presence of200pM 
arginine (right column), Bar; 50pm. Cells were stained with May-Grunwald-Giemsa, 
Panel B: Myogenic index (number of nuclei in myotubes as a fraction of the total number 
of nuclei; mean ± SEM of 5 experiments) in cultures shown in panel A. The formation of 
myotubes is arginine-dependent. Panel C; Dependence of the late myogenic 
differentiation marker creatine kinase on ambient arginine concentration (mean ± SEM 
of 3 experiments). 
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Figure 4. Arginine deficiency activates the integrated stress response. Panel A: Western 
blot of C2C12 cell extracts cultured for the indicated times in 0 or 200pM arginine. Top 
two panels: total eIF2a(36 kDa); middle two panels: p51-phosphorylated eIF2a (no 
phosphorylated eIF2 a was detected in the presence of arginine (left column)); bottom 
panels: superimposition of top and middle panels (phosphorylated elF2a colocalizes 
with total eIF2a (right column)). Data shown are representative of 3 Western blots. 
Panels B and C: Dependence of ATF4 (panel B) and CHOP mRNA expression (panel C) 
on ambient arginine concentration in C2C12 (left Y-axis) t and GH3 cells and B~ 
lymphocytes (right Y-axis). Values were correctedfor the concentration of 18S rRNA. 
TheATF4 mRNA concentration was only increased in the total absence of arginine 
(panelB); ATF4 levels were -3.5-foldhigher in C2C12 than in GH3 cells (CI: 2.2-
5.3). The CHOP mRNA was reduced to basal levels at 50/jM, with CHOP levels being 
~3-fold higher in C2C12 than in GH3 cells (CI: 1.5-6.3). Data represent the mean ± 
SEM of 3 experiments. 
Phosphorylation of eIF2a induces the accumulation of the transcription factors ATF4 
and CHOP. C2C12, GH3 and mouse primary B lymphocytes were cultured for 24 hours 
in the presence of varying concentrations of arginine (Figure 4B and C) before ATF4 
and 
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Figure 5, The stress-kinase pathway is activated in the F/A2 mice. Panel A: Sections of 
liver (L), muscle (M) and small intestine (G) of a 1-day-old F/A2 mouse and a wild-type 
littermate stainedfor the presence of total eIF2a (green) and phosphorylated eIF2a 
(red). Phosphorylated eIF2a was only expressed in F/A2 mice (top three panels of the 
right column). NEG: incubation without primary antibody. Representative for n~3 
animals per genotype. Panel B: ATF4 mRNA concentration in skeletal muscle (M), liver 
(L) and small intestine (G) of I- and 21-day-old F/A2 and wild-type mice, after 
correction for 1SS rRNA content. The ATF4 mRNA content in F/A2 muscle of 1-day-old 
mice wot ~3.5-fold higher than in wild-type muscle (CI: 2.5-4.5). Panel C: CHOP 
mRNA concentration was ~ 6-fold increased in muscle, liver and gut of 1-day-old F/A2 
compared to wild-type mice (CI: 4.3-8.8), At 21 days of aget CHOP mRNA 
concentration was still 4-fold increased (CI: 2.9-6.0). Data represent the mean ± SEMof 
8-12 mice per genotype. Panel D: Arginine concentration in muscle, liver and small 
intestine of 1- and 21-day-old mice. At Dl, arginine concentration was 3-fold lower in 
the muscle of the F/A2 mice compared to the controls (P= 0.01; unpaired t-test). At D21, 
muscle arginine concentration in F/A2 mice had increased 4.5-fold over that at Dl (P= 
0.05). 
CHOP mRNA levels were determined. In C2C12 and GH3 cells, ATF4 mRNA was >5-
fold higher when the cells were kept in arginine-free medium than when > 12.5jaM 
arginine was present. The dependence of ATF4 mRNA on the concentration of arginine 
in the medium was identical for the 2 cell lines, but C2C12 cells expressed ~3.5-fold 
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more ATF4 mRNA than GH3 cells. The response of CHOP mRNA expression to 
arginine deprivation was identical for the three cell lines with C2C12 cells expressing 3-
fold more CHOP mRNA than the GH3 and the B cells. The CHOP mRNA level 
gradually decreased with increasing ambient arginine and reached a baseline at 50}iM 
arginine. These data reveal that the integrated stress response is induced at arginine 
concentrations in the medium below 50pM. The data also confirm that CHOP mRNA is 
a more sensitive marker for the activation of the stress response than ATF4 mRNA.The 
stress-kinase pathway is activated in F/A2 mice 
Based on the findings in vitro, we determined the activation of the integrated 
stress response in F/A2 mice in vivo by staining sections of ND1 liver, muscle, and small 
intestine for the presence of total and phosphorylated eIF2a (Figure 5A). All tissues 
tested expressed eIF2a in both wild-type and F/A2 animals, but the phosphorylated form 
of eIF2a was only demonstrable in F/A2 mice. 
We then measured ATF4 and CHOP mRNA levels in liver, small intestine and 
muscle of ND1 and ND21 mice. A significant 3.5-fold upregulation of ATF4 mRNA 
was found in ND1 muscle (Figure 5B), but ATF4 mRNA levels were not significantly 
different from wild-type animals in the other two tissues. At 21 days, there was no 
difference in ATF4 expression in any of the tissues investigated. CHOP mRNA levels 
were significantly elevated in all F/A2 tissues investigated at ND1 and at ND21 (Figure 
5C), but the difference at ND1 was 3-4-fold that at ND21. 
We measured the tissue concentration of arginine in the three target tissues in 
1- and 21-day-old mice (Figure 5D). Interestingly, a significant 4.5-fold lower arginine 
concentration was found in F/A2 than in control muscle (Figure 5D), the only tissue that 
also showed induction of ATF4 mRNA, while the local arginine concentrations in liver 
and gut were 2-fold lower in F/A2 than in wild-type mice. The low concentration of 
arginine in the liver relative to the intestine can be ascribed to the high concentration of 
the urea-cycle enzyme arginase-1 in the liver. At 21 days, the concentration of arginine 
in F/A2 muscle had increased 2-fold relative to that at 1 day after birth and was no 
longer different from that in controls (Figure 5D). However, the concentration of 
arginine in liver and gut remained 2-fold lower in F/A2 compared to wild-type mice. In 
these newly weaned mice, arginine levels in the liver declined 3-fold and that in the gut 
even 10-fold relative to that of in neonatal mice, probably because of further maturation 
of the urea cycle in the liver. 
Phosphorylation of eIF2a induces translation of ATF4 (33). We determined ATF4 
protein levels in muscle of ND1 mice by Western blot analysis (Figure 6 A). All muscles 
of F/A2 mice showed the expected 38kDa band (bold arrow in Figure 6A) and a much 
weaker band at ~50kDa (arrow), whereas these bands were absent in wild-type mice. A 
much weaker band of ~47kDa was present in both F/A2 and wild-type muscle. The 
~47kDa and ~50kDa bands may correspond to the ubiquitinated forms of ATF4 (34). 
Because of the apparent specificity of the ATF4 antiserum, we stained whole-body 
sagittal sections of ND1 mice immunohistochemically for the presence of ATF4 protein 
(Figure 6B). Quantification of the optical density of the staining signal revealed -4-fold 
higher levels of ATF4 protein in most organs of F/A2 mice when compared to wild-type 
animals (Figure 6C), but in the brain, only a 2-fold difference was found. Together, these 
data show that the stress-response pathway is strongly activated in neonatal F/A2 mice. 
This activation persists to ND21, albeit that basal expression in wild-type control mice 
did increase. 
Activation of the stress-kinase pathway coincides with inhibition of IGF-l signaling 
To test whether the activation of the integrated stress response by arginine deficiency 
inhibits IGF-l-mediated signaling, C2C12 cells were cultured in the presence of 
different arginine concentrations with or without IGF-l for 48 hours (Figure 7). 
Immunofluorescent staining of the cells (Figure 7A) revealed that ATF4 accumulated at 
arginine concentrations below 25 (iM, whereas the size of the myotubes and the cellular 
concentration of myosin heavy chain (MHC) protein increased with increasing arginine 
concentrations. 
CHOP mRNA levels decreased at increasing ambient arginine concentration as 
shown before, irrespective of whether IGF-l was present or not (Figure 7B). As expected 
from the arginine-dependent increase in the size of the myotubes and the accumulation 
of MHC protein, MCK mRNA accumulated at > 25pM arginine. More importantly, IGF-
1 
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Figure 6. ATF4 protein is expressed ubiquitously in F/A2 mice. Panel A: Western blots 
of muscle extracts of 1-day-old mice stainedfor the presence ofATF4. Lanes 1-4:1-day-
oldF/A2 mice; lanes 5-7: 1-day-old wild-type mice. The left panel is stained with 
Ponceau-S to demonstrate equal protein loading, while the right panel shows the blot 
after staining for A TF4. Native form of ATF4 corresponds with the prominent 38kDa 
band (bold arrow). A fainter band at ~50 kDa was also present in F/A2 extracts only 
(thin arrow) which corresponds to the ubiquitinatedform. Panel B: Immunodetection of 
ATF4 protein in sagittal sections of 1-day-old F/A2 and wild-type mice. The 4 subpanels 
show magnifications of muscle (M), lung (Lu), liver (L), and small intestine (G). 
Representative of n = 3 per genotype. Panel C: Optical density (OD) in ATF4-positive 
cells as measured with the QWin program. Significant differences in OD were found 
between wild-type and F/A2 mice in muscle (P = 0.001), gut (P= 0.021), liver (P = 
0.000), lung (P = 0.001), and brain (P = 0.05). Data represent mean ± SEMof 3 mice 
per genotype. 
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Figure 7. IGF-1-mediated muscular hypertrophy is inversely proportional to stress-
response activation. Panel A: Expression of myosin heavy chain (MHC; green) and 
ATF4 (red) after 2 days of culture in differentiation medium plus 2 days of culture in the 
presence of the indicated concentration of arginine with or without 10ng/pL IGF-1. 
Lower arginine concentrations resulted in higher A TF4 expression, smaller myotuhes, 
and less MHC expression. Panel B: CHOP mRNA concentration declines with 
increasing arginine concentration in the culture medium, irrespective of the presence of 
IGF-1. Panel C: MCK mRNA expression increased at > 2 5pM arginine in the culture 
medium. Addition of IGF-1 to the culture medium increased MCK mRNA concentration 
at > 25pM arginine. Data represent the means of 3 experiments ± SEM. 
also increased MCK expression only at > 25 pM arginine (Figure 7C). These data show 
that muscle differentiation and the effects of IGF-1 on muscle differentiation are 
inhibited at low ambient arginine concentration, probably as a result of the activation of 
the stress response.GCN2 mediates the activation of the stress response in arginine-
deficient neonatal mice 
To demonstrate that GCN2 is the stress kinase that is activated in neonatal 
F/A2 mice, we crossed Gcn2"A mice with F/A2 mice. Figure 8 lists the genotypes of the 
offspring and compares the observed frequencies with the expected Mendelian ratios. 
Inspection of these data shows that all mice that were transgenic for arginase and 
deficient for GCN2 (F/A2tg/?/Gcn2'A ) died within 72 hours after birth. F/A2 neonates had 
a 3-fold lower plasma arginine concentration than control neonates irrespective of 
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Figure 8. GCN2 is responsible for the induction of the integrated stress response in 
arginine-deficient mice. Panel A: Distribution of genotypes in the offspring of crosses of 
hemizygous F/A2 (F/A2tg/~) mice and heterozygous Gcn2 (Gcn2+/-) mice. Six different 
genotypes could be identified by PCR (no difference could be made between transgenic 
F/A2tg/- and F/A2tg/tg mice; F/A2-/- mice denote wild-type animals). A total of 60 mice 
(dead and alive) were analyzed. 4 newborn mice disappearedfrom the nests in the first 
two days and could not be analyzedA chi-square test revealed that the chance of 
survival of a F/A2tg/?/Gcn2-/- neonate was <0.0001. Panel B: Arginine concentration in 
trunk blood of 1-day-old mice with genotype F/A2-/-/Gcn2 +/+ (wild type; group 1), 
F/A2tg/?/Gcn2+/+ (arginine-deficient; group 2), and F/A2tg/?/Gcn2-/~ (both arginine-
& Gcn2-deficient; group 3). Compared to the wild-type mice, the circulating arginine 
concentration was decreased 3.5-fold in F/A2 mice, irrespective of whether Gcn2 was 
functional or not (F/A2tg/?/Gcn2-\-/-\- and F/A2tg/?/Gen2-A, respectivelyj. Panel C: 
CHOP mRNA expression in the same three genotypes as shown in panel B. F/A2 mice 
lacking active Gcn2 (F/A2tg/?/Gcn2-/~) cannot mount the induction of CHOP seen in 
mice with an active Gcn2 gene (F/A2tg/?/Gcn2 +/+). In muscle, there was a 12-fold 
increase in the group 2 animals compared to group 1 (CI: 8.3-18.5) and a 14-fold 
increase in group 2 compared to group 3 (CI: 8.3-25.0). In liver; there was a -6-fold 
increase in group 2 compared to group 1 (CI: 3.3-9.7), ~2.5-fold in group 2 compared to 
group 3 (CI: 1.5-4.4), and -2 fold in group 3 compared to group 1 (CI: 1.5-3.3). In gut, 
there was a ~12-fold increase in group 2 compared to group 1 (CI: 8.3-18.5), ~6-fold in 
group 2 compared to group 3 (CI: 3.5-9.0), and a-2-fold in group 3 compared to group 
1 (CI: 1.5-3.3). 
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whether GCN2 was or was not expressed (Figure 8B). In addition to GCN2, three other 
stress kinases can phosphorylate eIF2a. 
To investigate whether GCN2 was solely responsible for activating the stress 
response, we determined CHOP mRNA levels in neonatal wild-type mice (F/A2"'" 
/Gcn2+/+), F/A2 mice (F/A2tg/?/Gcn2" /+) and F/A2 mice that were also GCN2-deficient 
(F/A2tg/?/Gcn2v") (Figure 8C). As expected, CHOP mRNA levels were low in muscle, 
liver and gut of wild-type (F/A2";7Gcn2+/+) mice and elevated in the same organs of F/A2 
(F/A2tg/?/Gcn2+/+ ) mice. However, the elevation of CHOP mRNA levels was not found in 
muscle, liver and gut of the F/A2 neonates that were, in addition, deficient for Gcn2 
(F/A2tg/7Gcn2'A ). These findings demonstrate that GCN2 activation is necessary for 
postnatal survival in F/A2 mice and that the induction of CHOP expression is dependent 
on GCN2 activation. 
Discussion 
Our study shows that arginine-deficient F/A2 mice suffer from an inhibition of GH 
secretion by the pituitary gland, from an absolute, but not a relative decline of IGF-1 
production upon a GH challenge in target organs, such as liver and intestine, and from 
activation of the GCN2-dependent stress response. The activation of this latter response 
was shown to be necessary to cope with deficiency of arginine in the neonatal period. 
The GH/IGF-1 axis is repressed during arginine shortage 
We investigated the fate of GH in the somatotropes of the pituitary gland of 21-day-old 
mice, because F/A2 mice show the most pronounced phenotype at this age. The increase 
in GH content in the somatotropes was clearly related to the genotype of the mice and, 
hence, with the circulating concentration of arginine (11,13). Since the increased cellular 
content of GH could be due to a block in secretion or an increase in synthesis, we studied 
the effects of arginine on the secretion of GH in rat GH3 cells. These experiments 
revealed that ambient arginine concentrations below 50|iM inhibited secretion (at Oj.iM 
arginine, GH content of the cells and the medium combined was -90% of that at lOOfiM 
arginine). In vivo, the effects of arginine deficiency on growth become apparent when 
circulating arginine levels decline below 30-35% of the age-matched control animals 
(11). It is well established that GH does not affect growth until after the second postnatal 
week, whereas IGF-1 affects growth from the fetal stage of development onward 
(35,36)). The growth characteristics of F/A2 mice, therefore, resemble those of a general 
deficiency of IGF-1 rather than GH. In agreement, Igf-1 mRNA levels in 2 target tissues 
of GH, liver and muscle, were 11-fold lower in F/A2 mice than in wild-type controls. 
Although GH injections elevated liver and muscle Igf-1 mRNA levels substantially, they 
remained 2-3-fold lower than in untreated wild-type controls. However, the absence of 
any effect of the GH treatment suggested that additional mechanisms inhibited growth. 
Argiftine deficiency induces the integrated stress response 
The lack of a single amino acid is sufficient to activate the integrated stress response via 
GCN2 kinase (21,37). In agreement, arginine withdrawal caused phosphorylation of the 
translation factor eIF2a in muscle cells in vitro. Of the more downstream targets of 
GCN2 kinase (3 8), CHOP was the more sensitive marker for arginine deprivation at the 
mRNA level, whereas ATF4 was, as expected (39), mostly regulated at the protein level. 
This response to arginine deprivation was seen in all tissues investigated. 
Based on the degree of phosphorylation of eIF2a and the expression of CHOP mRNA, 
the GCN2 signaling pathway was already activated at postnatal day 1 in all tissues of 
F/A2 mice tested. ATF4 mRNA levels were upregulated in skeletal muscle of 1-day-old 
mice, but not in liver or small intestine, in agreement with the severe muscle phenotype 
of F/A2 mice. The arginine concentration in plasma and muscle of F/A2 mice was 3- and 
4.5-fold lower, respectively, than that in control mice, with a 4-5-fold concentration 
gradient between plasma and muscle in both mouse lines. F/A2 hemizygotes and F/Al 
homozygotes have a milder muscle phenotype, even though circulating arginine 
concentrations are only slightly higher than in F/A2 homozygotes (11). Furthermore, 
F/A2 homozygotes resume growth around weaning (11), in all likelihood due to the 
increase in cellular arginine concentration. In combination, these data, therefore, indicate 
that the GCN2 signaling pathway in muscle in vivo becomes activated when muscle 
arginine levels decrease below ~500jaM arginine. The neonatal gut appears to have a 
similar sensitivity to arginine with respect to GCN2 activation, but we have no 
explanation why this sensitivity declines towards weaning. Furthermore, we do not know 
why the liver is less sensitive to activation of GCN2 by arginine. In any case, GCN2 
becomes activated in muscle and intestine at intracellular levels of arginine that exceed 
the Km of arginyl-tRNA synthetase >20-fold (16). 
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Expression of ATF4 upon activation of the stress response is primarily regulated at the 
translational level (40). We therefore used ATF4 immunohistochemistry in 1-day-old 
mice to evaluate whether the response to arginine deprivation was general or restricted to 
a few organs only. ATF4 protein was ~4-fold upregulated in all tissues of F/A2 mice 
except brain, indicating that nearly all tissues reacted similarly to arginine deficiency. 
This finding is in agreement with earlier data that at least one of the three known 
isoforms of GCN2 is expressed in any mouse organ (21). The 2-fold lower response of 
ATF4 protein expression in brain suggests that this organ may be relatively shielded 
against amino-acid deficiencies during its rapid postnatal growth phase. The cerebral 
expression of the protein "Impact", which inhibits the effects of GCN2 activation by 
inhibiting eIF2a phosphorylation (41), may account for this protection. 
Gcn2 is necessary to survive arginine deficiency 
Although our in vitro data implied that GCN2 mediated the effects of arginine 
deficiency, we used GCN2-deficient mice to demonstrate a causal relation. Since GCN2 
deficiency indeed prevented eIF2a phosphorylation and CHOP expression in F/A2 mice, 
the anticipated causal relation apparently exists. In addition, the experiment showed that 
GCN2 was essential for the survival of the arginine-deficient pups. Although it has been 
demonstrated previously that GCN2 is required to survive a deficiency of the essential 
amino acid leucine (21), our experiments with F/A2 mice show that the deficiency of a 
conditionally essential amino acid also activates GCN2 and that this activation is 
necessary for survival. 
The integrated-stress response opposes the effects of GH-IGF-1 signaling 
IGF-1 and the integrated-stress response signaling pathway that is activated by GCN2 
have opposite effects on mRNA translation - IGF-1 promotes global protein synthesis 
and cell growth, whereas the integrated-stress response mediates the repression of global 
protein synthesis. As might perhaps be expected, the GCN2-mediated effects prevail 
over the IGF-1-dependent effects. In fact, we observed in vitro a reciprocal relation 
between the activation of the stress response as deduced from CHOP expression and the 
growth- and differentiation-promoting effects of IGF-1, with a transition between both 
effects at ~25pM arginine in the medium. 
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Figure 9. Proposed mechanism underlying the arginine-deflcientphenotype in mice, 
Arginine is the precursor for NO, poly amines, and creatine synthesis, and regulates 
ADP-ribosylation. The developmental impairment of F/A2 mice is, however, not 
mediated by these molecules. Instead, the GH/IGF-1 axis did not function properly in the 
absence of arginine. This deficiency could not be rescued by supplementation due to 
activation of the Gcnl-mediated integrated stress response. The integrated stress 
response blocks the GH-IGF-1 axis and general protein synthesis. 
Conclusion 
The discussion of arginine-dependent signaling in tissues often focuses on arginine 
metabolites, such as NO, agmatine, polyamines, creatine, or arginine-mediated 
modifications such as ADP-ribosylation. This and previous studies of the F/A2 mouse 
(11-14) demonstrate, however, that the arginine-deflcient phenotype does not involve 
arginine metabolism (Figure 9). Instead, arginme deficiency appears to be a signaling 
entity in its own right, activating the Gcn2 signaling pathway. We would like to propose 
that many of the effects of arginase-I overexpression are mediated by GCN2 activation 
(Figure 9). Similarly, growth of F/A2 neonates could be rescued by arginine-
supplementation (11). Unfortunately, the premature death of F/Atg/?/Gcn2v" mice 
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prevented us from definitively establishing that arginine deprivation suppresses IGF-1-
mediated growth via the GCN2-mediated integrated stress response. 
Our studies have further shown that the low circulating levels of arginine also 
suppress GH secretion. However, the low levels of tissue IGF-1 and the diminished 
response to exogenous GH administration probably reflect the dominant effects of GCN2 
activation (Figure 9). Our study of F/A2 mice, therefore, strongly supports the 
conclusion that the phenotype of arginine deficiency is determined by activation of 
GCN2 kinase and the subsequent inhibition of the growth-promoting activity of IGF-1. 
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Appendix: 
Table 1. Primers and probe set specifications 
annealing 
primer name sequence 5' - 3' T manufacturer 
Igf-1 Fow CAAGCATGCGTGAGAGGATA 70 Genosys, Sigma 
Igf-1 Rev CAAACCTTTCCCTCCTTTCC 70 Genosys, Sigma 
MCK Fow AGGTTTTCCGCCGCTTCT 60 Genosys, Sigma 
MCK Rev CGGTGCCCAGGTTGGA 60 Genosys, Sigma 
18S Fow TCCGGAACTGAGGCCATGAT 60 Genosys, Sigma 
18S Rev CGAACCTCCGACTTTCGTTCT 60 Genosys, Sigma 
primer & probe annealing 
set code r j p manufacturer 
Chop Mm 00492097 ml 60 ABI 
Atf4 Mm 00515324_ml 60 ABI 
18S Hs99999901s! 60 ABI 
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Table 2. Antisera and incubation conditions 
Antibody name dilutions used cat # manufacturer 
eIF2a; anti-mouse monoclonal 1:500 AH00802 Biosource 
eIF2a [p51]-phospho-specific 
antibody; rabbit anti-mouse polyclonal 1:1000 44-728G Biosource 
ATF-4; rabbit polyclonal 1:1000 sc-200 Santa Cruz 
Growth Hormone;rabbit monoclonal 
antibody 1:1000 4750-2809 Biogenesis 
MHC; monoclonal, skeletal, fast 1;200 M4276 Sigma-Aldrich 
Alexa fluor ®555 goat anti-rabbit IgG 1:500 A21429 Invitrogen 
Goat anti-mouse IgG FITC 1:500 M32101 Invitrogen 
Goat anti-rabbit AP conjugate 1:50 A3687 Sigma-Aldrich 
IRDye 800 CW Goat anti-mouse 1:50 926-32210 Licor 
IRDye 680 Goat anti-rabbit 1:50 926-32221 Licor 
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I- Introduction 
The development of techniques that allow the modification of the DNA sequence of an 
allele of a gene in embryonic stem cells enables us, in combination with microinjection 
techniques, to deliberately modify the expression of genes in a living organism, usually 
the mouse. The deletion (knock-out) or replacement (knock-in) of specific genes has 
proven to be a powerful tool. In this chapter, we comment on our experience with the 
generation of conditional knockout mice of the genes that code for Argininosuccinate 
Synthetase (ASS; VM), Arginase 1 (Argl; SS) and Cationic Amino-Acid Transporter 1 
(CAT 1; CdT). 
Conventional knock-out mice (deletion of a specific gene in every cell of the 
organism) are often not viable. This problem can be overcome by making "conditional" 
knock-out mice that allow the deletion of a gene in a specific tissue or at a specific 
developmental stage. Deletion in specific tissues or at a specific time point can be 
achieved with just one genetic modification of the gene of interest, that is, the insertion 
of two recognition sites for an enzyme with recombinase activity. Mice harboring such a 
modified allele are crossed with mice expressing the recombinase under control of a 
promoter that determines the spatiotemporal expression of the recombinase and thereby 
the spatiotemporal deletion of the DNA fragment surrounded by the recombinase 
recognition sites. Two systems are most widely used and discussed in this chapter, viz, 
the cre/loxP system and the_/7p/frt systems. LoxP and frt refer to the recombinase 
recognition sites, and ere and flp to the respective recombinases (1-4). There are now 
more than 100 ere mice available (see http://www.mshri.on.ca/nagy/), permitting 
deletion of genes in specific cell types (macrophages, B-cells, enterocytes, hepatocytes, 
endothelial cells to name a few) or at specific times using a recombinase that is modified 
to contain the ligand-binding domain of a member of the steroid-hormone receptor 
family. Most often, this ligand-binding domain is modified itself to respond only to a 
ligand that is not endogenously produced. In practice, the combination of a modification 
of the estrogen-receptor ligand-binding domain and the ligand tamoxifen is most often 
used. 
The first step in the generation of a conditional knock-out mouse is the design 
and construction of an appropriate vector that is then introduced into embryonic stem 
cells by transfection. This chapter describes a PCR-based method for vector construction 
and specifies screening protocols for the embryonic stem cells after transfection. 
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1 
Construction of the targeting plasmid 
A targeting plasmid consists of two regions with target homology (hereafter called 
flanking regions; Figure 2), the region of the gene to be deleted, and genes that are used 
as selection tool. The flanking regions are placed at either end of the sequence to be 
deleted and are identical to the sequences surrounding target sequence. The flanking 
regions are required for homologous recombination, that is, for the site-specific insertion 
of the construct into genomic DNA. In our strategy, the exon(s) or gene to be deleted is 
flanked by loxP sites, whereas the selection tools (neomycin phosphotransferase ("neo") 
and viral thymidine kinase ("tk")) are surrounded by fit sites. 
i. design targetplasmid 
II, construction of targetplasmid 
III. transfection ES cells 
IV, selection neo-resistantceiis 
V selection homologous recombinants 
VI, removal selection cassette 
f m target region 
frt & loxP sites 
^ m nea-tk 
flanking regions 
v. vector sequences 
VIL blastocyst injection 
VIII. chimeric mice 
IX, breeding knockoutmice 
Figure 1: Overview of the design and construction of the targeting plasmid, the selection 
and characterization of the targeted ES cells, and the procedure to modify the germline 
of mice. 
Vector construction has been greatly facilitated by the availability of the complete mouse 
genome (http://w ww.ncbi.nlm.nih.gov, http://www.onderzoekinforrnatie.nl) and 
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additional information on SNPs and strain differences. This made it possible to use a 
> 
PCR-based approach for vector construction, which also facilitates the introduction of 
additional restriction sites necessary for later cloning steps. The advantages and pitfalls 
of this approach will be discussed. 
frt frt loxF ioxP 
vector flanking selection target flanking vector 
DNA region cassette region DNA 
Figure 2: Structure of a targeting construct. The fragment to be deleted is surrounded by 
"IoxP " sequences ("floxed"). Adjacent to the floxed sequence, a selection cassette is 
inserted\ which itself is surrounded by "frt" sequences for later removal. The target 
sequence and the selection cassette are located in between the "flanking regions which 
are identical to the sequences surrounding the part of the gene that is to be deleted. At 
both ends of the construct, fragments of the vector can be left behind to facilitate 
selection. See text for details. 
a) Selection of target region to be excised 
One can delete one or more crucial exons or the entire coding sequence to inactivate the 
gene of interest. Deletion of one or a few exons is often preferable, since the efficiency 
of the CRE recombinase seems to be at least partially dependent on the distance between 
the IoxP sites (5). 
The region chosen for deletion should either code for domains that are 
important for the function of the gene product (eg. the active site of an enzyme) or 
should result in a frame shift with premature stop codons. One should nevertheless be 
aware of alternative splicing which could result in a partially functional gene product 
excision (e.g. (6)). Literature data on lethal mutations in man and mouse should be 
consulted, because they can be very valuable for the development of the knockout 
strategy. Examples are: natural mutants (in the case of the arginosuccinate synthetase 
gene, we selected exon 13 for deletion, because the deletion results in a frame shift and 
natural mutations in this exon led to undetectable levels of enzyme activity (7) or results 
known from conventional knockout mice (in the case of the arginase-1 gene, we selected 
exon 4 for deletion, because the conventional arginase I knockout mouse was made by 
deleting this exon and died between 10-14 days after birth (8)). 
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b) Prerequisites for homologous recombination: length of the 
homologous regions 
Between 2 and 10 kb, the relationship between the length of the homologous region and 
the frequency of targeting events is exponential and shows saturation at 14 kb of 
homology (9). Therefore, a minimum length of 2 kb is recommended for the flanking 
region to support optimal homologous recombination. However, 1.5 kb of homologous 
region at one end and 5 kb at the other end proved sufficient for efficient recombination 
of the Glutamine Synthetase gene (Y. HE, AMC Liver Center, Amsterdam). In our case, 
we used approximately 4.5 kb of homologous region on either side of the construct. 
Although this was thought to be advantageous for homologous recombination, long 
flanking regions as e.g. found in pROSA26 (10) make screening of clones by Southern 
or PCR more difficult. For this reason, many constructs contain a long and a short 
flanking region. 
Comment; 
An important parameter that is often neglected when selecting a target region for vector 
construction is the presence of repeats in the sequence to be amplified. Such repeats 
should be avoided since they are troublesome during amplification by PCR. 
c) Recombinase systems 
Cre-loxP system 
The PI bacteriophage cyclization recombination {ere) recombinase recognizes a pair of 
loxP sites flanking a DNA sequence. LoxP sites are 34 bp long and composed of an 8bp 
core, which determines directionality, flanked by 13 bp of palindromic sequence on 
either side (Figure 3A). The natural occurrence of this exact sequence is unlikely in any 
eukaryotic genome. Sequences flanked by loxP sites are said to be "floxed". The ere 
enzyme brings the two loxP sites into juxtaposition. If the loxP sites flank a DNA 
segment in a cis arrangement and are oriented in the same direction, CRE recombinase 
mediates excision and circularization of the flanked segment (Figure 3B). If the loxP 
sites flank the DNA segment in a cis arrangement and are oriented in opposite directions, 
CRE recombinase mediates the inversion of the segment (Figure 3C). 
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Flp-frt system 
The yeast Jlp recombinase (4, 11) recognizes target sites called frt (12, 13). A full-length 
fit site is 48 bps long and, similar to a loxP site, consists of an asymmetric central 8bp 
spacer sequence, flanked by 13bp inverted repeats (Figure 4). However, in contrast to 
loxP sites, it contains a third 13bp direct repeat at one side (14). Because the Flp/frt 
system is derived from S. cerevisiae, its optimal working temperature is 25-30°C. At 
37°C, the activity of the enzyme is dramatically reduced (15, 16), so that Flp is less 
suitable and less frequently used to engineer genome modifications in mammals. 
A ATAACTTCGTATAGCATACATTATACGAAGTTAT 
B 
C 
Oi l A 
I 
1111 11 i"l 11 l'<l I I ' f ^ p ' l i t ' J 1 
/ • 
Jjfp-
| t t » M I I » i t > H ' 
Figure 3; (A): The nucleotide sequence of loxP sites. Note the inverted repeat 
surrounding the asymmetric core sequence. Due to their asymmetric core, the 
orientation and position of the loxP sites determines the outcome of the recombination 
event. In conditional knockout strategies, the aim is excision of the fragment which is 
achieved by placing 2 loxP sites on each side of the sequence of interest in the same 
orientation (B). With an opposite orientation of the loxP sites, an inversion of the floxed 
region is obtained in presence of Cre (C). 
Attempts to overcome this limitation have led to the development of an "enhanced" 
mutant FLP (FLPe) by cycling mutagenesis. FLPe is said to have a better thermostability 
and activity (16, 17) and a more efficient function in mammalian cells (16, 18). 
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d) Selection tools 
A homologous recombination is a very rare event compared to random integration. 
Based on our experience, homologous recombination occurs in -50% (ROSA locus; M. 
Konings) to 0.05% of all integration events (arginase I locus). Selection is therefore 
necessary to identify the clones in which homologous recombination has occurred 
» » 4 
GAAGTTCCTATTCCGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTC 
Figure 4: The nucleotide sequence of frt sites. Note inverted repeat surrounding 
asymmetric core sequence, which contains a convenient Xbalrestriction site. Also note 
that the left-sided repeat needs to be present as 2 copies for higher efficiency. 
and to distinguish these clones from the clones in which the modified sequence is 
randomly integrated into the genomic DNA. To achieve this, a positive-negative 
selection protocol is commonly used (19). The positive selection tool is used to identify 
ES cells with the targeting sequence integrated into their DNA. Neomycin 
phosphotransferase (neo) is often used as a positive selection marker to select for ES 
clones in which the construct is integrated. Only clones that have integrated the construct 
will be able to grow in G418-containing medium as neomycin phosphotransferase will 
detoxify the compound. 
The negative marker can be used to select for homologous recombination of the 
targeting construct or to select for successful removal of the positive selection marker in 
the ES cells prior to blastocyst injection. As a tool to select for homologous 
recombination, the negative selection marker has to be placed at the outer end of one of 
the flanking regions, whereas the positive selection marker is placed in the middle of the 
construct. 
Positioning the negative selection marker at one extremity of the targeting 
construct (Figure 6A) will lead to elimination of this marker during homologous 
recombination. Addition of the selection compound to the medium will then kill all cells 
that still express the negative selection marker due to random integration, whereas clones 
with homologous recombination will not be affected. Viral thymidine kinase (tk) is a 
commonly used negative selection marker, as it confers sensitivity to ganciclovir in the 
ES cells. Phosphorylated ganciclovir is a toxic substance, so that cells can only grow if 
thymidine kinase is not or no longer present. 
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Removal of selection markers 
To select for successful removal of the positive selection marker, both positive and 
negative selection tools have to be present in between the two flanking regions (Figure 
2), There are 2 strategies to remove the selection markers. One approach uses three loxP 
sites that surround the target sequence and the selection marker. In the other approach, 
the target sequence and the selection markers are surrounded by loxP and frt sites, 
respectively. After selection for the positive selection marker and identification of a 
correct clone by the appropriate screening protocols, the selection tools are removed by 
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Figure 5: Gene targeting using solely loxP sites can be used to inactivate a specific gene 
in a desired cell type. In the standard homolous recombination protocol, tf/ree loxP sites 
are introduced along with a selection tool "M" at the target locus "A Subsequent 
transient transfection of a ere recombinase-expression plasmid or breeding a chimeric 
mouse with a deleter-cre mouse results in recombination between the three loxP sites. In 
the desired Type I recombination, only the selection tool is removed. Both other 
recombinations generate convential unconditional knockouts. 
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A 
homologous j recombination 
Figure 6: The two applications of a negative selection marker. In panel A, a negative 
selection marker is placed at either end of the construct to select against random 
integration. In panel B, the negative marker is placed in the middle of the construct and 
surrounded by recombinase recognition sites for removal after recombination. 
transient transfection with either a ere- or flpe-Qxp res sing plasmid, depending on 
whether the selection tools are surrounded by loxP (Figure 5) or frt sites (Figure 2). In 
vivo, loxP sites are preferable over frt sites as recognition sites for a recombinase, 
because CRE is a more efficient recombinase than FLP and because there are many more 
mouse strains harboring tissue-specific expression of ere than flp. 
Therefore, the gene fragment to be excised in vivo is usually surrounded by 
loxP sites.Figure 5 shows the use of 3 loxP sites for gene targeting. Transient 
transfection of ES cells with a cre-expressing plasmid will ideally yield three products: 
cell clones, in which only the selection tool is deleted, cell clones in which only the 
target sequence is deleted, and cell clones with excision of both the selection tools and 
the target sequence. The first type of clones is the desired outcome, whereas the second 
and third type of clones will generate conventional knockouts. It is unfortunately not yet 
possible to predict if the desired type of clones can be obtained. We, therefore, chose for 
an approach in which the targeted gene fragment is placed between loxP sites and both 
positive and negative selection tools are present in the middle of the construct in between 
frt sites (Figure 2). This allowed us to first select for integration of our constructs into the 
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genomic DNA and then to select for deletion of the positive-negative selection tool 
before the injection of ES cells into blastocysts. 
Comments 
1 An alternative to "select" against random integration by including a negative 
selection marker at the outer end of the targeting construct is the use of a high 
throughput screening protocol, e.g. a PCR-based screening for the presence of remaining 
vector sequence. This strategy will be discussed in section III A, 
2. Multiple copies of loxP can lead to chromosomal instability during expression 
of ere (20). 
3. An alternative to plasmid transient transfection with ere or flp to remove the 
selection tools is to cross mice carrying the properly recombined targeting construct that 
still contains the selection marker with a mouse expressing ere or flp in early 
development, i.e., before the germline is set apart. An example of a cre-expressing mice 
is the II2a-ere mouse (21), while the "flipper" mouse is an example of an often used flpe-
expressing mouse (22). The availability of the efficient flipper mouse (~50% frt excision 
(22)) has made the use of a negative selection marker like thymidine kinase obsolete, 
because the positive selection marker can now be removed in vivo. The use of solely the 
neo selection tool and its removal in vivo has 3 additional advantages: 
4 One round of in vitro selection can be avoided (see section IV B), which 
decreases the chance that pluripotency of the ES cell is lost; crossing the mice with a 
flpe-deleter mouse on a pure background spares one round of breeding towards a new 
background; a targeted allele containing neo is available. Such alleles are often cripple 
(19, 23-26), allowing one to obtain not only animals with 0, 50% and 100% gene 
expression of the gene of interest, but also animals with intermediate expression levels 
(0-50% and 50-100%). 
Cloning the target and flanking regions 
PCR 
Homologous recombination requires a 1.5 kb - 5 kb stretch of DNA on either side of the 
construct that is identical to the sequence to the wild type DNA (27), The efficiency of 
homologous recombination depends on the degree of sequence similarity. When the 
93 
construct is generated by PCR, the use of a high fidelity of the DNA polymerase for the 
amplification of the flanking regions from genomic DNA is therefore a prerequisite. 
The different commercially available thermostable DNA polymerases show a 
~20-fold difference in error rates (28, 29). The DNA polymerases from thermophilic 
bacteria (e.g. Thermus aquaticus) miss proof-reading 3'-5'- exonuclease activity and 
lack the ability to synthesize products larger than 5 Kb. DNA polymerases from 
hyperthermophilic archaea (e.g. Thermococcus fumiculans ("Tfu") and litoralis ("Vent") 
and especially Pyrococcus furiosus ("Pfu") and abyssi) have low error rates, but the 
stronger the proofreading activity, the lower the product yield of long DNA fragments. 
Therefore, blends of the non-proofreading Taq and a proof-reading enzyme are often 
used: "LA" (long and accurate (30)) PCR. According to the manufacturer, the Accutaq 
LA DNA Polymerase (Sigma), which we used for amplifying the homologous arms, has 
a 6.5-fold greater fidelity than Taq polymerase. However, in 3 different targetings, we 
observed 27 differences with published sequences in 6.9 kb of DNA (0.4%). Some of 
these differences may reflect strain differences (published sequences are often C57BL/6 
or BALB/c, whereas the ES cell line came from 129P2/OlaHsd mice). In the case of 
arginase I construct, we found 5 mismatches in the exonic sequences which did not lead 
to a change in amino-acid coding. We did not correct sequences, if they did not affect a 
consensus splice site or a coding sequence. However, when a coding sequence was 
affected (e.g. (GCG (Ala) to GTG (Val) in exon 6 of the arginase-1 gene), we did correct 
the mismatch. 
Another problem of the PCR approach that we encountered was the presence of 
highly repetitive sequences in the region to be amplified. In the 5'-flanking region of the 
ASS targeting construct, for instance, a 36 bp TA repeat was present in the middle of the 
4.2 kb fragment. To amplify this sequence, we tried several high-fidelity Taq enzymes 
(Pfu "Ultra High" Fidelity and "Herculase" DNA Polymerases (Stratagene); AccuTaq 
Polymerase (Sigma), but none of them was able to amplify the sequence. Eventually, we 
had to break up this flanking region into 4 fragments of approx. 1 kb each. 
Comment 
Our choice to amplify the flanking regions using genomic rather than plasmid- (BAC-) 
derived DNA was based on the limited availability of BAC clones when we designed our 
approach. However, since BAC-derived DNA is -30,000-fold purified per weight unit 
for a particular 100 kb fragment relative to primary genomic DNA, the number of PCR 
cycles necessary to amplifly the DNA is reduced by -17, which strongly reduces the 
fidelity issue. 
Electrop oration of the targeting construct 
Purification of the targeting construct 
Prior to electroporation in the ES cells, the construct is either linearized by restriction 
enzymes cutting in the vector backbone or digested with two restriction enzymes to 
remove the vector backbone. Complete removal of the backbone of the vector has the 
advantage of working with a "clean" construct without additional sequences that might 
interfere with homologous recombination in the cell. On the other hand, linearization 
avoids extra steps of purification of the targeting construct. Furthermore, the additional 
vector sequences can be used for a PCR screening strategy to eliminate clones with 
random integration quickly. This approach is described in section III. a (Elimination of 
randomly integrated clones). 
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Figure 7: Panel A: Schematic representation of the electro-elution system used to purify 
the targeting vector prior to electroporation. The two cylindrical reservoirs 
communicate through a buffer compartment on top. DNA migrates in an electric field 
(open arrow) from the agarose slices (in large reservoir, left) onto the dialysis 
membrane (in small reservoir, right). Panel B: after electroelution, the DNA 
concentrates on the dialysis membrane. The left picture shows an efficient transfer of 
DNA to the dialysis membrane, whereas the right picture shows an inefficient transfer (a 
high proportion of DNA remained in the agarose). 
There are several methods to purify large DNA fragments by electrophoresis 
(purification with commercial kits, electrophoresis in low melting point agarose followed 
by acid-phenol extraction or electro-elution). We used electro-elution, using a bridging 
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dialysis membrane 
system to concentrate the DNA on a dialysis membrane (Figure 7A). The purified DNA 
was then precipitated in ethanol for electroporation. 
Comments 
1 DNA that is to be used to generate transgenic animals should be protected as 
much as possible from UV light (i.e. day light, UV light box). Long-wave UV light or a 
Dark Reader® using visible light (Clarechemicals), is recommended to visualize DNA. 
We are aware of a case in which undue exposure to UV light caused mutations in the 
majority of otherwise successfully targeted ES cells. 
2 Residual ethidium bromide will interfere with the efficiency of homologous 
recombination. Traces of ethidium bromide in a DNA preparation can be easily detected 
on an agarose gel from which ethidium bromide has been omitted. If DNA is detectable 
under UV light, the preparation should be re-extracted. For the same reason, working 
surfaces and equipment (UV tray; scalpels) have to be clean, when isolating fragments 
from agarose gels. 
3 During electroelution of DNA, the agarose blocks should be stacked properly 
to ensure efficient transfer (Figure 7B, left picture). Floating pieces of agarose result in 
inefficient transfer of DNA (Figure 7B, right picture) and are a major source of DNA 
loss. 
Choice of ES cell line 
The choice of ES cell line is an important factor to achieve high success rates. The 
129P2/01aHsd-derived IB10 ES cells (a subclone from (male) E14 ES cells (31)) was 
used successfully by our group for the generation of 4 conditional knockout and 3 
knockin mice. 
Electroporation of IB10 ES cells 
fS 
ES cells from an 80% confluent 25cm culture flask were electroporated with 25 \xg 
DNA in a final volume of 200 p.L sterile PBS. At a setting of the capacitance at 1 (xF, the 
time constant should not exceed 0.1. After electroporation, the ES cells were seeded in 
two 10 cm dishes, containing medium without selection compound. 
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A B C 
Figure 8: The phenotype of ES cell pictures cultured in vitro. Picture A; a colony of 
undifferentiated ES cells cultured on mouse embryonic fibroblasts (MEFs). The cells are 
spherical and show no boundary at the circumference of the colony. Picture B: a colony 
of differentiated ES cell with part of the cells exhibiting a high degree of differentiation 
(arrow). The cells are no longer spherical. Picture C: a colony ofES cells grown in 
BRL-conditioned medium. Although still undifferentiated, this ES colony is very different 
in appearance from one grown on MEFs. 
The exposure of the electroporated ES cells to the selection medium (200 ng/mL G418) 
was started 24 hours after electroporation. Five days later, resistant colonies become 
visible, with individual colonies becoming visible after 6 to 8 days. The colonies should 
not be left to grow too big, since this induces differentiation of the ES cells. Figure 8A 
shows an undifferentiated ES colony with cells retaining their spherical shape. On the 
other hand, when the ES cells become differentiated, they acquire a rectangular shape 
(Figure 8B) and should be disgarded. Series of 16 undifferentiated colonies were picked 
and transferred to 96-well plates containing neomycin-resistant mouse embryonic 
fibroblasts (neo-MEF). After 2-3 days, when the cultures are around 60% confluent, they 
are split onto two plates, one containing neo-MEFs and the other 150 \iL of BRL 
(Buffalo Rat Liver) conditioned medium. The cultures on neo-MEFs were grown to 
semiconfluence (2-3 days) and frozen. The colonies on BRL medium were expanded for 
isolation of genomic DNA. Note that these ES cells look different from MEF-supported 
ES cells (Figure 8C). 
Comment 
Recombinant ES cells should be grown under selection pressure until the selection tool 
has been excised to suppress the growth of wild-type cells. The requirement for a "deep 
split" (see section IV.a.) shows that selection pressure should be a standard part of the 
procedure. 
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Ill- Screening for homologously recombined clones 
Once neomycin-resistant clones originating from single cells have been picked, they 
need to be screened for proper integration of the construct into the targeted gene. The 
picked clones are seeded individually in 96-well plates. It was common to observe 
differences in the growth rate among the recombinant cells. Therefore, care was taken 
not to allow cells to grow too confluent, thereby avoiding differentiation. Because 
screening is a tedious and time-consuming procedure, it is recommended to temporarily 
freeze an aliquot of promising ES colonies, while going through the selection with the 
remaining portion of the clone. Two ways of freezing down the cells were used. A 
computer-assisted cooling device in which the cryotubes were placed in a temperature-
controlled chamber with a reduction in the temperature of 1 °C per minute to -80°C 
before transferring the tubes to liquid nitrogen. When this machine was not available, we 
cooled the cryotubes in a foam box containing liquid isopropanol based on the same 
principle as the Mr Frosty labware (Nalgene) in a -80°C freezer before transferring them 
to liquid nitrogen, 
a) Elimination of randomly integrated clones 
After electropration of the targeting vector, the vector either integrates randomly in the 
genomic DNA (RI) or recombines homologously with the gene of interest (HR). An 
interesting difference between these two ways of insertion is that the extremities of the 
vector are kept during randing integration, but lost during homologous recombination 
(Figure 9A). We used this difference for a preliminary test to remove clones with 
randomly integrated DNA. We left the multiple cloning region (MCR) on either end of 
the linearized fragment or only linearized targeting construct. A MCR- or vector-specific 
primer and a construct-specific primer were used. Since the outer ends of the construct 
are lost during homologous recombination, only randomly integrated clones still have 
the MCR- or vector-specific sequence necessary for primer binding (Figure 9B). This 
"short" PCR approach worked well for some targeting vectors, e.g. ASS, that is, -70% 
of the clones that were randomly integrated could be eliminated. We therefore suggest 
linearizing the targeting construct near the shortest flanking sequence. When the 
construct was restricted at the outer side of the MCRs before electroporation, leaving no 
backbone, this short PCR did not work efficiently. Probably, the extremities of the 
construct are nibbled off by nuclease activity before integration. Clones yielding a PCR 
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product were discarded; clones negative for this PCR were treated as potential 
candidates for proper homologous integration and investigated further. 
b) Selection of homologously recornbined clones 
Long PCR 
Clones negative for the "short PCR" were subjected to a "long PCR". To discriminate 
the recornbined allele from the wild-type allele, the primers for the long PCR were 
chosen to be specific for the recornbined allele. The target-specific primer sequences 
random 
integration 
5 6 7 B 
A 
homologous 
recombination 
5 6 7 S 
neo-tk 5 6 7 8 
EcoRI ¥ POP, primers 
427 fcb 
Figure 9: Panel A: Configuration of a targeting construct after random integration or 
after homologous recombination. The vector-specific sequences at the ends of the 
targeting construct (black) remain only present if the construct is randomly integrated. 
Panel B: This structural feature allows a negative selection for properly integrated 
clones by "short" PCR. Primers are designed specifically for these sequences which will 
only give a bandfor randomly integrated clones. It is obvious that PCR at the right side 
(long vector sequence left) is less sensitive to "nuclease nibbling" than PCR at the left 
side. Panel C: Screening for homologous recombination by "long" PCR By using 
primers in the endogenous DNA outside the targeting construct and in the selection 
marker or recombination sites, a PCR product that is unique for the recornbined allele is 
produced. This PCR product can then be used to sequence crucial parts of the modified 
allele without interference from the wild-type allele. 
were chosen in the selection markers, the lox P sites, or the fit sites in the center of the 
construct and in the genomic sequence outside that present in the targeting vector 
99 
sequence (Figure 9C). This PCR yields a specific PCR product with a known size, when 
homologous recombination has taken place. The PCR product is then restricted with 
appropriate enzymes and sequenced to confirm the exact insertion of the targeting 
vector, The long PCR yields very detailed information on the integration of the DNA. 
We, therefore, recommend performing this long PCR on both sides of the integrated 
vector, if this is possible. Finally, all crucial sequences are sequenced to check for any 
mutation. 
Southern blot 
Clones positive for the long PCR on both sides were further tested by Southern blot to 
check for clonality, that is, checked for the presence of an equal number of copies of the 
recombined and the unmodified endogenous allele to test for the presence of wild-type 
ES cells that were not removed during the positive selection procedure.This Southern-
blot does also reveal the presence or absence of additional random integrations. 
The DNA sequence used to probe such a Southern blot should be localized 
external to the flanking regions of the construct. The quality of the probe determines the 
quality of the result. We found that a relatively short probe that is specific and contains 
no repetitive elements is more efficient than longer probes containing such repetitive 
elements. Also, it should be close to the boundaries of the construct to avoid excessively 
long sequences. Exons are preferable to introns because introns more often contain 
repetitive sequences and, therefore, bind non-specifically to sequences elsewhere, 
resulting in smears as depicted in Figure 10A. However, sometimes the next exon is so 
far away that intronic sequences have to be used as probe. Any candidate probe should 
be checked for its specificity by blasting for the occurrence of relatively short sequences 
(>12 bp) that are shared with other regions (comparison with the mouse genomic 
database) and then tested on a Southern. There is no golden rule to select a sequence for 
a Southern probe, in the sense that intronic probes can be as good as exonic probes as 
shown in Figure 10B, where we used an intronic sequence of 300 bp for the Southern 
probe and obtained high specificity. 
100 
A D E# 
* , ' ' , » * » * « » 
.... 
• v v . P:-ss8. 
- m 
• •.v. 
. . : ; 
• v . 
t f - . " V 
positive c lone 
recombinant 
endogenous 
•V. < .'. 
J V 
. . .V '> 
" • \ .v. 
4 4 -J* * •» • 
II p 
x > • 
• ' 'i-y.-i 
t 
'A'. 
.S'.V 
-V-V. 
' ' ' 
r; " " 
Figure 10: Southern blotting as tool to identify homologous recombination. Panel A: ES-
cell DNA was digested with Xmn-I, blotted\ and hybridized with an external intronic ASS 
probe (LI 7kb). The probe generated the same staining pattern as ethidium bromide, 
demonstrating non-specific hybridization. Panel B: ES-cell DNA was digested with Blb-
1, blotted, and hybridized with a short 300bp intronic Arginase-1 probe. The wild-type 
allele is 6.1 kb long and the recombined allele 8.5 kb. Note the difference in intensity of 
the wild-type and recombined allele. The excess of wild-type DNA suggests that wild-
type cells had escaped removal during neomycin selection. R: Recombninant DNA 
fragment; E: Endogenous DNA fragment. 
Comment 
DNA isolated for genotyping may be difficult to dissolve. If the centrifugational force is 
limited, a more homogenous solution is usually obtained. Prolonged centrifugation 
during precipitation should, therefore, be avoided. 
IV- Removal of selection tools 
a) Clonality of the recombined clone ("deep split") 
The picked ES colonies are often contaminated with WT ES cells. These contaminant 
cells need to be removed before blastocyst injection. The clonality test, a Southern blot-
based technique, allows us to visualize the intensity (that is, the prevalence in the 
population) of both the endogenous and recombinant alleles and to compare them. If the 
ES cells used on the blot originate from a pure recombinant clone, the intensities of the 
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two bands should be equal. On the other hand, if the intensity of the endogenous band is 
stronger than the recombinant one, there is most likely a contamination with wild-type 
ES cells (Figure 10B). We observed contamination with wild-type ES cells in many 
cases as long as we stopped the G418 selection after picking the clones. It is therefore 
highly recommended to continue the drug selection throughout the whole procedure. To 
remove the remaining wild-type cells, a deep split has to be done and the resulting 
"single-cell" ES cultures have to be subjected to a new round of G418 selection. 
b) Removal of the neo-tk cassette 
The presence of a selection cassette can interfere with the expression of a nearby gene 
(19, 23-26). Furthermore, ES cells that express tk are less likely to be incorporated into 
the male germ line (23, 32). It is therefore recommended to remove the neo-tk cassette or 
any other selection cassette in the selected ES-cell clones prior to blastocyst injection. 
The excision of the cassette can be achieved by transient expression of either flpe or ere 
recombinase through electroporation of either a flpe~ or ere-expressing plasmid. In our 
constructs, we use the Cre-LoxP system to achieve specific gene inactivation, so that the 
Flp-Frt system remained to remove our selection cassette. 
Comments 
The/^-expression plasmid (Figure 11 A) is a fastidious plasmid. After electroporation 
into e.g DH5-a bacteria according to the Biorad standard electroporation protocol, the 
incubation temperature of the bacteria should not exceed 30°C. At 37°C, the apparent 
size of the plasmid doubled (Figure 1 IB). Forty-eight hours after transformation, 
colonies were picked for inoculation of 5 mL cultures. When incubated at 30DC with a 
constant agitation of 180 rpm (instead of 270 rpm), these cultures yielded the proper-
sized plasmids (Figure 11C). Large-scale cultures were grown under the same 
conditions. 25fxg aliquots of the plasmid were stored in sterile PBS at -20°C until 
electroporation. 
The thymidine kinase protein that is encoded in the neo-tk cassette is as stable 
as cellular bulk protein with an estimated long half-life of around 40 hours (33), meaning 
that the deletion of the gene does not make the cell insensitive to ganciclovir for several 
days. In order to make sure that no tk is left in the cells, they were grown in selection-
free medium for 5 days before ganciclovir was added. Due to this long time period, the 
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cultures have to be split between transfection and selection. Care should therefore be 
taken that independent clones are generated. After the deep split, a pure ES cell clone 
n 
was expanded to 25 cm , trypsininzed, and electroporated with 25|ig FLPe plasmid. One 
tenth of the cells were seeded onto the wells of a 6-well plate containing wild-type 
mouse embryonic fibroblasts (wtMEFsJ. Two-three days after electrop oration, the cells 
of each 6-well were split onto two 6-well plates at a dilution of 1:30 and 1:100. After 
another 2-3 days, ganciclovir selection was started. 
Ganciclovir is a nucleotide analogue that may cause mutations. We therefore 
resequenced crucial sections of the recombined alleles. In the ASS allele, we did indeed 
find a mutation in the targeted exon that resulted in a frameshift (ATC to TTT - Ala to 
Val). This mutation was not present before FLPe-mediated excision and ganciclovir 
selection, and would have inactivated the enzymatic activity (34). 
F//?e-deleter ("flipper") mice (22) are available and have already shown their usefulness 
in excising selection cassettes (see ILd.l, comment 3). 
V- Injection of ES cells into blastocysts 
A clone that passed all tests was karyotyped before injection into the blastocyst. Despite 
all quality checks, ES cells may incur damage during transfection, freezing, selection, 
and culture procedures that is not detected. Therefore, the karyotype of the ES cells of 
each ES line was routinely tested. At least 15 metaphase spreads were counted, of which 
at least 80% should have the proper karyotype (40 chromosomes). 
To exclude artifacts due to DNA modifications in the ES cells, germ-line 
chimeras of at least two independent modified clones should be generated. To eliminate 
DNA mutations outside the locus of interest that have accumulated during many 
generations of in vitro culture of the ES cells, newly generated genetically modified mice 
should be bred into wild-type mice for several generations. 
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Figure 11: Picture A: Schematic representation of the pCAGGS- expression vector. Flpe 
expression is driven by the chimeric chicken actin/CMVpromoter-enhancer (18). The 
ampicillin (amp) and puromycin resistance genes are present for selection in bacteria 
and eukaryotic cells, respectively. The flpe sequence harbours four amino-acid changes 
(P2S, L33S, Y108N, S294P) that collectively improve the in vitro recombination activity 
4-fold at 37 °C compared with wild-type flpe (16). Picture B: The plasmid was 
electroporated into XL-1 Blue bacteria, using a standard mini-preparation. The 
observed size of the super coiledform of the 7.7 kb plasmid appeared to exceed 12 kb. 
Picture C: Under optimized bacterial culture conditions (180rpm; 30°C), the linearized 
plasmid was 7.7kb long and the uncut super coiledform ~5.5kb. 
Comment 
Prior to blastocyst injection, the ES cells should pass the following checklist: 
Correct DNA stoichiometry by Southern hybridization (1:1 ratio between wild-type and 
recombinant allele). 
Morphology check (undifferentiated status, Figure 8B) 
Karyotyping 
104 
VI- Breeding Schemes 
a) Chimeras 
A rule of the thumb is that the best - in the sense of germline transmission - chimeras 
should be moderately chimeric. However, we do not know in advance whether the 
genetically modified ES cells that we produced are still sufficiently pluripotent. In the 
case of arginase I, the best chimeras gave 5 floxed animals out of 20-25 offspring. Since 
the percentage of ES cells that populates the germline is always relatively small and 
since an ES cell can populate the germline without carrying the modified allele, it can be 
very reassuring to identify a germline transmission of a modified ES cell that, as a result 
of meiosis, does not carry the floxed allele. This is possible based on the coat colour of 
the offspring. 
-L rtfi 
The 129P2/Hsd01a line carries the coat colour alleles A/A and c /c , whereas 
the important colour alleles of the C57B1/6 donors of the blastocysts are a/a and C/C. A 
stands for agouti and is the normal brown wild-type colour of mice, whereas "a" stands 
for non-agouti, making the mice black. In addition, however, the c or C alleles influence 
the development of the colour determined by the a/A alleles. C stands for albino, 
meaning a c/c mouse will be white, whereas C will support whatever colour is L 
determined by A. The allele c stands for chinchilla and will result in dilution of the 
colour determined by the A-allele, yielding beige or grey mice. An a/a, C/C mouse is a 
black mouse, such as the C57B16. An A/A, cch/cch mouse (donor of the stem cells) shows 
a beige coat (and red eyes). In the chimera, those cells originating from the donor 
blastocyst are a/a C/C, whereas those cells originating from the modified ES cells are 
A/A cch/cch. The fur coat therefore reveals whether offspring is chimeric. 
When chimeric males are bred with C57B16 or 129P2/Hsd01a females, the 
beige coat colour of the offspring will indicate that there was germline transmission of 
the ES cells injected into the blastocysts, independent of the demonstration of the 
recombinant gene. This is because the male chimera can donate either a/C (wild type) or 
A/coh (derived from the ES cells) sperm cells, while a C57B16 mother has a/C eggs. After 
fertilization, the offspring will either be a/a C/C (pure C57B16), yielding a black and 
therefore wild-type animal. If the offspring is A/a C/cch, resulting in a brown (agouti-
coloured) animal, germ line transmission of the ES cell line has taken place. 
Coat-colour can be used in a similar way to check for germline transmission in a 
crossing of male chimeras with 129P2/Hsd01a mice. Again the male chimera provides 
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sperm cells that are either a/C or A/cc\ while the female 129P2/Hsd01a has A/cch egg 
cells. Two types of offspring colour can be expected: a brown (agouti) animal with the 
genotype A/a C/cch, showing that the chimera donated a wild-type allele, or a cream-
coloured, red-eyed animal (like the mother), meaning that the chimera donated the 
colour alleles from the injected ES-cells. Therefore, cream-coloured animals are 
evidence for germline transmission. 
Animals with a proper coat colour still need to be genotyped for genetic 
modification, because crossing over may segregate the floxed allele from those 
conferring coat colours. Nevertheless, an animal with a proper coat colour shows that the 
chimeric male that sired, is a promising candidate for offspring carrying the floxed allele. 
A chimeric mouse that only yields black offspring (>20 pubs) should not be used for 
further breedings. Furthermore, even when brown or light-brown offspring are obtained, 
one might have to analyze several nests before ever getting a positive offspring showing 
germline transmission. For the ASS project, a chimeric male breeding with Ola females 
gave 10 nests with a total of 61 offspring. Although the offspring were predominantly 
brown, the first 52 offspring (first 9 nests) gave no positive animals for the ASS 
construct. We had to wait for the 10th nest to get one mouse positive for the ASS 
construct. 
There are actually more alleles determining coat colour, that these alleles do 
not play a role here. Depending on the ES cell line used, it may be worthwhile to check 
the genetics beforehand and use this information to decide on crossings that yield a 2-
fold higher rate of ES-cell derived offspring. A comprehensive review of coat colour 
alleles and their interaction can be found on www.jax.org by Willys K. Silvers (1979), 
The coat Colors of Mice; a model for mammalian gene action and interaction. 
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b) Breeding tissue-specific knockout mice 
The ES cells injected into the blastocysts have one floxed allele and one wild-type allele. 
The chimeras obtained are bred to find offspring that carry the floxed genotype in their 
germline. This mouse is then bred to increase the number of floxed offspring. It is also 
crossed with a Cre mouse, in which cre is expressed under control of the Ella promoter. 
This promoter is expressed at the zygotic stage, i.e. before the germline is set aside, so 
that we obtain a hemizygous knockout mouse (35). This hemizygous knockout will be 
crossed with hemizygous floxed mice. 
del-cre 
V \ J 
X+/fi Y+/fl y v y + / -/ V cre+/"/X+/+ 
J v J 
Y V 
V 
J 
Figure 12: Breeding scheme to generate tissue-specific knockout mice. Chimeras are 
bred with wild-type mice to obtain mice with 100% germline transmission and with "del-
cre" mice to obtain mice which are heterozygous for the target gene. The resulting X-
/flox mice (left arm of scheme) are interbred to obtain Xflox/flox mice, which can be 
produced with a high efficiency. The heterozygous X+/- mice (right arm of scheme) are 
bred with cre mice to generate cre+/-/X+/- mice. These mice are then crossed with the 
Xflox/flox mice to obtain cre+/-/X-/flox mice, which have gene Xdeleted in a tissue-
specific manner. This scheme is advisable if cre is suspected to remove the floxed 
fragment inefficiently. However, all cells in the organism have the X+/~ genotype. If cre 
efficiently removes floxedfragments, one can better use mice with a cre+/-/Xflox/flox 
genotype, because the targeted sequence is deleted in the tissue of interest only. 
It takes at least three generations of mice from the chimera to the genetically 
modified animal (Figure 12). If we first work with a floxed allele and a tissue-specific 
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ere, we go for a safe breeding protocol, meaning that X™0 mice are crossed with X+/" 
lcre}~ mice. The advantage of this approach is that ere has to inactivate only one allele in 
the tissue of interest, doubling the chance that the cells in the tissue of interest do not 
express the gene X. The disadvantage of this approach is that all cells in the body only 
contain 1 functional allele of gene X and, hence, usually only 50% of the normal protein 
content. If excision proves efficient, we prefer matings between Xnox/flox and X+/n°7cre+A 
mice, because all cells in these mice contain 2 functional copies of gene X, 
VII- Conclusions 
The following are the important factors to be considered from our experience. 
Constructing the targeting vector: If using the PCR-based approach to amplify the 
homologous arms from genomic DNA, BAC clones should be used to decrease the 
number of amplications. Furthermore, repeats in the regions to be amplified should be 
avoided as they are very difficult to amplify by PCR. Finally, sequence differences 
between strains should be taken into account when selecting the homologous sequences: 
they may interfere with the efficiency of the homologous recombination and should not 
be interpreted as mutations. 
Selection of the recombinant ES clone: The clone to be injected into blastocysts should 
contain only homologously recombined cells. To achieve this, selected colonies should 
be continuously cultured in presence of the appropriate selection drug to avoid the 
growth of wild-type cells. 
Screening against random integration: The "short" PCR method to eliminate the 
randomly integrated clones described in IILa. is an easy, fast and reliable method to 
eliminate randomly integrated clones, if the target DNA is not be located totally at the 
end of the constructs. 
Screening for homologous recombination: The "long" PCR procedure to identify and 
characterize recombination events is faster and more informative than Southern blots. A 
draw back is that the primer pair cannot be tested and optimized before the recombinant 
clone is available. 
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Selection of probes for Southern blotting: Intronic probes have to be checked for the 
presence of repeats. A 300bp probe can suffice for sensitive and specific detection. 
Selection with ganciclovir: Ganciclovir causes mutations. It is therefore necessary to 
resequence the clone after the excision of the selection cassette. 
Coat colour as a marker for germline transmission: Coat colour as a marker doubles 
the chance to identify a male with proper germline transmission of the floxed allele. 
Breeding set-up: The best genotypes to study physiological effects of gene knock out 
are flox/flox and flox/flox-Cre. In all our modified mice (ASS, Arg-1 and CAT-1), we 
obtained very good excision efficiency in vivo of both alleles with ere. It is therefore 
recommended to set up breeding schemes that yield these genotypes. 
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Summary 
In mice and man, neonatal deficiency of ornithine transaminase and ornithine 
trans carbamoyl as e causes severe hypoargininemia, because endogenous citrulline 
synthesis must offset the deficient supply of arginine via the milk. Suckling mammals, 
including mice, differ from adults in the abundant expression of enzymes synthesizing 
arginine from citrulline in their enterocytes, but arginine can also be synthesized outside 
the gut. The importance of the small intestine for whole-body arginine synthesis was 
tested by crossing "Assn/fl" mice (that have exon 13 of the argininosuccinate-synthetase 
gene surrounded by loxP sites) with mice (that transgenically express Cre in 
their enterocytes). To reduce the extra-intestinal capacity to synthesize arginine, VilCre 
mice were also crossed with ASS" mice. 
In suckling VilCretg/7Assfl/fl and 
VilCretg/7Ass"/fl mice, ASS was completely deleted in the enterocytes, but no signs of the 
arginine-deficiency syndrome (hypoargininemia, deficient muscle and hair growth, or 
underdevelopment of Peyer's patches) developed. The systemic loss of one Ass allele, 
nevertheless, increased circulating citrulline with ~50pM and the loss of intestinal ASS 
expression with an additional ~80pM. Using microspheres, we showed that 80±3% of 
the transhepatic blood flow of neonatal day 14 mice originated in the portal vein and 
19±3% in the hepatic artery. Kidney perfusion was only 20±3% of that through the 
splanchnic region. Relative to Ass+/+ mice, arginine production in the splanchnic region 
was abolished in all experimental genotypes, whereas citrulline production had 
increased. The elimination of ASS expression in the enterocytes with genetic tools 
demonstrates that arginine biosynthesis in the small intestine is dispensable for murine 
neonates. 
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Abbreviations: 
ASS: 
ND: 
mice: 
VilCretg/7Ass+/+ mice: 
VilCre^VAss™ mice: 
VilCretg/7Ass+/" mice: 
ASS-KO/I mice: 
argininosuccinate synthetase [EC 6.3.4.5]; 
neonatal day; 
mice that transgenic ally express Cre in their small-
intestinal enterocytes; 
control animals; 
mice with absent ASS expression in the 
enterocytes only; 
mice with a single functional Ass allele only; 
mice without ASS expression in the small-
intestinal enterocytes (VilCrete/7Ass"m or VilCrelg/" 
/Ass™). 
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Introduction 
Arginine is a substrate for the synthesis of nitric oxide, urea, ornithine, citrulline, 
creatine, agmatine, glutamate and proline (1,2). The rate-determining enzyme of 
arginine synthesis from citrulline and aspartate is argininosuccinate synthetase (ASS) 
(EC 6.3.4.5) (3). The endogenous biosynthetic capacity for arginine suffices to meet the 
daily requirement under normal conditions, but a dietary source of arginine becomes 
necessary when demand increases under anabolic or catabolic conditions (4-6). For this 
reason, arginine is a conditionally essential amino acid. 
These general conclusions apply to postweaning individuals that can adapt their 
sources of food. However, neonatal arginine metabolism differs considerably from that 
in the adult, probably because the rapidly growing suckling animals have no choice of 
food. Since the supply of arginine via the milk is not sufficient to support protein 
synthesis (7-9), suckling animals need a higher endogenous capacity for arginine 
synthesis. The abundant expression of the enzymes necessary for de novo arginine 
biosynthesis in the enterocytes of the small intestine of perinatal rodents (10-13), piglets 
(14-17) and humans (Koehler et al., submitted) and the absence of cytosolic arginase 
expression (18, 19) implicate the intestine as an important site for neonatal arginine 
production. In fact, it has been demonstrated that the small-intestinal mucosa accounts 
for -50% of the endogenous production of arginine in normally fed suckling piglets and 
that hypoargininemia develops when this source of arginine production is bypassed as 
during parenteral feeding (18,20-22). Finally, we have shown that suckling mice that 
transgenically overexpress arginase-I in the small-intestinal enterocytes suffer from a 
deficient hair and muscle growth and underdevelopment of Peyer's patches due to 
impaired B-cell maturation (23, 24). The capacity of the intestine to produce arginine 
becomes limited to citrulline synthesis in the weaning period, when the expression of 
ASS and ASL in the intestines declines in humans and pigs (Koehler et al, submitted) 
(10,25-27), and stops in rodents (10, 25-27). It is, however, not known whether 
intestinal arginine biosynthesis is essential for suckling animals, as would be expected 
from the above mentioned arguments. 
To specifically address the question to what extent small-intestinal arginine 
synthesis is essential for suckling mice, we have eliminated the expression of 
argininosuccinate synthetase (ASS) in the enterocytes, using the Cre-loxP recombinase 
system. Since the homozygous deletion of Ass is lethal (28), exon 13 of the murine Ass 
gene was surrounded by loxP sites, using genetic techniques. Excision of the "floxed" 
exon was accomplished using the transgenic VilCre mouse (29), which expresses the 
recombinase Cre protein in the enterocytes of the small intestine only. Suckling VilCretg/" 
/Ass"/fl and VilCretg/7Assfl/n mice were completely devoid of ASS in their enterocytes, but 
unexpectedly did not suffer from growth retardation or, as far as we have been able to 
establish, any other functional impairment. Even though intestinal citrulline synthesis is 
essential for neonatal mice to maintain normal circulating arginine levels (30), the 
present model shows that intestinal arginine biosynthesis is not essential for normal 
growth and development and implicates that other tissues can compensate for the loss of 
arginine synthesis in the gut. 
Methods 
Plasm id construction and recombinant ES cell selection 
The mouse Ass gene is located on chromosome 2. Protocols were obtained from (31, 
32). The targeting vector (14.384 Kb) consisted of the 3' 4.2 Kb of intron 12, a Neo-TK 
selection cassette flanked by frt sites (33, 34), exon 13 flanked by loxP sites (35, 36) and 
the 5' 3.5 Kb of intron 13 (Figure 1). The targeting construct was sequence verified with 
respect to splice junctions, exon 13 and recornbinase-recognition sites, digested with 
AscI and Pmel (introduced by PCR for cloning purposes), and purified by 
electrophoresis and electro-elution. Twenty-five j.ig of the targeting fragment was 
electroporated into the mouse ES cell line E14IB10 (129/Ola). Selection with G418 (200 
jag/mL) was started 24 hours after electroporation. Short vector sequences that were left 
on either end of the targeting construct allowed a PCR-based screen against random 
integrations. Long-distance PCR, using AccuTaq (Sigma), an ASS-specific primer 
outside the targeting construct and a loxP-specific primer, was used to demonstrate 
homologous recombination at the 3' side in the remaining clones. Proper recombination 
of the 5' end was demonstrated with Southern blotting and probing with a Neo fragment. 
The Neo-TK cassette was removed by transient transfection with an FLPe recombinase 
expression vector (kindly provided by Dr. Francis Stewart, EMBL, Germany). Selection 
with ganciclovir (5p.M) was started 5 days after electroporation. The recombined allele 
was again sequence verified (ganciclovir introduced a mutation in 1 of 4 clones tested). 
Two clones containing 40 chromosomes were selected for blastocyst injection. 
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Generation of transgenic mice and husbandry 
ASS-recombinant ES cells were injected into C57B1/6J blastocysts. Chimeric males were 
bred with females on an Ola background (The Jackson Laboratories, Bar Harbor, Maine) 
and with deleter-Cre females on a C57B1/6 background (kindly provided by Dr. Ursula 
Lichtenberg, University of Cologne, Germany) to delete Ass exon 13 in the germ line 
(37). Mice were genotyped with primers ASS-F1 and ASS-R1 (supplementary Table 1, 
Figure 1), yielding a 360 bp wild-type allele and a 390 floxed allele. The Cre-excised 
allele was detected by PCR with the primers ASS-F2 and ASS-R1. To specifically delete 
the floxed ASS allele (Assfl) in the enterocytes of the small intestine, mice were crossed 
with VilCre mice (29) that were obtained from Jackson Laboratories. Animals were 
genotyped for the presence of VilCre by PCR with primers Vil-F and Vil-R (see 
supplementary Table 1), yielding a 1,100 bp band for VilCre-positive animals. 
Animals were housed in humidity- and temperature-controlled rooms on a 12-
hour light/12-hour dark cycle with food and water ad libitum. The animal studies were 
reviewed and approved by the institutional animal care and ethical committee (DEC) of 
Maastricht University. 
Blood and tissue collection 
Animals were sacrificed by decapitation on neonatal day (ND) 14, 18, 21, and 35. Blood 
samples from the hepatic vein, portal vein, renal vein and left ventricular cavity were 
taken from 14-day-old mice under 2% isoflurane (Abbott, # B506)/ 90% 0 2 anesthesia, 
as described for adult mice (38), Tissues were fixed in 4% buffered formalin and 
embedded in paraplast. 
Amino-acid concentration 
Blood was collected into heparin-coated tubes and centrifuged at 2,000*g for 5 min at 
4°C. 80 pL of plasma was added to 6.4 mg of lyophilized sulphosalicylic-acid, vortexed 
and stored at -20°C. Amino-acid concentrations were determined by HPLC as described 
(39). Amino-acid fluxes were calculated as described (38). 
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Blood flow distribution using radioactive microspheres 
Radioactive microspheres (15 p.m diameter), labeled with the radioisotope Ruthenium-
103, were purchased from Perkin Elmer USA (NEM082A100UC). Fourteen-day old 
mice (~6 gram bodyweight) were anesthetized by intraperitoneal injection of 100 pg/g 
ketamine (Pfizer)/ 20 jjg/g xylazine. After opening the thorax through the fourth left 
intercostal space, 50 fiL of a 0.01% Tween-80/saline solution containing 10,000 
microspheres (0.56 ja,Ci) was injected into the left ventricle of the mouse. Organs were 
isolated, transferred to a plastic counting vial containing 2 mL of saline and measured 
with a gamma counter (Wallac 1480). 
Western blotting and histology 
Tissues were crushed in a liquid nitrogen-cooled mortar, sonicated in RIP A buffer (25 
mM Tris*HCl (pH=7.6), 150 mM NaCl, 1% NP-40, 1% Na-deoxycholate, 0.1% Na-
dodecylsulfate), containing a protease inhibitor cocktail (Complete; ROCHE, The 
Netherlands). Twenty-five p.g of protein, as determined with the Bradford assay, were 
loaded per lane. ASS was visualized by incubation the blots with rabbit anti-mouse ASS 
antiserum (1:1,500; (23, 24)), followed by alkaline phosphatase-coup led goat anti-rabbit 
antibody and "Super Signal West Femto Maximum Sensitivity Substrate" (Pierce # 
34095). Duodenum (2 cm distal to the pyloric sphincter) and ileum (2 cm proximal to the 
ileocecal junction) were sectioned at 7 jim. Goblet cells were visualized with 1% Alcian 
blue (BDH, The Netherlands) in 3% acetic acid (pH = 2.5) for 30 min. Nuclei were 
visualized with 1 % Nuclear Fast Red (Chroma, Fluka) for 3 min. For immunostaining, 
sections were subjected to antigen retrieval (10 min at 100°C in 10 mM Na citrate (pH 
6.0)), blocked with Teng-T (10 mM Tris (pH-7.6), 5 mM EDTA, 150 mM NaCl, 0.25% 
gelatin, 0.05% Tween-20) /10% normal goat serum (NGS, Gibco, The Netherlands) for 
30 min, and incubated overnight in a 1:1,000 dilution of the ASS antibody (23, 24) in 
Teng-T/10 % NGS. After washing with PBS and another blocking step with Teng-T 
/10% NGS for 15 min, sections were incubated with goat anti-rabbit antiserum (Sigma 
A3687; diluted 1:200 in Teng-T /10% NGS) for 90 min. After washing, the slides were 
incubated with nitroblue tetrazolium chloride/5-bromo-4-chloro-3-indolyl phosphate 
(NBT/BCIP; Roche 169471) at 37°C until staining reached an optical density not 
exceeding 0.8. 
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Visualization of Peyer's patches 
The small intestine was immersed for 5 min in 10% acetic acid (v/v) before fixing them 
in 10% neutral-buffered formalin, as described previously (40). 
Quantitative PCR 
RNA was extracted from cells and tissues with guanidinium thio cyan ate (TRI Reagent, 
Sigma). RNA integrity was assessed by denaturing gel electrophoresis and RNA 
concentration with a NanoDrop-NDlOGO spectrophotometer (Isogen Life Sciences). One 
jig of total RNA was reverse transcribed with the iScript cDNA synthesis kit (Bio-Rad), 
PCR was performed using iQTM SYBR® Green Supermix (Biorad 170-8882) in an iQ5 
real-time PCR detection system (Biorad). The extension temperature was 60°C for all 
primer pairs. cDNA samples were diluted 60-fold before use for mRNAs and 600-fold 
for 18S. Primary fluorescent data were exported and analyzed using the Lin-RegPCR 
program (41). All primers (supplementary Table 1) were obtained from Genosys 
(Sigma). 
Statistics 
Between-session variation in replicate experiments was corrected using Factor 
Correction (42). All quantitative values are presented as means ± SEM. Statistical 
differences for the amino acids fluxes between genotypes were based on homogeneity of 
variances between the blood sources per genotype followed by one-way analysis of 
variances using known means and standard deviations. P-values were calculated through 
multiple comparisons (43). 
Results 
Characterization of Ass conditional knockout mouse 
To study the function of ASS in the enterocytes of the small intestine, we generated a 
conditional ASS knockout, in which the critical exon 13 is flanked by loxP sites. Mice 
with Ass"/fl and Assm genotypes are healthy and fertile. Figure 2A shows that flanking 
exon 13 with loxP sites does not affect ASS protein expression. To test if deletion of 
exon 13 in the mouse is as effective (lethal) as deletion of exon 4 (28), we interbred 
Ass+/" mice (generated by crossing Ass mice with deleter-Cre mice (37)). Figure 2B 
demonstrates that none of the Ass"/_ neonates survived longer than 1 day after birth, as 
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Figure 1. Production and molecular analysis of conditional Ass knockout mice. Panel A: 
schematic representation of the Ass-targeting construct (AscI - Pmel). The AscI and 
Pmel sites flanking the construct (14.38 Kb) were introduced by PCR. The Xmnl and 
EcoRI sites upstream from the recombination arms of the targeting construct were used 
for Southern-blot characterization. Panel B: Identification of successfully targeted ES 
cells. Top subpanel: PCR amplification of vector sequences downstream of AscI (left) or 
upstream ofPmel (right) identify clones that carried random integrations of the 
targeting vector. Middle subpanel: Long PCR to demonstrate homologous 
recombination on 3' side with primer in loxP site and primer downstream of Pmel\ 
yielding a band of 7kb. Bottom subpanel: Southern blot of ES cell DNA with proper 3' 
homologous recombination after digestion with Xmnl and EcoRI. Two fragments of the 
expected size (8.663kb and 10.158kb) were detected with the internal Neo probe. Panel 
C: Wild-type (Ass+) exon-13 allele, floxed (Assfl) allele, and Ass-deficient (Ass-) allele, 
together with remnant frt and loxP sites. Fl, F2, and R1 indicate the position of the 
primers used to identify these genotypes (for sequence, see supplementary Table 1). 
Panel D: Mouse genotyping. Top subpanel: The Fl and R1 primer pair yield a band of 
360 bp for the allele and 390 bp for the Assfl allele. Middle subpanel: The F2 and 
R1 primer pair yield a band of340 bp for the Ass- allele. Bottom subpanel: The presence 
of the VilCre construct was detected with primer pair Vil-F and Vil-R, giving a band of 
-1,100 bp. 
was found for the conventional knockout mouse (28). Together, these data show that 
mice harboring the Assfl allele are a good model to investigate the effects of tissue-
specific Ass deletions. 
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VilCre efficiently and specifically eliminates Ass in the enterocytes 
To evaluate the development of the small intestine in the absence of ASS expression in 
the enterocytes, intestines of ND14, ND18, and ND21 mice were sectioned and stained 
with haematoxylin and eosin or with Alcian blue and Nuclear Fast Red. No qualitative 
differences in the architecture of the duodenum and ileum were found between VilCretgA 
/Ass™, VilCretg/VAss"/fl and VilCretg/7Ass+/+ mice at any of the ages investigated (not 
shown). Staining the duodenum and the ileum of these mice (Figure 3) for the presence 
of ASS reveals a complete elimination of ASS expression in the enterocytes, whereas 
ASS expression in the enteric ganglia remained unaffected. Although both ASS and 
villin are expressed in the proximal tubules of the kidney (44, 45), the VilCre transgene 
is not (29). Accordingly, we did not observe ablation of ASS expression in the kidney 
(Figures 2C and 3). 
ASS expression in the skin was lower in VilCre^VAss™ mice (Figure 2C). 
Although we did not anticipate ablation of Ass in the skin, both ASS and villin are 
coexpressed in the epidermis (46, 47).Development in the absence of ASS expression in 
the enterocytes F/A2 mice, which cannot synthesize arginine in their enterocytes due to 
the transgenic expression of arginase-1 in these cells, suffer from impaired hair and 
muscle growth and underdevelopment of Peyer's patches due to impaired B-cell 
development during the suckling period (23,24). 
Despite the complete elimination of ASS expression in their enterocytes, 
VilCre^7Ass"/n and VilCre^VAss™ mice show an unimpaired increase in body weight 
(Figure 3D), hair growth (Figure 3E), and development of Peyer's patches (Figure 3F). 
Changes in the circulating concentration of amino acids in the absence ofASS 
expression in the intestine 
Circulating amino acids in arterial, portal, hepatic and renal blood of Ass+/+, Ass+/", Ass" 
/fl, and Ass1™ mice expressing Cre in their enterocytes (VilCretg/") were determined at 
ND14 (supplementary Table 2). In addition, the summed concentrations of all amino 
acids are presented. Compared to wild-type mice, no significant changes in the 
circulating concentration of arginine were observed in the arterial blood of the 
experimental groups, while its levels had decreased to -70% of wild-type values in the 
portal blood of Ass"/n mice and to -70% of wild-type values in the hepatic blood of all 
three experimental groups. In the renal vein, arginine concentrations had increased to 
130% of control values in of Ass+/" mice. 
Circulating levels of the arginine precursor citrulline changed more profoundly 
(Figures 4 and 5B), increasing 1.5-2-fold in the arterial and portal blood, and 2-3-fold in 
the renal-vein blood of all experimental animals. In the hepatic vein, citrulline levels had 
increased -1.6- and -2.5-fold in Ass+/" and Ass"/fl mice, respectively. These changes 
could be attributed to a -50 pM increase for the systemic loss of one functional Ass 
allele, while the loss of the capacity to synthesize arginine in the enterocytes amounted 
to approximately 80 jiM (Figure 5B). We could not reliably determine the level of 
aspartate, the other substrate of arginine biosynthesis. Changes in the levels of further 
upstream substrates, such as ornithine, glutamate, and alanine (Figure 5A), did not 
change in a uniform manner (Figure 4). Lysine, which shares the transmembrane CAT 
transporters with arginine, had decreased markedly in the portal vein of Ass"/fl mice only 
(Figure 4). 
Changes in the fluxes of amino acids in the absence of ASS expression in the intestine 
To be able to estimate the fluxes across the intestine, liver and kidneys of the suckling 
ND14 mice, we determined the distribution of radioactive microspheres injected into the 
left ventricular cavity (Figure 5C). At this age, 80 ± 3% of the transhepatic blood flow 
originates in the portal vein and 19 ± 3% in the hepatic artery. 
We were not able to measure references samples in the abdominal aorta of 
these small mice, so that we could only use the data to calculate relative metabolic fluxes 
in the portal drained viscera and liver (therefore expressed as "units" in Figure 4). 
Assuming no large differences in the cardiac output between the genotypes (all 
genotypes grew equally well during the entire suckling period (Figure 3D), we calculated 
the flux of these amino acids across the portal-drained viscera, the liver, and the kidneys. 
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Figure 2. Biological effects of modification of exon IS of the mouse Ass gene. Gray bars 
indicate VilCretg/-/Ass +/+ and black bars VilCretgNAssfl/fl mice. Panel A: Western 
blot demonstrating that the loxP sites surrounding exon 13 do not affect ASS expression 
at the protein level (25jug total protein was loaded per lane; quantification of band 
intensity on right-sidedsubpanel). Panel B: Cre-mediated homozygous elimination of 
exon 13 causes neonatal death, as was previously shown for elimination of exon 4 (58, 
59). Panel C: ASS protein in ND14 VilCre tg/-/Assfl/fl mice is eliminated in the 
enterocytes of the small intestine only. Note that the residual ASS expression in the small 
intestine reflects the presence of the ASS-positive enteric ganglia (see Figure 3). Panels 
D-F; VilCretg/-/Assfl/fl mice grow normally during the first 4 postnatal weeks (D), have 
normal hair growth (ND14; E) and normal development ofPeyer's patches in the small 
intestine (ND14; F). 
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Figure 3. Expression of ASS in the small intestine, kidney and liver ofND14 mice. Gray 
bars indicate Vi I Cre tg/-/A ss +/+ and black bars Vil Cre tg/-/A ssfl/fl mice. ASS protein 
expression in the duodenum (left 2 columns) and ileum (right 2 columns) of control (gray 
bar) or VilCretg/-/Assfl/fl animals (black bar) is visualized by semiquantitative 
immunohistochem is try. The second row ofpanels shows magnifications of the top row. 
Note that expression of ASS in controls is limited to the top portion of the villus. Further 
note that the elimination of ASS expression is complete in the enterocytes of 
VilCretg/-/Assfl/fl mice, but unaffected in their enteric ganglia (arrows). The bottom row 
ofpanels shows expression of ASS in the S3 segment of the proximal tubule of the kidney 
and the periportal region of the liver ofVilCretg/-/Ass+/+ and VilCretg/-/Assfl/fl mice. 
Bars: 8 pm (overviews) and 1 pm (magnifications). 
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Figure 4. Circulating levels andfluxes of amino acids in ND14 mice. Panel A: 
Circulating concentrations of arginine (Arg), citrulline (Cit), ornithine (Orn), glutamate 
(Giu), alanine (Ala), lysine (Lys) and the sum of all amino acids (EAA) in 
VilCretg/-/Ass+/+(white), VilCretg/~/Assfl/fl (light gray), VilCretg/-/Ass+A (dark gray), 
and VilCretg/-/Ass-/jJ (black) mice. The source of the blood is indicated. Panel B: 
Production and consumption of arginine, citrulline, ornithine, glutamate, alanine, lysine, 
and the sum of all amino acids across the splanchnic region, portal-drained viscera 
(PDV) and liver, assuming the blood flows as determined by microsphere injection 
(Figure 5C). 
Relative to Ass+/+ mice, the production of arginine by the splanchnic region had 
become non-significant in all experimental genotypes, whereas citrulline production was 
jte j «m < a 
and Ass" relative to Ass++ mice. The sum of all amino 
.+/+_„ J A ~/fl 
increased, as expected, in Ass 
acids produced in the splanchnic region was similar in Ass"^ and Ass"'" mice, but ~1.5-
fold lower in Ass+/" and -4-fold lower in Ass™ mice than in Ass+/+ mice (Figure 4). The 
differences between the respective genotypes in the splanchnic production of most amino 
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acids followed this trend (supplementary Table 3) only in Ass"/fl mice, whereas citrulline 
production had increased in only Ass™ mice. Ornithine production was highest in Ass+/+ 
and Ass™ and lowest in Ass+/" mice, while glutamate production was similar in all 
genotypes. Lysine production was highest in Ass™ and lowest in Ass"/fl mice. As noticed 
for the splanchnic region, the differences between the respective genotypes in the 
intestinal production of the remaining amino acids (supplementary Table 3) could be 
largely understood from the fact that the sum of all amino acids produced was similar in 
Ass+/+ and Ass™ mice, but -2-fold lower in Ass+/" mice and -4-fold lower in Ass"/fl mice 
than in Ass+/+ mice (Figure 5). 
The liver of Ass™ and Ass+/" mice consumed some arginine, while citrulline 
was released from the liver of Ass /n mice and ornithine from that of Ass+/+, Ass+/~, and 
Ass"/fl mice. The liver of Ass™ mice was a net consumer of amino acids, whereas the 
sum of all amino acids produced in the liver of Ass+/+ mice was similar to that of Ass+/" 
and Ass"/n mice, although the production in Ass"/fl livers was almost 2-fold bigger than 
that in Ass+/" livers (Figure 5). The differences between the respective genotypes in the 
hepatic production of most amino acids followed this trend (supplementary Table 3). 
Adaptive changes in metabolism of the kidney. 
The main difference between the genotypes in the concentration of amino acids in the 
renal vein were those of citrulline, that was -2-fold increased in Ass+A and Assfl/fl and 
-3-fold in Ass-/fl mice relative to Ass+/+ mice (260 ± 15 pM; supplementary Table 2). 
However, arginine levels were not different in the experimental genotypes relative to the 
Ass+/+ genotype. Furthermore, branched-chain amino acids, reflecting similar trends in 
valine, isoleucine and leucine, were -1.5-fold increased in Assfl/fl relative to Ass+/+ 
mice. Due to the relative tiny rate of perfusion of the kidneys (20 ± 3% of that through 
the splanchnic region), the contribution of the kidney to amino-acid metabolism is still 
minor at 14 days after birth (supplementary Table 3). 
Discussion 
The main findings of the present study are that the elimination of ASS expression from 
the enterocytes of the small intestine of suckling VilCretg/"/Ass™ and VilCretg/7Ass'/fl 
mice was complete and specific for enterocytes (Figure 3), but unexpectedly did not 
affect the animal's growth and development. In agreement, no differences in the 
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production of arginine across the portal drained viscera were found in ND14 knockout 
and control mice. Only a higher concentration of citrulline in the portal vein revealed the 
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Figure 5. Metabolic routes in the intestine leading to arginine synthesis (panel A), 
increases in citrulline levels in 4 vessels and 4 Ass genotypes (panel B), regional 
perfusion in neonatal day 14 mice as assessed by microsphere distribution (panel C), 
and significant changes in the flux of amino acids across the splanchnic region, the 
portal drained viscera and the liver in the respective Ass genotypes (panel D). In panel 
A, amino acids are shown in rectangles. In panel B, the average concentration of 
citrulline in the respective vessels is shown (cf supplementary Table 2). In panel D, dark 
gray fields represent differences with P < 0.05. Differences with 0.05 <P <0.07 (light 
gray) are also shown, because the power of our calculations sufferedfrom the fact that 
all blood samples were taken from individual 9-10 gram pups. 
absence of ASS in the enterocytes. The use of genetic tools to eliminate Ass selectively 
and completely from the enterocytes has, therefore, allowed us to demonstrate that 
arginine biosynthesis in the small intestine is dispensable for murine neonates. 
Specificity of the intestinal ASS-deficient mouse model 
We developed the Assfl mouse model in which ASS can be specifically and completely 
inactivated by breeding them with Cre-expressing transgenic mice (Figure 1) to assess 
the contribution of intestinal arginine production to normal postnatal development. The 
"Cre-loxP" approach enables one not only to delete a gene in specific tissues, but also to 
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do so in animals in which the expression of the "floxed" gene is eliminated in the 
targeted tissue only (Ass™ genotype) or the expression of Ass in other ASS-positive 
cells is additionally reduced by 50% (Ass"/fl genotype). In the latter mice, the 
compensatory capacity of arginine-producing cells outside the gut would presumably be 
compromised. We chose to surround exon 13 with loxP sites, as deletion of this exon 
causes the complete loss of ASS expression in human neonates (48). Floxing exon 13 of 
the mouse Ass gene did not affect its expression (Figure 2A), whereas the Cre-mediated 
deletion of exon 13 in the germ line caused neonatal death, as was observed after 
homozygous deletion of exon 4 in the mouse (Figure 2B; (28)). 
Elimination of exon 13 in the small-intestinal enterocytes by VilCre-mediated 
excision resulted in undetectable levels of the ASS protein in the targeted cells only 
/fl 
(Figures 2 and 3). The observation that excision of 1 floxed Ass allele (as in Ass" mice) 
was as complete as that of 2 alleles (as in ASS™ mice) demonstrates the highly efficient 
excision obtained with the VilCre transgene and the easy accessibility of the floxed Ass 
alleles to the Cre enzyme. It was, therefore, to some extent unexpected that the VilCre-
mediated complete elimination of Ass from the enterocytes of neonatal mice did not 
cause hypoargininemia or any other detectable arginine-dependent deficiency, 
irrespective of whether these mice carried the Ass™ or Ass"/fl genotype. We, therefore, 
carefully evaluated the consequences of the genetic modification. Since the gut of ASS-
KO/I mice still contained -20% of ASS that was present in control mice (Figure 2C), we 
checked ASS expression throughout the small intestine and found it absent in the 
enterocytes only (Figure 3). ASS expression in other tissues, such as the enteric ganglia, 
kidney tubules, and hepatocytes was not affected (Figures 2 and 3). 
The metabolic consequences of intestinal deletion of ASS 
We had anticipated that we would be able to differentiate the effects of the Assfl and Ass" 
alleles by pair-wise comparisons of the VilCretg/7Ass+/+, VilCretg/7Ass+/", 
VilCretg/7Ass™, and VilCretg/7Ass"/fl mice, but the metabolic consequences of deleting 
ASS in the enterocytes proved less distinct than those of overexpression arginase-1 in 
these cells (23, 24). The most remarkable difference was, of course, the maintenance of a 
normal circulating arginine level in the ASS-deficient mice and the selective decline of 
this level in arginase-overexpressing mice. The present finding that arterial arginine 
levels remain in the control range in animals without intestinal arginine synthesis 
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demonstrates that extra-intestinal tissues must have a considerable and adaptively 
adjustable capacity to synthesize arginine. Unfortunately, we have not yet been able to 
identify this tissue, even though its capacity still suffices in the VilCrels/7Ass"/fl genotype, 
which misses both the intestinal contribution to arginine synthesis and 50% of the whole-
body capacity due to the ubiquitous presence of the inactive Ass" allele, The kidneys do 
contain a sizable concentration of ASS, but only have a marginal metabolic role in 
suckling mice, as their perfusion is still minor. Only for citrulline, we found a significant 
correlation between circulating concentration and genotype, the concentration increasing 
- 5 0 j l iM for the systemic loss of one functional Ass allele and - 8 0 j i M for the loss of the 
capacity to synthesize arginine in the small intestines. 
We have tried to assess the fluxes of amino acids across the portal drained 
viscera, liver and kidney. The most pronounced differences were found between the 
VilCre^VAss™"VilCrets/7Ass"/n genotypes and the VilCretg/7Ass+/+ and VilCretg/VAssfl/fl 
genotypes, although the latter did not differ significantly for any amino acid in the portal 
drained viscera. In contrast the VilCretg/VAss+/" and VilCretg/7Ass"/fl, and in particular the 
VilCrelg/7Ass+/+ and VilCrets/7Ass+/" were remarkably similar, Furthermore, the much 
larger number of significant differences in the flux across the liver contrasted with the 
paucity of significant differences across the gut as target organ. At present, we have no 
explanation for these trends. 
Because we could not measure the cardiac output, we have assessed to what 
extent this (lack of) information can affect our interpretations. A change in the relative 
contributions of the portal vein and hepatic artery to liver perfusion from 80:20 to 70:30 
or 85:15 hardly affected the calculated fluxes. If the cardiac output would differ between 
the genotypes without effect on the distribution of the blood flow, the patterns would not 
change either. If the blood-flow distribution would also change, it would result in 
comparing in the extreme case a 70:30 distribution for one genotype with a 85:15 for 
another. Although such an unnoticed difference could (partially) undo the relatively low 
production of amino acids in the portal drained viscera of VilCretg/7Ass"/fl mice, it would 
not change another unexplained observation, viz. the relatively high uptake of amino 
acids in VilCre^/Ass™1 livers. We, therefore, do not think that our lack of information of 
the cardiac output and distribution of the blood affects the outcome of our study in any 
major way. 
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Comparison with the transgenic F/A2 model 
Even though ASS expression and, hence arginine biosynthesis, was completely 
eliminated from the enterocytes of ASS-KO/I mice, we did not observe deficient hair 
and muscle growth and underdevelopment of Peyer's patches (Figure 2D-F), features 
that characterize "F/A" mice, in which intestinal arginine biosynthesis is eliminated by 
transgenic overexpression of arginase-1 in the enterocytes (23, 24), The circulating 
concentration of arginine and the phenotype of F/A mice correspond with the degree of 
overexpression of arginase-1 in the enterocytes (23, 24). Except for the circulating 
concentration of arginine and glycine, no amino acid changes in concentration in F/A 
mice. The "healthy" phenotype of mice that lack ASS expression in their enterocytes as 
compared with mice that overexpress arginase in their enterocytes demonstrates that the 
phenotype of F/A mice is not only due to elimination of de novo arginine biosynthesis in 
the gut. Instead, the much lower circulating arginine concentration in F/A mice 
compared to that in ASS-KO/I mice shows that overexpression of arginase-1 causes the 
gut to function additionally as a sink for circulating arginine that passes the intestine. 
Apparently, the capacity of this sink exceeds the supply of arginine by its endogenous 
production and the absorption from the milk. In agreement, the half-life of a 
subcutaneous bolus of arginine was shortened at least 3-fold in F/A2 relative to wild-
type mice (49). The comparison of the ASS-KOA and F/A models therefore 
demonstrates that elimination of intestinal arginine biosynthesis does not produce an 
arginine-deficient phenotype in mice. 
Comparison with other arginine-deficient mouse models 
The intestine is the only net producer of ornithine, the precursor of citrulline and arginine 
(3). In the suckling intestine, ornithine is produced from proline rather than glutamate 
(50). A deficiency of ornithine aminotransferase (OAT), a common enzyme in the 
conversion of glutamate and proline into ornithine, and expressed at ~5-fold higher 
levels in the suckling than the weaned small intestine (30), results in a severe neonatal 
deficiency of ornithine, citrulline and arginine (30). Similarly, the Spf mutation in the 
enzyme ornithine transcarbamoylase (OTC), which severely decreases its capacity to 
convert ornithine into citrulline, causes a deficiency in circulating citrulline and arginine 
levels in suckling mice (51). These findings show that the suckling mouse needs to 
produce arginine endogenously to maintain normal circulating levels of this amino acid. 
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Since the present study demonstrated that intestinal arginine synthesis from citrulline is 
dispensable, the extra-intestinal production of arginine can apparently compensate 
completely for the elimination of arginine synthesis form the intestine in the suckling 
mouse. 
Comparison of intestinal arginine synthesis in suckling mice and piglets 
Hyperammonemia rapidly develops if piglets are parenterally fed with an arginine-
deficient diet (18). Extensive metabolic studies in chronically instrumented piglets have 
subsequently shown that oral feeding and intestinal arginine production are necessaiy to 
sustain normal circulating arginine levels and growth in piglets (20-22). In enterally fed 
piglets, proline can replace arginine in the diet (18), because the enterocytes convert 
proline into ornithine and arginine (20). Proline is preferred over glutamate as precursor 
of ornithine synthesis, because enteral glutamate is extensively catabolized in the gut 
(52-54). The capacity to synthesize citrulline is determined by the intestinal mass (21) 
and limits the capacity of arginine production to -50% of the daily requirement of 
arginine (20, 22). Citrulline is, therefore, a better exogenous precursor for arginine 
synthesis than proline or ornithine (55). In piglets, intestinal arginine production cannot 
be adaptively upregulated when arginine becomes deficient, but extra-intestinal tissues 
can upregulate arginine synthesis from proline -3-fold (56). The liver does not 
contribute to arginine production (57). These data show that arginine metabolism in 
suckling piglets and mice are very similar. 
Comparison with the human condition 
The analyses of the experimental genetic mouse models have demonstrated that 
intestinal citrulline, but not arginine synthesis is necessary to maintain normal circulating 
arginine levels during the suckling period. The outcomes of the nutritional experiments 
in piglets largely concur with this conclusion. It is therefore of interest that the 
necessarily less complete human data also show that total parenteral nutrition in 
premature neonates is associated with hypoargininemia and hyperammonemia (58, 59). 
In addition, some polymorphisms of the carbamoylphosphate synthetase (CPS-l) gene, a 
rate-determining enzyme of citrulline synthesis, are associated with deficient NO 
production (60). The interest in endogenous arginine synthesis was further boosted by 
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the hypothesis that the fore-mentioned CPS-1 polymorphisms (61) and hypoargininemia 
predispose premature infants to the development of necrotizing enterocolitis (62, 63). 
In the premature piglet, parenteral feeding has also been reported to sensitize 
the animal to a condition that closely resembles necrotizing enterocoltis (64), but, to the 
best of our knowledge, a condition closely resembling necrotizing enterocolitis has not 
been described in neonatal mice. In fact, the circulating arginine concentration in 
neonatal F/A2 mice is only -30% of control values (23, 24, 49), but we never observed 
any sign of ischemic lesions in their intestine. 
Conclusion 
For suckling mice, endogenous citrulline and arginine synthesis is necessary (30) to cope 
with the insufficient supply of arginine in the milk (51). In this respect, mice resemble 
piglets (7-9) and probably humans (18, 20, 21). Under normal physiological conditions, 
the gut releases arginine that is either absorbed from the maternal milk or produced by 
the enterocytes from proline and, to a lesser extent, glutamine (Figure 6A). In mice 
overexpressing arginase-1 in their enterocytes, this and circulating arginine is degraded 
(Figure 6B). After enterocyte-specific ASS inactivation, dietary arginine is still normally 
absorbed and transported, but the de novosynthesized citrulline is no longer converted 
into arginine (Figure 6C). Instead, it is secreted into the portal vein (Figure 6C), Since 
the selective and complete elimination of ASS from the enterocytes does not produce an 
observable phenotype, our experiments have convincingly demonstrated that intestinal 
arginine synthesis from citrulline is not crucial to sustain normal development and that 
an as yet unidentified extra-intestinal tissue is able to upregulate its arginine production 
to maintain circulating arginine levels. 
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Figure 6. Adaptation in arginine synthesis in F/A2 and Ass-KO/J suckling mice. Panel A. 
In control mice, the gut absorbs arginine from the milk (yellow arrow) and produces it 
de novo from citrulline (red arrow). In addition, some citrulline that is secreted to the 
portal vein (narrow red arrow) can be converted to arginine elsewhere, e.g. in the 
kidney. Panel B: Suckling F/A2 transgenic mice suffer from a severe arginine deficiency 
due to over express ion of arginase-1 in their enterocytes (23, 24). Circulating citrulline 
levels in these animals are unchanged (our unpublished observations), but it is unknown 
whether extra-intestinal arginine biosynthesis is upregulated. Panel C: Ass-KO/I 
intestine cannot synthesize arginine de novo, leaving milk as the only source. Due to the 
absence of intestinal arginine synthesis, the AssS-KO/I intestine produces more 
citrulline, while as yet unidentified "peripheral" organs (not the kidney) increase the 
expression of ASS. 
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Appendix: 
Supplementary Table 1: Primer sequences, annealing temperatures and expected PCR-
product lengths 
primer sequence °C length 
Ass-Fl 
(exon 13) 
5 'gaggaagggacagtggggtg3' 
60 
Ass+: Fl—> Rl: 360bp 
Assfl: Fl-> loxP Rl: 390bp 
Assfl: F2-*loxP-exonl3-loxP«-Rl: 
1,000bp 
Ass": F2~+loxP«—Rl: 340bp 
Ass-Rl 
(intronl3) 
5' actgctcagggcacgcatgtg3' 
Ass-F2 
(*) 
5 'tctagaactagtggatcacctcag31 
Vil-F 5 'tgcctggcctaaagctcac3' 
62 1,100 bp 
Vil-R 5' cgacagtatcggcctcagg3' 
*: new sequence between frt and loxP sites 
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Supplementary Table 2: Amino acid concentrations in plasma (pM; mean i 
SEM) of VHCre&fASS* \/ifCre®'/Assm and ViiCre^/Ass* and VilCre^'/Ass^ 
mice, Statistical evaluation was performed by ANOVA. 
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Summary 
An early feature of endothelial dysfunction is a decline in arginine-dependent nitric 
oxide (NO) production, but the relatively mild phenotype of mice lacking all three NO-
synthesizing (NOS) enzymes suggests that NO bioavailability itself is not highly 
pathogenic. NOS produces NO and citrulline in the presence of arginine and 
tetrahydrobiopterin. If either substrate is deficient, NOS '"uncouples" and produces the 
oxygen radical superoxide. These findings suggest that arginine deficiency is more 
detrimental for endothelial function than NO deficiency. We therefore investigated the 
effects of endothelial inactivation of argininosuccinate synthetase (Ass; arginine 
resynthesis from the NOS product citrulline) or Arginase-1 (Argl; arginine breakdown 
to ornithine and urea) by crossing mice with genetically modified Ass (Assflox) or Argl 
(Arglflox) alleles with Tie2-Cre mice that specifically express Cre in the endothelium. 
Ass and NO S3 are co-expressed in the endothelial cells of arteries of young wild-type 
animals, whereas no arginasel was detected in these vessels. Arteries lacking either the 
expression of Ass or Argl did not differ from wild-type arteries in their contractile 
response to phenylephrine or their relaxation response to acetylcholine. Only after 
challenging the arteries with repeated contractions-relaxation cycles, we could 
demonstrate that the relaxation of Ass-deficient arteries was rescued by arginine, but not 
citrulline, whereas the relaxation of Argl-deficient arteries had become more sensitive to 
both added arginine and citrulline than wild-type arteries. The exact mechanism by 
which arginine deprivation causes endothelial dysfunction will be further investigated. 
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Abbreviations 
CRC: Concentration Response Curve NO: Nitric Oxide 
PGI2: Prostacyclin 
EDHF: Endothelial- derived Hyperpolarizing Factor 
CNP: C-type natriuretic peptide 
NOS: Nitric Oxide Synthase 
COX: Cyclooxygenase 
ED: Endothelial Dysfimcion 
ROS: Reactive Oxygen Species 
ASS: Argininosuccinate Synthetase 
ASL: Argininosuccinte Lyase 
CAT-1: Cationic Amino Acid Transporter 1 
oxLDL: oxidized LDL 
ARG 1: Arginase 1 
ARG2: Arginase2 
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Introduction 
The endothelium is the metabolically active tissue that lines the lumen of all blood 
vessels. Its vasoprotective effects include the suppression of platelet aggregation and 
monocyte adhesion, and smooth-muscle cell growth and relaxation (1). Endothelium-
dependent agonists such as acetylcholine and bradykinin, in addition to physical vascular 
stimuli such as shear stress, stimulate endothelial cells to release the vasodilators nitric 
oxide (NO), prostacyclin (PGI2), and endothelium-derived hyperpolarizing factor 
(EDHF). The identity of EDHF is still unknown, although K+ ions, cyclic AMP, 
cytochrome P450-2C products, H202, spread of electric current, and, most recently, C-type 
natriuretic peptide (CNP) have been suggested (2, 3). As long as EDHF remains 
unidentified, its involvement in regulating vascular tone is defined as the response that 
persists after blocking NO synthase (NOS) and cyclooxygenase (COX) (2). For this 
reason, NOSS^/Coxl"'" double-knockout mice are also known as EDHF mice (1). NO 
and PGI2 are the predominant endothelium-derived vasodilators in conduit arteries, 
whereas the influence of EDHF is more prominent in resistance arteries (4), probably 
because basal NO production tonically inhibits the synthesis of prostaglandins and the 
responses to EDHF (1, 5). Male NOSS^VCoxl"7" knockout mice suffer from hypertension, 
whereas their female counterparts do not, suggesting that EDHF could be more 
functional in females than in males (1, 2, 5, 6). 
Endothelial dysfunction (ED) is the impaired ability of vascular endothelium to 
stimulate vasodilatation (7, 8). An early and key feature of ED is a decline in the 
bioavailability of NO as a result of a reduced synthesis and/or an increased degradation 
by reactive oxygen species (ROS). ED is, therefore, also associated with abnormal 
platelet aggregation and monocyte adhesion, and predisposes to both small-
hypertension) and large-artery disease (atherosclerosis). 
Endothelial NO is produced from L-arginine by the NOS isoform 3 (NOS3) 
(7). The functional link between arginine metabolism and NO synthesis is reflected in 
the common localization of NOS3, the L-arginine synthesizing enzymes 
argininosuccinate synthetase (ASS) and lyase (ASL), and the L-arginine transporter 
CAT-1 in the endothelial caveolae (Figure 1) (9-11), Factors that enhance the formation 
of caveolae, e.g. polymerization of the microtubular cytoskeleton, increase NO 
production (2), whereas factors that disrupt caveolae, such as oxidized LDL (oxLDL), 
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decrease NO production (12,13). NOS compete with arginase for their common 
substrate L-arginine. Mitochondrial arginase (ARG2) appears to be the constitutively 
expressed arginase isoform in the endothelium, whereas cytosolic ARG1 expression is 
upregulated in ageing (14, 15), diabetes (16), ischemia (17), and hypertension (18), 
implying that it is the inducible isoform. 
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Figure 1: Arginine and its pivotal role in the endothelial signaling. Three sources of 
arginine are available for the endothelial cell: 1) the synthesis from citrulline imported 
from the extracellular environment via the citrulline transporter (SN2), followed by the 
action ofASS and AL; 2) from the recycling of the NO S3 metabolite citrulline back to 
arginine, using the same two enzymes; or 3) from the direct absorption of arginine from 
the blood via an arginine transporter such as CAT-L Two enzymes in the endothelial 
cell compete for arginine as substrate: 1) NO S3, which produces NO and citrulline; and 
2) arginase, which produces ornithine and urea. NOS3 is activated by an increase in 
intracellular Ca2+ ions following Ach binding to its receptor (AchR) and is localized in 
a specific compartment, called the caveolae. The NO produced readily diffuses to the 
neighboring smooth-muscle cell At low intracellular arginine concentrations, NOS3 
uncouples and produces the oxygen radical superoxide (red) rather than NO. NO 
activates soluble guanylate cyclase (sGC), which metabolizes GTP intro cyclic GMP 
(cGMP) causing relaxation of the smooth-muscle cell (vasodilatation). Phenylephrine 
(Phe), on the other hand, by binding to its receptor on the smooth-muscle cell, causes 
contraction of this cell (vasoconstriction). In a similar way, K+ ions increase the 
concentration of the Ca2+ ions inside the smooth-muscle cell and cause a contraction. 
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The relatively mild phenotype of mice lacking all three NO-synthesizing (NOS) enzymes 
(19) indicates that NO bioavailability in itself is not the major determinant of ED. NOS 
produces NO and L-citrulline from L-arginine in the presence of the co-factor 
tetrahydrobiopterin (BH4). If either becomes deficient, NOS "uncouples" and oxidizes 
oxygen to superoxide (02") (20, 21), which enhances oxidative stress and BH4 oxidation 
(21, 22). These findings suggest that deficiency of L-arginine or BH4 is more 
detrimental for endothelial function than deficiency of NO. 
Many aspects of endothelial arginine metabolism, in particular the degree to 
which import of L-arginine from the plasma, intracellular recycling of L-citrulline to L-
arginine, and L-arginine catabolism by arginase contribute to the availability of L-
arginine as a substrate for NOS3 (Figure 1) remain incompletely understood. Obviously, 
mechanisms can be sorted out in cultured endothelial cells, but pathogenetic and 
therapeutic studies require animal models. In this preliminary study, we show that it is 
possible to generate mice which do not express Ass and Argl in the arterial endothelium 
by crossing mice with genetically modified ("floxed") Ass or Argl alleles with Tie2-Cre 
mice, which express the Cre recombinase in their endothelium. These mice do already 
exhibit a functional phenylephrine phenotype as young adults upon endothelial L-
arginine depletion with repeated contraction-dilation cycles of vessel segments. As a 
proof of principle, we could further show that exogenous L-arginine yielded a higher 
acetylcholine-dependent vasodilation in endothelial Argl-deficient vessels than in 
endothelial Ass-deficient vessels, and that L-citrulline supported vasodilation in this 
condition in endothelial Argl-deficient, but not in endothelial Ass-deficient mice. 
Methods 
Animal husbandry andgenotyping 
Animal studies were reviewed and approved by the institutional animal care and use 
committee of Maastricht University. Animals were housed in humidity- and temperature-
controlled rooms on a 12-hour light/ 12-hour dark cycle with food and water ad libitum. 
The generation of conditional knockout mice, in which "flox" sequences surround exon 
13 of argininosuccinate synthetase (Assfl) or exon 4 of arginase-1 (Arglfl) is described in 
chapters 2 and 3. The presence of Ass11 or Arglfl alleles was determined by PCR using 
the primers (Sigma Genosys) given in Table 1. Specific excision of the Ass or Argl 
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alleles in the endothelium was achieved by crcMing floxed mice with T*e2-Cre mice 
^ ft 3}, 
Tissue collection 
Mice were sacrificed bv 0»/C0~inhaIatHm. The thoracic aorta, mesenteric (first order 
side branches), femoral and saphenous arteries were dissected During direct ion, 
adipose and connective tissue were carefully removed from the arteries After direction, 
arteries were collected in Krebs-Ringer bicarbonate buffer (1IX.5 rnM NaCl. 12 mM 
MgS()4, 1.2 rriM KH P( )4, 1 25 rnM NaHCO,, 2 5 mM C aCl;.» and 5 5 rnM glucose) and 
kept at 4°C until assayed Other parts of the vessels were fixed in 4% buffered formalin 
and embedded in paraplast. 
Histology 
The aortic arch, the thoracic aorta, and the mesenteric and femoral arteries were 
sectioned at 7j,im. Some sections were stained with haematoxvlin and eosin. For 
immunostaining, paraffin-embedded tissues were sectioned at 5 jam. After 
deparaffmation, the sections were pre-incubated with Teng-T (10 mM Trix (pH 7.4), 5 
mM EDTA, 150 mM NaCl, 0.25% gelatin, 0.05% Tween-20) /1 (j % normal goat serum 
(NGS) for 30 min, followed by an overnight incubation with the ASS, ARG1 or NOS3 
primary antibodies diluted in Teng-T/10 % NGS. After washing with PBS and another 
preincubation with Teng-T/10 % NGS for 15 min, sections were incubated with goat-
anti-rabbit secondary antiserum (Sigma A3687; diluted in Teng-T/10 % NGS) for 90 
min. After washing, the slides were incubated with Nitroblue tetrazo 1 iurn 5-Bromo~4-
chloro-3-indolyl phosphate (NBT/BCIP) substrate (Roche 169471) at 37°C until staining 
reached an optical density not exceeding 0,8. After washing and dehydration, the slides 
were exposed to UltraClear and mounted with UltraKit Histograde (J.T.Baker). 
Myograph measurements 
Two-millimeter segments of the arteries were mounted on steel wires (diameter 40 ^m) 
in a myograph organ bath (model 610, Danish Myotechnology, J.P. Trading, Denmark) 
for isometric force measurements. Organ baths were filled with Krebs-Ringer 
bicarbonate buffer, maintained at 37°C, and aerated with carbogen gas (95% 0 /^5% 
CG2). The arterial segments were stretched until a transmural pressure corresponding to 
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13.3 N/m was reached. Arterial viability was assessed using a single dose of 10" M 
phenylephrine (Phe; Sigma P6126, The Netherlands) to stimulate contraction. 
Endothelium was judged to be intact, when subsequent addition of 3.10"5 M 
acetylcholine (Ach) induced an almost complete relaxation of the segments. Whenever 
this initial relaxation in response to acetylcholine was <50%, the endothelium was 
considered to be damaged and the vessel was discarded. Contraction-response curves 
8 5 
(CRC) for Ach (10" -3.10" M in half-log steps) were made following precontraction with 
Phe (3.10"5 M). In addition, Ach-dependent vasodilation after precontraction of the 
A A vessel rings with 4,10" M potassium was tested. Furthermore, the effect of 10 M of the 
n 
L-arginine analogue L-NAME, in the presence of either 10" M arginine or 10" M 
citrulline, was investigated. NO-dependent vasodilatation was also assessed by exposing 
the vessel rings to the NO-donor sodium nitroprusside (SNP; 10"8-3.10"5 M in half-log 
steps). 
L~Arginine depletion experiments 
Two-millimeter segments of femoral arteries were mounted and stretched in a myograph 
and subjected to 14 CRC cycles with Phe and Ach at 15 min intervals. Thereafter, the 
vessel segments were incubated in either 10"3 M arginine or 10"3 M citrulline in Krebs 
medium prior to a final Phe-Ach CRC. 
Statistics 
Results are shown as means ± standard deviation. Significance of the results was 
determined by paired t tests. A value of P < 0.05 was considered to denote statistical 
significance and was marked with an asterisk. 
Results 
ASS, NOS3, and ARG1 expression in the endothelium 
To confirm the presence of ASS, NOS3, and ARG1 in the endothelial cells, segments of 
different arteries were processed histologically and stained with haematoxylin/eosin to 
demonstrate the presence of endothelium and with specific antisera to demonstrate the 
presence of ASS and NOS3. Representative pictures of the aorta and the mesenteric and 
femoral arteries are shown in Figure 2. 
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The Figure shows that the endothelium, internal elastic lamina, tunica media and tunica 
adventitia were all similar in control and experimental mice. ASS protein was found in 
the endothelial cells in all three types of arteries, indicating that ASS is expressed both in 
the endothelial cells of the large elastic arteries and of the medium-sized muscular 
arteries. 
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Figure 2: Cellular localization of ASS and NOS3. Aorta andfemoral artery stainedfor 
the presence of Ass and NO S3. The endothelium of both vessels expresses Ass and N0S3 
(middle and right columns, respectively). Adjacent sections of both arteries (left panel) 
were stained with H&E to verify the presence of endothelial cells. Original 
magnification: 40X.staining is also observed in the tunica media of the aorta and in the 
tunica adventitia of the mesenteric artery. These cells correspond with Ass-positive 
nerve cells. The NOS3 antiserum produced a similar staining pattern as the ASS 
antiserum (Figure 2, right column) in the endothelial cells. This indicates that the 
endothelial cells of these arteries can produce NO and resynthesize L-arginine from L-
citrulline, the other NOS product No staining for ARG1 could be detected in the arteries 
of these young healthy mice (data not shown). 
Generation of mice with a deletion of ASS or ÂRG1 in the endothelium 
We initiated breedings to obtain mice that were deficient in their endothelium for Ass, 
Argl, or the cationic transporter Catl. Breedings were set to obtain the control groups 
Ass+/7Tie2-Cre"r'\ Argr/"/Tie2-CreT/~ and Caf'7Tie2-Cre"r/\ and the corresponding + / - + / - +/- + / -
experimental groups Ass/fl/Tie2-Cre"/_, Argl"/I7Tie2-Cre",'/" and Cat"/n/Tie2-Cre'tv". We 
opted to delete one allele in all cells to make sure that Tie2-Cre would excise the single 
+ / - -/fi +/ - -/  +/-
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remaining floxed allele in as many endothelial cells as possible. Unfortunately, Cat" 
/fl/Tie2-Cre+/" animals died 2-3 days after birth with the same symptoms as Cat-/- mice, 
viz severe anemia (C. de Theije et al, unpublished observations). The viable offspring 
was genotyped using specific primer pairs (Table 1) to detect the wild-type, floxed and 
excised alleles, and the Tie2-Cre construct. Figure 3 shows the typical result of 
genotyping Ass animals, yielding 360bp and 390bp bands with the AssFl and AssRl 
primer pair for Ass+ and Assfl alleles, respectively (top panel). The middle panel shows 
that the excised Assn allele yields a 340bp band with the AssF2 and AssRl primer pair, 
while the bottom panel shows that the Tie2-Cre-specific PCR yields a band of 3 60bp. 
For Argl mice, primer pair ArgFl and ArgRl yields bands of 351 bp and 384bp for the 
Argl+ and Arglfl alleles, respectively, while the excised Arglfl allele yields a 298bp band 
with primer pair AssF2 and Argl-Rl. 
com 
A s s f i : 3 9 0 b p 
A s s * : 3 8 0 b p 
Ass~: 3 4 0 b p 
T i a 2 ^ C r e : 3 8 0 b p 
Figure 3: Genotyping the Tie2-Cre/Ass+/fl mice. Panel A: Typical genotyping data to 
demonstrate the presence of the wild-type andfloxed Ass alleles (top panel, obtained 
when using primer pair AssFl & AssRl described in Table 1) in arteries. The middle 
panel reveals the presence of the excised Ass allele (obtained with the primer pair Ass F2 
and AssRl). In the bottom panel, the expression of Cre in arterial isolates (obtained with 
the Tie2 primer pair). Left to right: positive control, H20 (negative) controls, femoral 1, 
femoral 2, saphenous 1, saphenous 2, mesenteric 1 and mesenteric 2. 
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En doth elial-specific inactivation ofASS expression 
To verify that specific inactivation of Ass by Cre-mediated recombination had taken 
place inside the endothelial cells, paraffin-embedded sections of arteries from 
experimental animals (Ass"/fl/Tie2-Cre+/") and the corresponding controls (Ass"/+/Tie2-
Cre+/~) were stained for Ass.Figure 4 shows representative results for the femoral artery. 
There is clear staining for Ass in the endothelial cells in the control artery (top panel) 
compared to the experimental animals (middle panel). The negative control (bottom 
panel) shows no staining for Ass. The right column shows adjacent H&E- stained 
sections to confirm the presence of the endothelial cells. Similar results were obtained 
for the other arteries (data not shown). 
Role of L-arginine in the regulation of the vascular tone 
Vascular tone refers to the ability of vascular smooth muscle to maintain a permanent 
partial constriction based on equilibrium between the effects of vasodilator and 
vasoconstrictor antagonists. To establish whether L-arginine and endogenous NO 
production could play a role in contraction, the response of the aorta, femoral, saphenous 
and mesenteric arteries to cumulatively increasing concentrations of Phe was analyzed. 
The results of experiments conducted on the femoral artery are depicted in Figure 5A. 
These results were typical for all arteries analyzed, irrespective of genotype. The 
amplitude of the response in Krebs buffer was set at 100%. In Krebs buffer, the log IC50 
for contraction was -4.9 ± 0.1. In the presence of L-arginine (ImM), the response to Phe 
did not change (log IC5o: -4.8 ± 0.5), but in the presence of ImM L-citrulline, the log 
IC50 declined to -4.2 ± 0.2. Supplementing extracellular L-arginine or L-citrulline did not 
alter the contraction of arteries, irrespective of whether ASS was absent or not. Pre-
contracted arteries were then assessed for their ability to dilate in response to Ach in the 
presence of either L-arginine or L-citrulline. In Krebs buffer, the log IC50 of Ach for 
dilatation was -7.3 ± 0.4. There was no significant change in the response to Ach in the 
presence of L-arginine (log IC5o Ach: -7.5 ± 1.7 (Figure 5B). Surprisingly, the vascular 
response to Ach was significantly less sensitive in the presence of L-citrulline (log IC50 
Ach: -6.5 ± 0.6; Figure 5C). While L-arginine therefore tended to decrease the sensitivity 
of the arteries to Ach-mediated dilatation, L-citrulline decreased it by more than 10-fold, 
irrespective of genotype. 
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Figure 4: Specificity of Tie 2-Cre-mediated endothelial inactivation of Ass. Expression of 
ASS in the femoral artery ofAss+/-/Tie2~Cre+/~ control mice (top panel) and Ass-
/fl/Tie2- Cre +/- experimental animals (middle panel). The endothelial cells of the Ass +/-
/Tie2-Cre+/- animals do show a positive signal for Ass, whereas the simultaneously 
stained artery of an A ss-/fl/Tie2-Cre +/- mice did not. If no primary antiserum was 
added, the control artery did not stain either (bottom panel). To confirm the presence of 
endothelial cells in the arteries, adjacent sections were stained with H&E (right 
column). 
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Figure .V ( ontractiie and dilatory properties of experimental arteries The arterial 
contraction in the presence of phenylephrine (10-H-Ith4,5 M) in absentv or presence of 
I m M arginine or ei trull me was registered (panel Ar The amplitude of the response in 
Krebs buffer was set at UHino The contractile response was not dependent on the 
genotype Furthermore, neither arginine m>r cUrulline affected the contrac tion Ihe log 
IC50 for contraction was -4 (hO I in the control t ondition (Krehs buffer onh'}, -4,HiO,5 
in the presence of ImM arginine, and 3 2103 in the presence of ImM a trull me 
Citrullmv decreased the semitivitv to phenylephrine significantly. The amplitude of the 
contraction did not change in am condition In panels B and C, the arteries h o t 
precontracted with phenylephrine prior to exposure to ImM arginine or citrulline tpanel 
B and C respectively>. In Krehs buffer alone. the log IC50 for dilatation was - 7. j ±0, 4 
The addition of arginine to the incubation medium had no signif icant effect (log IC50; -
7.5±j, 7), whereas the vasc ular response to Ach declined in ihe presence of L-citndline 
(log IC50 -6 5til6). 
L-NAME inhibition of endothelial vasodilation 
L-NAMK is a nonselective competitive and, therefore, reversible NOS inhibitor that is 
often used to block NOS.3-mediated NO production. The amplitude of the response to 
Phe was significantly higher in presence of L-NAMK (P< 0.05) (Figure 6A). We then 
tried to reverse the effect of L-NAME by adding either L-arginine or L-cttrulline (Figure 
6B). However, neither L-arginine nor L-citrulline could, at the concentrations used (100 
and lOOOfiM, respectively) revert the effect of L-NAME on Phe-mediated arterial 
contractions (log IC50: -5.0 ± 0.1). We then investigated the effect of L-NAME on Ach-
mediated relaxation for the arteries. For both control and experimental groups of arteries, 
L-NAME significantly prevented the arterial relaxation of the arteries treated with Ach 
(log IC50: -6.7 ± 0,8; Figure 6C). Exogenous L-arginine or L-citrulline added at a 
concentration of ImM to the experimental medium could also not rescue the vascular 
response to Ach in the presence of L-NAME (log IC 50: -7.1 ± 0.8 and -6.6 ± 0.5 
respectively; Figure 6D). 
The findings shown in Figure 6 suggest that the effects of the L-arginine 
analogue L-NAME on NOS3 activity in the mouse are not easily reversible. In the rat, 
however, L-NAME has been described as a reversible inhibitor with inhibitory 
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properties that are reverted by a 10-fold excess (lOOpM) L-arginine (24-26). To verify 
our findings in the mouse, we checked the reversibility of the effects of L-NAME in rat 
aortic rings that were mounted in the myograph exactly as the mouse arteries. After Phe-
mediated pre contraction, we induced arterial relaxation by addition of Ach in presence 
normal medium with or without supplementation with either 100 \iM L-arginine or 1000 
jiM L-citrulline. In all three conditions, Ach induced a vasodilatory response (Figure 
7A). 
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Figure 6: Effect of arginine and citrulline on inhibition of NOSs by L-NAME. Arterial 
segments were precontracted with phenylephrine. The loglCSO for phenylephrine was -
5.0±0.1, whether or not O.lmML-NAME was present (panel A). However, the amplitude 
of the response to phenylephrine increased significantly in the presence of L-NAME (P < 
0.05). Addition of 1 OOpM arginine or citrulline did not reverse the effect of L-NAME 
(panel B; log ICS0: -5.0±0.2 and -4.9±0.1 for arginine and citrulline, respectively. The 
amplitude of the response remained unchanged\ In the presence of L-NAME (10-4M), 
vasodilation in response to acetylcholine was decreased significantly (log IC50: -
6.7±0.8; panel C). The addition of ImM arginine or citrulline (panel D) did not restore 
the vascular response to acetylcholine (loglCSO: -7.1 ±0.8 and-6.6±0.S, respectively). In 
addition, no affect on the amplitude of the response was seen. 
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The effects of L-NAME are reversible in rat vessels 
Pretreatment with L-NAME completely inhibited the Ach-induced vasodilation (Figure 
7B; square plot). This inhibition could be partially restored by supplementing the 
medium with extra L-arginine or L-citrulline (upright and inverted triangles plots, 
respectively). This confirms the reversibility of the effects of L-NAME in rats and 
strongly suggests that the effects of L-NAME are not as readily reversible in the mouse. 
The contribution of the intracellular arginine pool to vasodilatation 
To test if NOS3 activity becomes more sensitive to external L-arginine or L-citrulline 
after depletion of the intracellular arginine pools, femoral artery segments were mounted 
in the myograph and subjected to repeated CRC cycles in L-arginine- and L-citrulline-
tVi 
free Iscove's culture medium. After the 14 CRC cycle, the vasodilatory response to Ach 
was only 10% of the original one (Figure 8A; right and left top panels, respectively). 
After the 13th CRC cycle, arterial segments were then incubated for 1 hour in either 100 
|aM L-arginine or 1000 \xM L-citrulline, pre-contracted for the 14th time with Phe, and 
then subjected to Cre arteries and panel C with Ass"/fl/Tie2-Cre arteries. In both cases, 
the incubation with L-arginine restored the vasodilation, with a higher degree of 
vasodilation in Argl"/n/Tie-2-Cre arteries (-50% dilation at 10"5 M Ach) than in Ass" 
/n/Tie2-Cre arteries (-30% dilation at 10"5 M Ach). Treatment with L-citrulline, on the 
other hand, only caused a increasing concentrations of Ach. Panel B shows the results 
obtained with Argr/n/Tie-2- significant increase in dilation in Argl"/fl/Tie-2-Cre arteries. 
These findings show that the arterial endothelium in mice is sensitive to extracellular L-
arginine and can synthesize L-arginine from L-citrulline, in agreement with the presence 
of Ass protein (Figures 2 and 4). 
Discussion 
Performance of the animal models 
The aim of our study was to delete the expression of Ass, Argl and Cat-1 in the arterial 
endothelium to interfere with intra-endothelial recycling of L-citrulline to L-arginine, to 
inhibit intra-endothelial breakdown of L-arginine and to decrease L-arginine uptake from 
the plasma. We could not use endothelial Cat-1 -deficient mice, because Cat-l^/TieZ-
Cre mice died neonatally with much the same phenotype as Cat-l"'" mice (C. de Theije et 
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Figure 7: Reversibility ofNOS3 inhibition by L-NAME in the rat aorta. L-citrulline, but 
not L-arginine significantly sensitized the rat aorta to the vasodilatory effect of 
acetylcholine (panel A). In the presence of 10-4ML-NAME (panel B), acetylcholine~ 
dependent vasodilation was totally abolished (square plot), but vasodilation was 
restored by supplementing the medium with either arginine or citrulline only at high Ach 
concentrations (upright and inverted triangles plot% 
al, unpublished observations). We used mice with an Ass"/fl/Tie2-Cre or Argl"/fl/Tie-2-
Cre genotype, that is, with one allele already inactivated systemically, to assure that the 
floxed allele would be deleted in as many endothelial cells as possible. We followed this 
strategy with the reasoning that if Cre is not 100% efficient due to e.g. low expression 
levels, deletion of a single allele is more probable than deletion of two alleles. However, 
thus far, alleles appear to be removed equally efficient from fl/fl genotypes as from -/fl 
genotypes (data not shown). We have succeeded in the first 2 aims, because endothelial 
segments that were depleted of L-arginine by repeated contraction-relaxation cycles 
(Ach-dependent relaxation became near extinct) could be rescued by L-arginine. 
Because Ass"/fl/Tie2-Cre artery segments could not be rescued by L-citrulline, whereas 
Argr/fl/Tie-2-Cre artery segments were efficiently rescued, citrulline-to-arginine cycling 
must have been effectively abolished. Furthermore, Argr/fl/Tie-2-Cre artery segments 
were much more effectively rescued by L-arginine than Ass"/fl/Tie2-Cre artery segments, 
which implies that deletion of Arg-1 made more exogenous L-arginine available to 
NOS3. Interestingly, Argl was not detectable in the endothelium of these femoral 
segments when they were taken from the body. We will have to explore if Argl did 
become expressed in the course of this experiment, which took several hours, or whether 
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Figure 8; Ass- and Argl-deficient mouse arteries become sensitive to the effects of 
arginine and citrulline after repeated contraction-relaxation cycles. Femoral arteries 
from Tie2-Cre+/7Ass'/fl and Tie2-Cre+/'/Argl'/-/1 mice were mounted in a myograph. 
Directly after isolation, the log IC50 of acetylcholine in Ass- and Argl-deficient arteries 
(-6.4±0.4 and-6.5±0.2, respectively; panel A, left) did not differ from that of wild-type 
arteries (log ICS0: 6.7±0.8). After 14 cycles of 10' Mphenylephrine-dependent 
precontractions and acetylcholine-dependent dilations (10~8-l 0~4JM), the log IC50 was 
reduced to -3.5±0.25 and -5. 1±0.2 (panel A; right). The initial vasodilator response was 
75% at 10'5M acetylcholine, but after 14 cycles only ~1Q% remained. In panels B and 
C, Ass- (panel C) or arginase-deficient arteries (panel B) were (colored line) or were not 
(black line) incubatedfor 1 hour in the presence of either 100pM arginine or citrulline 
after contraction-dilation cycle #14. In the Argl-deficient arterial segments, the vascular 
response to acetylcholine significantly increased in the presence ofL-arginine or L~ 
citrulline (panel B, right). In the Ass-deficient arterial segments, no significant change in 
dilatation was found in the presence of L-citrulline (panel C, right; 35% relaxation), 
whereas in the presence of arginine (panel C, left), a significant response to 10'5M 
acetylcholine was seen (55% relaxation). 
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very low levels of Argl suffice to interfere with the intracellular availability of L-
arginine to NOS3. 
Response to extracellular L-arginine and arginine pools in the endothelium 
Although Ass"/fl/Tie2-Cre and Argl"/fl/Tie-2-Cre mice did respond as expected, they did 
so only after the intra-endothelial arginine pool had been depleted by repeated 
contraction-relaxation cycles. The problem with arginine pools in the endothelium is 
well established and often referred to as the "arginine paradox". In fact, the problem 
seems to be that the endothelium maintains several intracellular arginine pools (27). One 
pool can be depleted by extracellular lysine, which acts via the L-arginine transporters 
Cat-1 and CD98, whereas the second pool is not freely exchangeable with the 
extracellular space, but accessible to NOS3. Recycling of L-citrulline to L-arginine 
occurs in the second pool and could be inhibited by activating transporter System N1 
(SN1; Slc38A3), presumably by the removal of intracellular L-citrulline, one of its 
substrates. A third pool could not be depleted by any of the cationic or neutral amino 
acids tested and is fed by protein breakdown. This pool does not only generate L-
arginine, but also the posttranslationally modified L-arginine products NG-monomethyl-
L-arginine (L-NMMA) and asymmetric dimethylarginine (ADMA), which are inhibitors 
of NOS3. Since it is postulated that supplementation of L-arginine is primarily effective 
for conditions, in which endothelial ADMA production is enhanced (28), we should 
investigate whether the beneficial effects of L-arginine on the relaxation capacity after 
repeated contraction-relaxation cycles are due to enhanced proteolysis and ADMA 
release. 
Limitations of this study 
Vasodilation of arteries is primarily based on the additive action of NO, prostanoids and 
EDHF. The relative contribution of these factors depends on the location in the vascular 
tree (4, 29), the sex of the animals (1, 5, 6) and the adaptive upregulation of the 
remaining factors in case a factor is inhibited (1, 5). Most experiments that study 
endothelium-dependent relaxation, including those in mice (30, 31), analyze vessel rings 
with inhibitors for all these relaxants separately and in combination. We have not done 
so in the present study and should do so in future experiments. 
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Surprisingly, vascular dilatation in response to Ach did not respond to 
extracellular L-arginine or L-citrulline without prior L-arginine depletion. Rather, the 
addition of L-citrulline and, to a lesser extent, L-arginine inhibited the response to Ach 
in Phe-pre-contracted vessels. It has been reported that high concentrations of L-arginine 
(>100 jjM) exert an inhibitory effect on NOS3 activity by a process called "substrate 
inhibition" (29). We tested the optimal arginine concentrations in our settings and found 
it to be 100 |o,M for arginine and 1000 j.iM for citrulline (data not shown). 
The absence of a more extensive relaxation in the presence of extra ambient 
L-arginine could be due to inaccessible intracellular arginine pools in the endothelial cell 
that feed NO production (see above) or to an Ach-mediated vasodilation that is 
independent of L-arginine and NO. Indeed, it was recently demonstrated that under 
oxidative stress or tetrahydrobiopterin (BH4) depletion, the endothelium can produce 
and release hydrogen peroxide (H202) after exposure to Ach (32). H202, in turn, activates 
the downstream target of cyclic GMP (PKGIa) independently of cyclic GMP (33). 
Under these conditions, NO S3 is probably uncoupled, because H202-dependent 
regulation of the vessels wall is L-NAME-sensitive (32). 
As expected, the vasodilatory responses to Ach declined significantly in the 
presence of the competitive NOS inhibitors L-NAME and S-methylisothiourea (data not 
shown). However, supplementation with neither L-arginine nor L-citrulline restored the 
vasodilator response, even though these compounds should be able to compete with the 
L-arginine look-alike inhibitors. Therefore, L-NAME and S-methylisothiourea appear to 
behave as irreversible inhibitors in mice, even though they do not behave in this way in 
other species (24, 25). We could, for example, show that in a similar experimental set-
up, the effects of L-NAME in aortic-ring segments of the rat were reversible (Figure 7). 
In agreement with our findings, it has been shown that ImM L-arginine in the medium 
cannot undo the effects of L-NAME in mice (34). However, 30mM L-arginine could 
effectively antagonize L-NAME in that study, showing that mice may differ 
quantitatively, but not qualitatively from rats. 
Conclusions 
In the present exploratory study, we did show that mice with floxed Ass or Argl alleles 
are, after crossing with the deleter strain Tie2-Cre, useful models to study L-arginine 
metabolism in the arterial endothelium. Unfortunately, the Tie2-Cre deleter strain 
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generates Cat"7" mice that die neonatally, so that we have to try other endothelium-
specific Cre mice to delete Cat-1 mediated L-arginine import. The immunohistochemical 
assays showed that Ass is indeed expressed in all arterial endothelium we have studied 
so far, but that Argl was not detectable in the endothelium of young adult mice, in 
agreement with the notion that Argl only becomes induced in dysfunctional 
endothelium. Our myograph measurements yielded the expected genotype-dependent 
responses to L-arginine and L-citrulline, although thus far only after repeated 
contraction-dilatation cycles. Finally, recent experiments showed that NO production in 
vivo was reduced -2-fold in the kidney of Ass"/t1/Tie2-Cre mice compared to Ass"/fl mice 
(van Faassen & Koehler, unpublished observations). In conclusion, our observations 
therefore show that Ass"/fl/Tie2-Cre and Argl"/fl/Tie-2~Cre mice are promising mouse 
models to study the relation between endothelial arginine metabolism and endothelial 
dysfunction. 
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Appendix: 
primer sequence primer pair allele detected band size (bp) 
Ass F1 5'GAGGAAGGGACAGTGGGGTG 3' AssFl; AssRl Ass+ & Assfl 360 & 390 
Ass R1 5'ACTGCTCAGGGCACGCATGTG 3' AssF2; AssRl Ass" 340 
Ass F2 5 TCTAGAACTAGTGGATCACCTC 3' 
Tie2F 5'CGCATAACCAGTGAAACAGCATTGC 3' Tic2F; Tie2R Crctg 360 
Tie2R 5'CCCTGTGATAAGACAGAAATGAGA 3' 
Arg F1 5'GGAGAGCCTTCCTGCACTTT 3' ArgFl; ArgRl Arg+ & Argfl 351 & 384 
ArgRl 5'GTGCCTTGGTCTACATTGAACATAC 3* AssF2; ArgRl Arg" 298 
Supplementary Table 1: Primers used in the present study. Primer pairs AssFl and 
AssRl were used to detect the wild-type allele andfloxed alleles as bands of360bp 
(wild-type allele) or 390bp (floxed allele). The other primer pair Ass-F2 and Ass-Rl was 
used to detect the excised allele (exon 13) producing a band of340bp. In a similar 
manner, primer pair Arg-Fl and Arg-Rl was used to detect the wild-type allele and 
floxed alleles as bands of 351 bp (wild-type allele) or 384bp (floxed allele). The primer 
pair Ass-F2 and Arg-Rl was used to detect the excised allele (exon 4) yielding a band of 
298bp. Finally, the primer pair Tie2F and Tie2R yields a band of360bp in animals 
transgenic for the Tie2-Cre construct. 
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Chapter 6 
« 
Concluding discussion 
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In this thesis, I have described the experimental analysis of mice with a modified 
metabolism of arginine due to overexpression of arginase-1 or due to a tissue-selective 
elimination of argininosuccinate synthetase (ASS) in their small-intestinal enterocytes, 
or due to elimination of ASS and arginase-1 in the endothelium. The major findings are 
that overexpression of arginase-1 in the small-intestinal enterocytes causes the 
surprisingly specific "neonatal arginine deficiency syndrome" (hypoargininemia, 
deficient muscle and hair growth, or underdevelopment of Peyer's patches) in the 
suckling period (Chapter 2), whereas elimination of ASS in the same tissue does not 
(Chapter 4). Preliminary studies in mice with an endothelial deletion of ASS or arginase-
1 show that these manipulations do affect endothelial arginine availability, but only after 
stimulation of arginine turnover (Chapter 5). 
Overexpression of a specific gene in a given tissue can be brought about by 
combining that gene with a tissue-selective promoter/enhancer and introducing this DNA 
construct either into the germ line ("classical" genetically modified or transgenic mice) 
or directly into the somatic cells of a host animal. For metabolic studies, the large 
majority of host cells should express the transgenic construct to maximize the effect of 
the intervention. For this reason, only classical transgenic mice or mice virally 
transduced with genes are used. The level of expression of the transgene in classical 
transgenic mice can vary depending on its site of integration in the DNA and the degree 
of mosaic expression (1,2). Mosaic expression, that is, the heterogeneous expression of 
the transgene in a tissue, is the rule rather than the exception in a classical transgenic 
mouse line. In the case of our F/A mice, for instance, 6 founder lines were available. 
Four of these were strongly mosaic and without phenotype, even though the expression 
of the transgene in the F/A-3 and F/A-6 lines was similar to that in the F/Al line, which 
did have a phenotype. Furthermore, the level of expression of arginase-1 in the 2 lines 
that expressed this transgene in all small-intestinal enterocytes, differed 2-fold (3), 
emphasizing the effect of the integration site of the transgene. The importance of the 
level of expression is further demonstrated by the fact that the phenotype of mice with 
the highest expression of the transgene (line F/A2) is more severe than that of mice with 
the lowest expression (line F/Al). Moreover, in both lines homozygotes had a more 
severe phenotype than hemizygotes. 
Because a time-consuming extensive characterization of the pattern and level 
of expression of transgenes in classical transgenic mice is always necessary before the 
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line can be used in experiments, viral transduction can be attractive. In vivo, 
adenoviruses have a strong preference for the liver and can infect >90% of the 
hepatocytes (4). Although adenoviral transduction of genes is an attractive alternative to 
transgenesis for the liver, the situation is much less favorable for other tissues, including 
the endothelium (e.g. (5)). 
Deletion of the arginine-metabolizing enzymes ASS and arginase-1, and of the 
arginine-transporter CAT-1 is not compatible with life (6-8). For this reason, we have 
produced conditional knockout mice, that is, mice in which the gene of interest can be 
selectively deleted in a specific tissue. Because the production of such mice is a long and 
tedious process, in which many steps can be optimized for a better efficiency, we have 
compiled our experience and recommendations in Chapter 3. In this "practical 
approach'Mike chapter, we have also included the experiences that were simultaneously 
gathered in the generation of a conditional glutamine-synthetase knockout (He et al, 
submitted) and green-fluorescent protein "knockins" into the glutamine-synthetase and 
the phosphoewo/pyruvate-carboxykinase loci at our Amsterdam location. The major 
modification we would probably apply if we were to make yet another conditional 
knockout mouse would be to surround the neomycin phosphotransferase selection gene 
by "fit" sites and eliminate it only after chimeras are produced. The selection cassette 
would then be removed by crossing the chimeric mice with "flipper" mice (9), that is, 
mice that transgenically express the Flpe recombination enzyme before the establishment 
of the germ line, so that the selection gene is also eliminated in the germ line (10). This 
approach was not possible with the modified embryonic stem cells we made, because we 
used viral thymidine kinase as selection gene. This is because all fertile chimeric mice 
are males (the embryonic stem cell line used is male) and viral thymidine kinase does not 
allow transmission through the germ line (11). 
The modified approach would have the advantage that no negative selection of 
the embryonic stem cells with Ganciclovir is necessary. This would be preferable, 
because Ganciclovir can induce mutations, as we observed ourselves (Chapter 3). The 
other advantage would be that lines with the selection gene integrated inside the 
modified gene would become available. Because the expression of the modified gene is 
often hampered if another transcriptionally active gene is present within one of its 
introns, this approach would allow the production of mouse lines with attenuated 
expression from the allele still containing the selection marker (12-14). Especially in 
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cases where tissue-specific deletion of the gene of interest is lethal (as e.g. in the case of 
the Tie2-mediated deletion of the CAT-1 gene (Chapter 5), such intermediate levels of 
expression may be advantageous for an experimental analysis. Furthermore, the 
possibility to vary tissue-specific expression not only between 0 (complete knockout), 
-50% (heterozygous knockout), and 100% (wild-type mouse), but also in between (0%< 
expression/activity <50% or 50%< expression/activity <100%) would allow one to 
firmly establish the metabolic control of a particular enzyme in a pathway. 
The finding that F/A2 mice (and, to a lesser extent, F/Al mice) suffer from the 
neonatal arginine-deficiency syndrome, indicates that a drain of arginine via 
overexpression of arginase-1 in the small-intestinal enterocytes is more effective in 
decreasing circulating arginine levels (Chapter 2) than eliminating arginine production in 
the intestine (Chapter 4). This finding is remarkable, since the mere size of the small 
intestine indicates that it should materially contribute to whole-body arginine production. 
In fact, it does so in the neonatal piglet, in which it accounts for -50% of the daily 
endogenous synthesis (15, 16). The reason for this quantitative difference between 
suckling piglets and mice is not clear. Possibly, extra-intestinal arginine synthesis has a 
higher adaptive capacity in the mouse than in the piglet. Such a difference might also 
explain why the piglet appears to be more sensitive to the development of necrotizing 
enterocolitis (17), which may well be an arginine-deficiency disease (18-21). 
The arginine that is available to suckling mice, originates from the food (milk), 
from endogenous synthesis, and from protein catabolism (Figure 1). Mammalian milk, 
including mouse milk, does not contain sufficient arginine for growth (22-24). The 
arginine that derives from protein catabolism cannot serve as a steady-state source unless 
catabolism of arginine-containing proteins is balanced by the synthesis of arginine-
containing proteins. For these 2 reasons, the mouse neonate has to produce arginine 
endogenously. Arginine can only be synthesized from citrulline. Citrulline, in turn, is 
generated from ornithine and carbamoylphosphate. The only organ that can produce 
ornithine and carbamoylphosphate in sufficient quantities to provide the body with 
citrulline for arginine biosynthesis is the small intestine (25,26). In fact, the circulating 
citrulline concentration is a sensitive marker for the amount of healthy gut tissue (27). 
Ornithine derives from glutamate or proline (28). Because of the very rapid metabolism 
of glutamate in the neonatal intestine (29-31), proline is quantitatively the most 
important ornithine precursor. 
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In mammals, including mice and man, a neonatal deficiency of ornithine 
aminotransferase (which produces ornithine from either glutamate or proline) or 
ornithine transcarbamoylase (which produces citrulline from ornithine and 
carbamoylphosphate) does induce a severe citrulline and arginine deficiency (32-35), 
underscoring the crucial role of the small intestine in citrulline production. 
Human neonates often develop hyperammonemia and hypoargininemia, 
especially if premature and fed parenterally (19, 36). These observations mimic the 
finding in neonatal piglets that proline can only prevent hyperammonemia and 
hypoargininemia if administered enterally (16, 37) and demonstrate that intestinal 
feeding is necessary to allow endogenous citrulline production. By using intragastric and 
intraportal administration of label, it was then demonstrated that the small intestine does 
indeed contribute materially to whole-body arginine synthesis in the piglet (15, 38). In 
agreement with these findings, we and others have found that the enterocytes of the 
small intestine of all mammalian neonates investigated thus far, including those of 
human neonates, express the enzymes necessary to produce arginine from citrulline (39-
43), but do not express the main cytosolic arginine catabolizing enzyme arginase-1 (39, 
40, 44). In piglets at least, intestinal biosynthesis of arginine cannot be adaptively 
upregulated (45), suggesting extra-intestinal sites of arginine synthesis from citrulline. 
Our findings in mice indicate that, in this species, an as yet unidentified extraintestinal 
tissue can completely replace the intestine as far as synthesis of arginine from citrulline 
is concerned. Although the kidneys of suckling mice can produce arginine from 
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citrulline, their size is too minute to contribute materially. The skin as a very large organ 
would be another possibility, but its ASS expression declines in Ass-KO/I due to villin, 
and hence, villin-Cre expression (Chapter 4). 
The provision of arginine for cellular functions can proceed by import from the 
blood or by endogenous synthesis from citrulline. Since the distribution of ASS and 
argininosuccinate lyase (ASL) is near ubiquitous, many tissues can synthesize arginine 
from citrulline. Since arginine is rapidly catabolized by arginase, whereas the only 
metabolic fate of citrulline in mammals is arginine synthesis, citrulline is also a much 
more efficient source of cellular arginine than arginine itself. This could be important if 
arginine from arginine import and arginine synthesized from citrulline occupy different 
intracellular compartments, as has been suggested (46). In the special case of the 
arginine-metabolizing enzyme nitric-oxide synthase (NOS), the products of the reaction 
are nitric oxide (NO) and citrulline, so that resynthesis of arginine in the cell producing 
NO is possible. Resynthesis of arginine from citrulline has been shown in neurons and 
endothelium (47-49). Since the upregulation of arginase-1 expression seems to be 
characteristic for endothelial dysfunction (50-55) increased arginase expression may be a 
cause of the decline in arginine levels in dysfunctional endothelium and may explain 
why arginine supplementation is not always effective (56, 57). The preliminary findings 
that we report in Chapter 5 indicate that repetitive stimulation with acetylcholine, that is, 
repetitive rounds of NO synthesis are necessary to decrease endothelial arginine levels in 
young adult endothelium, even if that lacks ASS expression. This finding resembles a 
similar observation in sphincters, in which relaxation becomes dependent on exogenous 
arginine only after several rounds of stimulation (58). The upregulation of arginase-1 
may therefore be the precondition that makes dysfunctional endothelium arginine-
deficient. 
Among the many functions of arginine (Figure 2), signal transduction has 
drawn much attention lately. Our analysis of the arginine-deficiency syndrome in 
neonates heavily leaned on our hypothesis that this syndrome strongly resembled a 
deficiency of insulin-like growth factor-1 (IGF-1; Chapter 2). Even though it is well 
established that signaling via the growth-hormone (GH)-IGF-l axis becomes more 
efficient after weaning (59, 60), we observed a significantly lower IGF-1 concentration 
in several organs of arginine-deficient compared to wild-type neonatal mice. 
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Injection of GH increased tissue IGF-1 levels, but to a lesser extent in arginine-
deficient than in control mice, which indicates that arginine deficiency negatively affects 
GH-IGF-1 signaling. This finding led us to investigate the signaling pathways activated 
by amino-acid deficiencies. 
A deficiency of amino acids leads to the inhibition of protein synthesis via 2 
routes (Figure 3). A lack of activation of the mTOR (mammalian target of rapamycin) 
pathway (Figure 3) causes, among others, dephosphorylation of p70S6 kinase and 
eIF4E-binding protein (61). This dephosphorylation inactivates p70S6 kinase and 
activates eIF4E-binding protein. Active 4E-binding protein inactivates translation by 
binding and sequestration of the cap-binding protein eIF4E. Both leucine and arginine 
are very strong agonists of the mTOR pathway, whereas histidine, isoleucine, lysine, 
methionine, phenylalanine, threonine, tryptophan, cysteine, glutamine, and tyrosine are 
not (62). In some studies, glutamine even inhibits the mTOR-dependent phosphorylation 
of p70S6kinase (63). These data show that amino acids differentially affect the activation 
of the mTOR pathway. We still have to demonstrate whether or not arginine deficiency 
affects mTOR signaling in F/A2 mice. 
Activation of GCN2 (general control non-derepressing) by amino-acid 
deficiency causes phosphorylation of eIF2a and, hence, inhibition of the binding of the 
methiony 1 -tRNA/mRNA complex to the 40S ribosomal subunit(64, 65). Our analysis has 
primarily focused on the activation of the GCN2 pathway. Not all amino acids appear 
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Figure 3 The effects of amino-acid deficiency on protein translation. The figure 
illustrates the stages in translation initiation involving the binding ofmethkmyl-tRNAi 
(met) and mRNA to the 4 OS ribosornal subunit. The eukaryotic initiation factor (elF) 
eIF4E is depicted as a hexagon with the label 4E in the center of the shape. In addition, 
the regulation of el FIB activity by phosphorylation of the a-subunit of eIF2 and the 
sequestration of elF4E by e!F4E binding protein-1 (4E-BP1) are illustrated, mTOR, 
mammalian target ofrapamycin; AUG, the nucleoside triplet adenosine, uridine, 
guanosine; GCN2, general control nonderepressing eIF2 protein kinase 2. Green: 
Synthetic loop blocked by GCN2 activation; red: synthetic loop blocked by mTOR 
inactivation Modifiedfrom (96). 
equally potent in this respect, Thus, leucine appears to be more powerful than glycine, 
which in turn is more powerful than tryptophan (65). Our data, as well as similar data 
from the literature (66,67) show that arginine deficiency is also a powerful stimulator or 
GCN2 (Chapter 2), but the hierarchy in the activation potential among amino acids 
remains to be established. Furthermore» our findings show that not all tissues are equally 
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sensitive: neonatal muscle is exquisitely sensitive, whereas liver, almost devoid of 
arginine due to the action of the urea cycle enzyme arginase-1, hardly responds (Chapter 
2; cf. ref. (68) for a similar situation in piglets). Although circulating arginine levels do 
not increase after weaning in arginine-deficient F/A2 mice (3), muscle growth resumes, 
so that adult mice are only slightly smaller than their wild-type controls. Very recently, it 
was shown that C2C12 myoblasts do respond to amino-acid deficiency, whereas the 
more differentiated myotubes do not (69, 70). The exquisite sensitivity of neonatal 
skeletal muscles to arginine deficiency may, therefore, well be due to the fact that the 3rd 
phase of myoblast fusion, which generates the mature, multinuclear striated muscles, 
occurs perinatally in rodents (71). The rapid activation of protein synthesis by growth 
hormone requires signaling through mTOR (72). We hypothesize that activation of the 
GCN2 pathway, with or without inactivation of mTOR-dependent phosphorylation, 
blocks GH-IGF-1 signaling. To test the hypothesis that this hierarchical relation between 
amino-acid deficiency and GCN2 signaling exists, GH-IGF-1 signaling in C2C12 cells 
that constitutively express GCN2-specific RNAi is presently being investigated. 
Perspectives 
With the newly available conditional knockouts for ASS, arginase-1 and CAT-1 (Figure 
4), we can, in conjunction with already available constitutive knockouts, manipulate 
intracellular arginine levels. The limitations to generate attractive combinations are the 
complex breeding schemes (it may take more than a year of breeding to generate a 
specific double knockout with an appropriate Cre expressor) and the fact that we cannot 
yet delete the heterodimeric arginine transporters, which all share the 4F2hc heavy chain 
(Slc3A2) (73). We aim to specifically address arginine metabolism in endothelial cells 
and in macrophages. As we stated earlier, endothelial cells resynthesize arginine from 
the citrulline that is one of the products of NO synthesis. NO is a major vasodilatory 
agent. Endothelial dysfunction (ED) is the impaired ability of vascular endothelium to 
stimulate vasodilation (74) and predisposes to both small- (hypertension) and large-
artery disease (atherosclerosis). An early and key feature of ED is a decline in the 
bioavailability of NO as a result of its reduced synthesis and/or increased degradation by 
reactive oxygen species (ROS) (75). Quantitatively, NO synthesis is small compared to 
arginine synthesis and turnover in most tissues. This, and the fact that the KM of NOS for 
arginine is in the low micromolar range (76) should confer little control of arginine 
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aval lability over NO synthesis. The relatively rnild phenotype of mice lacking all three 
NO-synthesizing (NrOS) enzymes (77, 78) suggested to us, however, that NO 
bioavailability m itself may not be the major determinant of HD. NOS produces NO and 
citrulline in the presence of argmrne and the co-factor tetrahydrobiopterin (BH4) If 
either becomes deficient, NOS "uncouples" and releases free superoxide (Oj-) radicals 
(79, 80), which enhance oxidative stress and oxidize the NOS co-factor BH4 (75, 81) 
These findings suggest that deficiency of arginine (or BH4) is more detrimental for 
endothelial function than deficiency of NO per se. We can test this hypothesis by using a 
mouse model which is sensitive to HD (e.g. the low-density lipoprotein (LDI . preceptor 
knockout (82, 83)) arul is impaired in the synthesis of arginine (endothelial ASS 
knockout; this deletion should sensitize the animal to vascular pathology) ami a mouse 
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model which is sensitive to ED (the same LDL-receptor knockout) and is impaired in the 
degradation of arginine (endothelial arginase-1 knockout; this deletion should protect the 
animal against vascular pathology). We have recently obtained a grant from the Dutch 
Heart Foundation to test this hypothesis. 
Macrophages use arginine to synthesize NO or ornithine and urea. The 
macrophage population is heterogeneous, but two main phenotypes can be distinguished 
(84). The classical, IFN-y-induced activation of (Ml) macrophages is associated with 
cell-mediated immunity to intracellular pathogens and with TH1 lymphocyte responses. 
Ml macrophages express NOS2 and have a high microbicidal activity, immuno-
stimulatory functions and cytotoxicity. The alternative, IL4 and IL-13-induced activation 
of (M2) macrophages is strongly associated with extracellular parasitic infections, 
allergy, humoral immunity, and fibrosis. M2 macrophages express arginase-1 and have a 
high scavenging ability, promote tissue repair and angiogenesis, tune the adaptive TH1 
response and favour tumour progression (Figure 5), Since arginase-1 catabolizes 
arginine, M2 macrophages have little arginine available for the synthesis of NO. 
Furthermore, the arginine deficiency can activate GCN2 (Chapter 2; (85)) and suppress 
the expression of T-cell receptor £-chain in neighbouring effector T cells, which 
diminishes their activation and proliferation (86-88). The alveolar, M2-polarized 
macrophage plays a key role in the development and maintenance of asthma (89). For 
this reason, we presently investigate whether deletion of arginase-1 in macrophages 
affects the severity of ovalbumin-induced allergic asthma in mice. Tumor-associated 
macrophages (TAMs) also have an M2 phenotype and are thought to tolerize the host to 
tumors (90). Using the same approach as developed for asthmatic mice, we plan to study 
these macrophages. 
In addition to these 2 tissues, i.e. endothelium and macrophages, there are 
several other tissues in which arginine metabolism is intriguing. Since the kidney is 
considered the single most important tissue for arginine synthesis in its proximal tubules 
(91, 92), it would be most interesting and important to assess the consequences of its 
deletion. Unfortunately, a mouse line which selectively expresses the recombinase Cre in 
the Pl-3 segments of the kidney tubule is not yet available. The ASS-expressing 
thymocytes (Chapter 4) are another intriguing tissue for which the significance of 
arginine remains to be determined. The major limitation to the use of floxed conditional 
knockout mice is that these mice have their floxed gene deleted from the time the Cre 
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enzyme becomes expressed. The approach would therefore become even more elegant, if 
not only spatial (tissue specificity), but also temporal control of the moment of gene 
inactivation would be possible. In principle, such temporal control can be achieved by 
using tamoxifen-dependent Cre variants (93, 94). Unfortunately, the amount of 
tamoxifen (and, more importantly, its vegetable-oil solvent) that is necessary to achieve 
gene inactivation is too high to allow metabolic assessment soon after this treatment (Y. 
He, T.B.M. Hakvoort & W.H. Lamers, unpublished). Possibly, the development of more 
sensitive doxycyclin-dependent Cre-expressing transgenes (95) will meet the 
requirements. 
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In dit proefschrift staat het aminozuur arginine centraal. Arginine is een voorloper voor 
de synthese van eiwitten, stikstofoxide, creatine en agmatine, en is een intermediair in de 
ontgifting van ammoniak via de ornithine cyclus. Arginine behoort niet tot de essentiële 
aminozuren. In zoogdieren vindt de endogene aanmaak van arginine vooral in de 
proximale tubulus contortus van de nier plaats uit citrulline, dat op zijn beurt uitsluitend 
in de epithe el cellen van de dunne darm (enterocyten) gevormd wordt uit glutamine of 
proline. De capaciteit om zelf arginine te synthetiseren is laag in vleeseters zoals katten 
en fretten, intermediair in de mens, en relatief hoog in snel and blijvend groeiende dieren 
zoals varkens en knaagdieren. In de volwassen mens voorziet de endogene synthese van 
arginine onder normale omstandigheden in de dagelijkse behoefte. Onder sterk anabole 
of katabole omstandigheden wordt een externe bron van arginine noodzakelijk. Om deze 
reden wordt arginine tegenwoordig een "conditioneel" essentieel aminozuur genoemd, In 
snelgroeiende pasgeboren zoogdieren voorziet de relatief geringe bijdrage van arginine 
uit de melk niet in de behoefte voor eiwitsynthese ten behoeve van groei, zodat endogene 
synthese van arginine in deze periode noodzakelijk is. Verschillende onderzoekingen, 
inclusief onderzoek uit onze groep, wijzen erop dat de darm in deze periode een 
belangrijker bron van arginine vormt dan de nier. 
In hoofdstuk 1 wordt allereerst een overzicht gegeven van het evenwicht tussen 
de behoefte, de eigen aanmaak, en de stofwisseling van arginine in het lichaam. 
Vervolgens wordt de regulering van het transport van arginine over de celmembraan 
besproken en tenslotte komen de tot nu toe beschreven muizen met een deletie van een 
van de genen uit de aanmaak, transport, en afbraak van arginine aan de orde. 
Transgene "F/A2" muizen brengen arginase-1 in hun enterocyten tot expressie. 
Het gevolg daarvan is dat F/A2 zuigelingen lijden aan te lage bloedspiegels van arginine, 
verminderde spier- en haargroei, en een geremde rijping van B cellen. Het arginine 
deficiëntiesyndroom lijkt op een tekort aan Insuline GroeiFactor (IGF)-l. In hoofdstuk 2 
hebben wij daarom de hypothese getoetst of het arginine deficiëntie syndroom het 
gevolg is van een interactie tussen de GroeiHormoon (GH)/IGF-1 as en de GCN2 stress 
kinase signaaltransductie route die geactiveerd wordt door een tekort aan een bepaald 
aminozuur. De activering van GCN2 kan gevolgd worden door de fosforylering van 
translatie initiatie factor eIF2a en de concentratietoename van de transcriptiefactoren 
ATF4 en CHOP te bepalen. Deze bepalingen zijn uitgevoerd in cellen die in vitro 
gekweekt werden onder verschillende arginine concentraties en in F/A2, Gcn27", of 
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F/A2//Gcn2~/~ muizen. Een tekort aan arginine remt de secretie van GH in hypofyse 
cellen. In arginine deficiënte F/A2 muizen was de GH eiwitconcentratie in de hypofyse 
2.5-voudig verhoogd en de Igf-1 mRNA concentratie in lever en spier 8-10-voudig 
verlaagd. Tweemaal daags toedienen van GH verhoogde de Igf-1 mRNA concentratie 
3-voudig in zowel wildtype als F/A2 muizen, maar stimuleerde de groei niet. In 
celkweken werd de GCN2 signaaltransductie route geactiveerd zodra de arginine spiegel 
van het medium onder 50 juM daalde, terwijl IGF-1 myoblast differentiatie stimuleerde 
indien de arginine spiegel hoger dan 25 joM was. In 1 -dag oude F/A2 muizen was de 
arginine concentratie 4.5-voudig verlaagd en was GCN2 in alle onderzochte organen 
geactiveerd. Muizen waarvan het Gcn2 gen geïnactiveerd was (Gcn2"/ ) vertoonden geen 
toegenomen ATF4 and CHOP expressie en stierven vlak na de geboorte. Deze 
waarneming laat zien dat alleen het stress kinase Gcn2 verantwoordelijk was voor de 
stress kinase response. Op grond van deze waarnemingen hebben wij geconcludeerd dat 
de symptomen van het arginine deficiëntiesyndroom ontstaan door GCN2 activering, 
onderdrukking van GH secretie, en remming van de groeistimulerende effecten van 
IGF-1. 
Binnen de afdeling Anatomie & Embryologie zijn de afgelopen jaren 
"conditionele" knockout muizen gemaakt voor de arginine-gerelateerde eiwitten 
argininosuccinaat synthetase, arginase-1 en de cationic amino-acid transporter-1. In een 
conditionele muis wordt een essentieel deel van het structurele gen geflankeerd door een 
32bp lang DNA fragment ("loxP") dat de functie van het gen niet beïnvloedt. Doordat dit 
fragment herkend wordt door een enzym met "recombinase" activiteit ("Cre"), kan het 
geflankeerde DNA selectief verwijderd worden door kruising met muizen die Cre 
transgeen tot expressie brengen. Indien de transgene muis Cre via een weefselspecifieke 
promoter/enhancer tot expressie brengt, wordt een weefselspecifieke knockout 
verkregen. In hoofdstuk 3 hebben we onze ervaringen met de vervaardiging van deze 3 
conditionele knockout muizen samengevat. Belangrijke aspecten om rekening mee te 
houden blijken te zijn: 
De gekozen strategie om de "targeting" vector (het DNA molecule dat 
modificatie van het DNA in de embryonale stamcel (ES) teweeg brengt) te construeren. 
Indien een op PCR gebaseerde methode wordt gebruikt om de homologe "armen" van de 
vector te kloneren, dient bij voorkeur een "bacterial artifïcial chromosome" (BAC) 
kloon als uitgangsmateriaal te worden genomen om het aantal amplificatiestappen te 
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minimaliseren. Ook dienen gebieden waarin veel "repeats" (herhaalde, aansluitend achter 
elkaar liggende sequenties van > 2 nucleotiden) voorkomen vermeden te worden omdat 
ze moeilijk foutloos te amplificeren zijn. 
De selectie van de recombinante ES kloon voor injectie in blastocysten. Om te 
bewerkstelligen dat de geselecteerde kloon daadwerkelijk alleen homoloog 
gerecombineerde ES cellen bevat dienen geselecteerde ES klonen voortdurend onder 
selectiedruk gekweekt te worden om de overleving van wildtype cellen te voorkomen. 
De eerste screening tegen "random integration" van een targeting vector in het DNA van 
een ES cel kan het best geschieden door aan de zijde van de "lange" homologe arm een 
stuk vector DNA te laten zitten. Deze vector sequentie komt niet voor in het DNA van de 
ES cel en verdwijnt bij homologe recombinatie. De aanwezigheid ervan bewijst random 
integratie. 
Screening op homologe recombinatie met behulp van een lange PCR aan de 
zijde van de "korte" homologe arm van de targeting vector is sneller en informatiever 
dan de klassieke Southern blot. Een nadeel van deze aanpak is dat het te gebruiken paar 
PCR "primers" pas niet kan worden getest en geoptimaliseerd voordat de recombinante 
ES kloon beschikbaar is. 
Sondes ("probes") om Southern blots te screenen dienen, indien ze uit intronen 
afkomstig zijn, te worden gecontroleerd op de aanwezigheid van repeats. Een probe van 
~300bp blijkt voldoende lang te zijn voor een gevoelige en specifieke selectie. 
Na selectie met ganciclovir om de selectiecassette te verwijderen dienen ES klonen 
opnieuw gesequenced te worden omdat ganciclovir mutageen gebleken is. 
Succesvol homoloog gerecombineerde ES cellen zijn slechts op één van beide 
allelen gemodificeerd. De kleur van de vacht is een goede marker voor de aanwezigheid 
van homoloog gerecombineerde cellen in de kiembaan van chimere muizen. Dit kan van 
groot belang zijn indien niet onmiddellijk muizen met een gefloxt gen worden verkregen. 
De zorg dat de activiteit van transgeen Cre recombinase onvoldoende is om twee 
gefloxte allelen in één cel te verwijderen is ongegrond gebleken. De beste genotypes om 
de fysiologische effecten van gen deletie te bestuderen blijken flox/flox and flox/flox-
Cre te zijn, omdat het fenotype van dieren met één constitutief en een conditioneel 
verwijderd allel moeilijk te interpreteren is. 
Afwezigheid van het enzym ornithine transaminase of ornithine 
transcarbamoylase veroorzaakt een ernstig tekort aan arginine in pasgeboren muizen en 
mensen, omdat endogene synthese van citrulline nodig is om het voor groei te geringe 
gehalte aan arginine in de melk te compenseren. Pasgeborenen verschillen van 
volwassenen in de zin dat de enzymen die nodig zijn voor de synthese van arginine uit 
citrulline in sterke mate tot expressie komen in de epitheelcellen ("enterocyten") van de 
dunne darm. In hoofdstuk 4 hebben wij het belang van de arginine synthese in de dunne 
darm voor de arginine voorziening van de muizenzuigeling onderzocht door het enzym 
argininosuccinaat synthetase (ASS) selectief in de enterocyten van de dunne darm te 
elimineren. Eliminatie van ASS expressie werd bewerkstelligd door Assm muizen (in 
deze muizen wordt exon 13 van het Ass gen geflankeerd door loxP sites) te kruisen met 
transgene "Vil" muizen (deze muizen brengen het recombinase Cre selectief in de 
enterocyten tot expressie). Om de bijdrage van ASS activiteit buiten de darm te beperken 
werden bovendien Ass"/fl met Vil muizen gekruist. De gevolgde strategie bleek effectief 
om ASS expressie in de enterocyten geheel te elimineren. Desondanks ontstond geen 
tekort aan arginine in muizenzuigelingen met het Vil/Assfl/n of Vil/Ass"/fl genotype (de 
verschijnselen van een tekort aan arginine in zuigelingen zijn in hoofdstuk 2 
beschreven). De systemische eliminatie van één Ass allel deed de circulerende citrulline 
spiegel met ~ 5 0 j j M toenemen, terwijl de eliminatie van een Ass allel in de enterocyten 
verantwoordelijk was voor een additionele stijging met ~80|iM. Met behulp van 
microsferen konden we aantonen dat -80% van het bloed dat door de lever van 14 dagen 
oude muizen stroomt van de vena portae afkomstig is en -20% van de arteria hepatica. 
Ten opzichte van wildtype (Vil/Ass+/+) muizen bleek de arginine productie in alle 
experimentele genotypes effectief geëlimineerd, terwijl de citrulline productie, zoals 
verwacht, toegenomen was. In zuigelingen dragen de nieren nog nauwelijks bij aan de 
productie van arginine omdat de doorstroming van de nier slechts -20% 
vertegenwoordigt van dat wat door het maagdarmkanaal stroomt. Deze resultaten tonen 
aan dat arginine synthese in de dunne darm niet essentieel is voor muizenzuigelingen. 
Een van de eerste kenmerken van disfunctie van het endotheel (de cellen die 
bloedvaten bekleden) is een vermindering van de productie van het vaatverwijdende 
stikstofoxide (NO) uit arginine. Het relatief milde fenotype van muizen waarin alle 3 NO 
synthetiserende (NOS) enzymen zijn geëlimineerd impliceert dat een tekort aan NO op 
zich niet zeer pathogeen is. NOS enzymen produceren NO en citrulline in aanwezigheid 
van arginine en de co-factor tetrahydrobiopterine. Als een van beide in onvoldoende 
mate aanwezig is, "ontkoppelt" NOS en produceert het het zuurstofradicaal superoxide in 
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plaats van NO (>p grom! hiervan hebben wij gehypothekeerd dat een tekort aan 
argmme .schadelijker ss vm>r de functie \ m het endothee 1 dan een tekort aan NO Om die 
reden hebben witfhwïfdstuk 5! de effecten van een Mslectieve eliminatie van ASS en 
argmase-1 m het endothee! nagegaan door Ass ' 1 of Arg 1f,'f' rnui/en te kruisen met Tie2-
( r e mui/en (de/e mui/en brengen het ( re recombmase selectief m het cndotheel tot 
expressie*. ASS en het eralotheel «specifieke NOS? komen samen tot expressie in het 
artenële endoihecl van jonge wildtvpc mus/en, terwijl Argmasel daarin <nog met) tot 
expressie komt Artenfcn /onder ASS of Arginasel expressie in het endothee! 
verschilden niet van wiidtype artenen in hun vernauwing na blootstelling aan 
phenylephrine of ui hun verwijding na hlont&teliing aan acetylcholinc. Alleen na 
herhaalde inductie van vaatvernauwing en -verwijding bleek dat toevoeging van argintne 
aan het orgaanbad de vaatverwijding in arteriën /onder ASS herstelde, terwijl citrulline 
(zoals verwacht) geen effect had. Na de/elfde voorbehandeling bleken arteriën /onder 
Arginasel daarentegen gevoeliger voor toegevoegd argmme en citrulline dan wildtype 
controles. De/e voorlopige resultaten laten zien dat resynthese van arginine uit citrulline 
in het endothee! ook in vivo optreedt en belangrijk is voor een goede functie van het 
artenële epitheel 
190 
s 
Acknowledgements 
191 
Finally, after all these months of writing and corrections, I am able to write this 
acknowledgment section. This is actually more difficult than anticipated and this is why 
I took all the thesis books from my once-was-an-A.I.O. fellows and tried to figure out 
how they did it. Unfortunately, this approach was not very fruitful since most of the 
acknowledgements sections are in Dutch. Damn I should really have worked more on 
my Taal Vital lessons. Anyway, I will try my best to thank each and everyone who 
helped me through all these years I spent working on my PhD. 
To start, I am very grateful to Professor Toon Stegmann. As it was one said, Holland 
occupies less than one percent of the earth's surface... but like its airline (KLM for those 
who don't know), the Dutch scientists cover the rest. Indeed, you can always meet a 
Dutch scientist in every big western city and this is how I met Toon Stegman at the 
University Paul Sabatier in Toulouse. I was searhing a PhD position and he was the one 
who suggested me the Netherlands and helped me got one. So erg bedankt, Toon. 
Wout, it has been a pleasure being your PhD student. I really appreciated the scientific as 
well as the non-scientific discussions we shared. Moreover, you invested all your 
knowledge and experience in keeping the course of my PhD, especially through the 
doubtful moments we've been through and I'm really grateful for this. 
Naturally, the next person I have to thank is Leo, my co-promotor and friend. She has 
always been very good in making the experiments go smoothely. Through the years we 
spent working in generating and studying the mice, she has tried her best to find the 
appropriate answers to the numerous questions I had. Her most frequent answer which I 
dislike was: Vincent, you have to do it again!!! Also a big thank for your non-stop caring 
in making our everyday life as enjoyable as possible. 
Also big thanks to my 2.122-room-mates, Rinus and Selvi for all these years of turmoil 
and laughters we had together. My buddy Rinus, de palm boom, has always made sure 
that all our data were safely stored. I am still amazed how you could memorise all our 
technical stuff and use them as if you were also doing a PhD on arginine metabolism. 
To my other room-mate, Selvi, our Indian lady. I am sure everyone in the department 
remembers our fights just about anything. It's true that it took a while for us to become 
192 
friends and you to stop calling me a "paradesi" which means beggar for those who don't 
understand Tamil. But once the turmoil was over, I really enjoyed the time I spent with 
you in the lab and outside during the dinners where I would be choking due to your spicy 
food. So thank you for your help in the lab and for your friendship. 
I would alo like to thank all the members of the Anatomy & Embryology Department for 
their help. A special thank to Paul, my histological mentor, who taught me all the tricks 
to obtain nice results from making sections, staining them and taking pictures. Thank 
you also for your extra attention like your home-made saté sauce. I would never have 
been able to cut all these sections without it. That was lekker. I also want to thank Chiel 
who made sure I would have everything available to perform my research. He was also 
able to find out my errors and made me correct them which in the end made me get my 
mouse. I am also very grateful to Johan in helping me with all the mouse experiments 
and tried, in vain, to teach me golf. To Greta, if I recall well you have a cup on which is 
written "the best secretary". This is totally true; you always manage to have all paper 
work fixed while I would be bringing you a cup of coffee. Also a big thank-you for 
having been such a pleasant neighbour who took care of my plants when I was gone. I 
don't forget the other members of the department, Els, Henny, Arno, Leon, Rogier, 
Hans, and Professor Drukker and all the others for their support during these years. 
Big thanks to the members of the Population Genetics Department Franck, Hanneke, and 
Sofia and to all others who were always friendly when I came to perform my 
experiments. Also to Kim Salvekouls and Sherry Wheppler from the Maastro Lab who 
gave me all the required technical support during my experiments. 
Of course all the experiments would not have been possible without the work from the 
members of the animal facility ( CPV) and in particular Richard. It's been a pleasure 
working with you. 
Last but not least, I would like to express all my gratitude to my ever-supporting wife 
Celine, my father Daniel, my mother Denise, my brothers François and Gérald, my sister 
Vanessa and to the rest of my family and other animals 
193 
Thanks! That's what makes it all worthwhile. 
194 
Curriculum vitae 
195 
Vincent Marion was born April 21st, 1976 in Mauritius. He received his secondary 
schooling at the catholic college of Saint Esprit, where he obtained his Higher School 
Certificated (H.S.C.) from Cambridge University (U.K.) in 1995. He then started 
studying Biological Sciences at the University of Paul Sabatier in Toulouse, France. He 
obtained his Master in Science in Structural and Functional Biochemistry in 2002.after 
performing an internship at the University Hospital Center of Purpan, Toulouse, France, 
where he took part in the characterization of an enzymatic activity required by the 
human cytomegalovirus for infecting human cells. In October 2002, he obtained a PhD 
position in the Department of Anatomy & Embryology at Maastricht University to work 
on a project aimed at finding the role of the amino acid arginine in the organ 
development and function. Currently, he has a post-doc position in the Laboratory of 
Medical Genetics at the University of Strasbourg, France, where he is focusing on how 
the primary cilium regulates the development of tissues in humans. 
196 
